|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/8/18 ¤U¤È 09:24:17²Ä 424 ½g¦^À³
|
·s¥[©Y¬F©²°òª÷¤£¶R¦b·s¥[©Yµo®iªº¥Í§Þ¤½¥q¡A ¨º¤~©_©Ç«¨¡A ¥u¤£¹L¡A¶R¤F¬O¤@¦^¨Æ¡A¥iÃįण¯à«OÃÒÀò±oÃÄÃÒ¡A ¤S¬O¥t¥~¤@¦^¨Æ¤F¡A ¤S§j¤S¾Ýªº¡A ¬ü°ê¥P¤¦ÃĮĤG¡B¤T¤Ñ«á´N¡uµL®Ä¡v¤F¡A ¹L°}¤l¡A§O説 §A¤S©ß±ó¤F¨È¬w·à¡A¥h¥_·¥§äµVµV¤F |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/18 ¤U¤È 08:20:49²Ä 423 ½g¦^À³
|
§ó¥¿ BV Healthcare II Pte Ltd (¥Nªí¤H: Damien Lim) 7542±i(2017,11,09)¡X-·s¥[©Y²H°¨¿ü°òª÷¤Uªº BV Healthcare II(6%) 2018¦~²Ä¤G©u ·s¥[©Y²H°¨¿ü ¥H¥§¡¨CªÑ54.9¤¸¥x¹ô¡A¦¬Áʬü°ê¨È·à±dADR 12,660,000¬ü¤¸.¦@142¸UªÑ¡C ·s¥[©Y²H°¨¿ü(·s¥[©Y100%ªº°ê®a°òª÷)É]³õ¦¬Áʨȷà±d¬ü°êADR 12,660,000¬ü¤¸. ¦@142¸UªÑ ,¦û¬ü°êADR Á`µo¦æ600¸UªÑ ,23.67% ,¨CªÑ¦¨¥»8.915¬ü¤¸,§é¦X·s¥x¹ô54.9¤¸/ªÑ. 1420x5=¬ù7100±i(§é¥xªÑ) ¥h¦~©³¦b¥xªÑ¨È·à«ùªÑ7542±i 7100¡Ï7542=¦@14,642±i(¥xªÑ) 14,642/160,000=9.15% ¬°¨È·à±dªº³Ì¤jªÑªF ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ®Ú¾Ú¬ü°êÃÒ¨é¥æ©ö©eû·|13F¥Ó³ø¤å¥ó¡AÁZ®Ä¨ô¶Vªº·s¥[©Y¥DÅv§ë¸ê°òª÷²H°¨¿ü±±ªÑ¦b²Ä2©u«×§¹¦¨²Mܬü°ê¤W¥«»È¦æ«ùªÑ¡AºM°h©ó°ª²±¡B¼¯®Ú¤h¤¦§Qµ¥¾÷ºcªº§ë¸ê¡C¦P®É¡A¶i¤@¨B§ë¸êª÷¿Ä¬ì§Þ©M¨ä¥L·s¸gÀÙ»â°ì¡C ¨ä¤¤¡A¼W¥[¤F¦blobal Payments¡BPayPal¡BCenturyLink©MVisaµ¥¤½¥q«ùªÑ¡CºI¦Ü6¤ë30¤é¡A²H°¨¿üªºCenturyLinkªÑÅv»ùÈ23»õ¬ü¤¸¡A¦bVisaªº«ùªÑ»ùÈ5.7»õ¬ü¤¸¡C·s¼W§ë¸ê 142¸UªÑAslan Pharmaceuticals¡C¦P®ÉÅã¥Ü¡A´î«ù¤Fªü¨½¤Ú¤Ú¡B¨È°¨»¹¡BAmyris©M½u¤WÅé¨|¹s°â°ÓNetshoes Cayman¡C hk.on.cc/hk/bkn/cnt/finance/20180815/mobile/bkn-20180815090910013-0815_00842_001.html |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/18 ¤U¤È 06:32:20²Ä 422 ½g¦^À³
|
¨È·àCEO ³Å«i³Õ¤h Carl Firth, ¥¼¨Ó3Ӥ릳 3³õ·s¥[©Y¤Î1³õ¯Ã¬ùªº¥Í§Þ/ÂåÀø§ë¸êºtÁ¿ ASLAN CEO Dr Carl Firth to speak at Biotech Investment Summit, 31 October-2 November 2018, Singapore ASLAN CEO Dr Carl Firth to speak at IQVIA 2018 APAC Healthcare Summit, 11 October 2018, Singapore ASLAN CEO Dr Carl Firth to speak at Milken Institute Asia Summit, 13-14 September 2018, Singapore ASLAN CEO Dr Carl Firth to present at H.C. Wainwright 20th Annual Global Investment Conference, 5 September 2018, New York City Firth °õ¦æªø Carl Firth³Õ¤h¬°¨È·à±d¤½¥qªº³Ð¿ì¤Hº[°õ¦æªø¡C Carl Firth³Õ¤h¦b³Ð¿ì¨È·à±d«e´¿¥ô¾©ó¬ü»È¬üªLÃÒ¨é (Bank of America Merrill Lynch) ¾á¥ô¨È¬wÂåÀø¥Í§Þ²£·~Á`ºÊ¡At³dÂåÀø¥Í§Þ¤½¥q¦UÃþ«¬¤§¶Ò¸ê¬¡°Ê¤Î¨ÖÁÊ¥æ©ö®×¥ó¤§¿Ô¸ßÅU°Ý¡C ¦b§ë¨»È¦æ·~¤§«e¡ACarl Firth³Õ¤h®Ä¤O©óªü´µ¯S±¶§Q±d»sÃÄ (AstraZeneca) ¡A¾á¥ô¥«³õ¾P°â¤Î¬ãµoµ¥¦hºØ¾°È¡A¥]¬A¨È¤Ó°Ï¨Æ·~µo®iÁ`ºÊ¥H¤Î¤¤°ê·s²£«~µo®iÁ`ºÊ¡C Carl Firth³Õ¤h¥Ø«e¬°·s¥[©Y½Ã¥Í»P¥Íª«Âå¾Ç°ê»ÚÅU°Ý©eû·|©eû¡A¥ç¬°·s¥[©YExploit Technologies ¤§¿W¥ß¸³¨Æ¡AExploit Technologies¬°·s¥[©Y¬ì¬ã§½ (A*STAR) ±M¥q°Ó«~¤Æ¤§³¡ªù¡A¨ä¥Dn³z¹L±À°Ê³Ð·s»P±N·s¥[©Y¬ì¬ã§½ªº¬ã¨s¦¨ªG°Ó«~¤Æ¡A¨Ó¨ó§U·s¥[©Y¬ì¬ã§½¶i¦æ¸gÀÙÂ૬¡C Carl Firth³Õ¤h´¿©ó2014¦~4¤ë¦Ü2017¦~11¤ë´Á¶¡¾á¥ô»´ä¤W¥«¤½¥qUni-Bio Sciences¤§¿W¥ß¸³¨Æ¡A¸Ó¤½¥q¬°º©}¤@«üªº¤¤°ê¥Íª«»sÃĤ½¥q¡AP¤O©ó¤¤°êÂåÀø«O°·¥«³õªº¬ã¨s¡B¶}µo¡B¥Í²£¤Î°Ó·~¤Æ¡C Carl Firth³Õ¤h¬°§ù§J-·s¥[©Y°ê¤jÂå¾Ç°| (Duke-NUS Medical School) Ý¥ô±Ð±Â¡A¨Ã¾Ö¦³¼C¾ô¤j¾Ç¤T¤@¾Ç°|¤§¤À¤l¥Íª«¾Ç³Õ¤h¾Ç¦ì¡BÛ´°°Ó¾Ç°|ªºEMBA¥H¤Î¼C¾ô¤j¾Ç¤À¤l¥Íª«¾Ç¾Ç¦ì¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/18 ¤W¤È 11:21:33²Ä 421 ½g¦^À³
|
¤µ¦~²Ä¤G©u ·s¥[©Y²H°¨¿ü ¥H¥§¡¨CªÑ54.9¤¸¥x¹ô¡A¦¬Áʨȷà±dADR 12,660,000¬ü¤¸.¦@142¸UªÑ¡C ·s¥[©Y²H°¨¿ü(·s¥[©Y100%ªº°ê®a°òª÷)É]³õ¦¬Áʨȷà±d¬ü°êADR 12,660,000¬ü¤¸. ¦@142¸UªÑ ,¦û¬ü°êADR Á`µo¦æ600¸UªÑ ,23.67% ,¨CªÑ¦¨¥»8.915¬ü¤¸,§é¦X·s¥x¹ô54.9¤¸/ªÑ. 1420x5=7100±i(§é¥xªÑ) ¥h¦~©³¦b¥xªÑ¨È·à«ùªÑ6.8%(130,000x6.8%=8840±i) 7100¡Ï8840=¦@15940±i(¥xªÑ) 15940/160,000=9.96% ¬°¨È·à±dªº³Ì¤jªÑªF ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ®Ú¾Ú¬ü°êÃÒ¨é¥æ©ö©eû·|13F¥Ó³ø¤å¥ó¡AÁZ®Ä¨ô¶Vªº·s¥[©Y¥DÅv§ë¸ê°òª÷²H°¨¿ü±±ªÑ¦b²Ä2©u«×§¹¦¨²Mܬü°ê¤W¥«»È¦æ«ùªÑ¡AºM°h©ó°ª²±¡B¼¯®Ú¤h¤¦§Qµ¥¾÷ºcªº§ë¸ê¡C¦P®É¡A¶i¤@¨B§ë¸êª÷¿Ä¬ì§Þ©M¨ä¥L·s¸gÀÙ»â°ì¡C ¨ä¤¤¡A¼W¥[¤F¦blobal Payments¡BPayPal¡BCenturyLink©MVisaµ¥¤½¥q«ùªÑ¡CºI¦Ü6¤ë30¤é¡A²H°¨¿üªºCenturyLinkªÑÅv»ùÈ23»õ¬ü¤¸¡A¦bVisaªº«ùªÑ»ùÈ5.7»õ¬ü¤¸¡C·s¼W§ë¸ê 142¸UªÑAslan Pharmaceuticals¡C¦P®ÉÅã¥Ü¡A´î«ù¤Fªü¨½¤Ú¤Ú¡B¨È°¨»¹¡BAmyris©M½u¤WÅé¨|¹s°â°ÓNetshoes Cayman¡C hk.on.cc/hk/bkn/cnt/finance/20180815/mobile/bkn-20180815090910013-0815_00842_001.html |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/18 ¤W¤È 11:15:33²Ä 420 ½g¦^À³
|
To¡AÙçÙç¤j theratechnologies.s3.amazonaws.com/prod/media/nr-th-10042017-en.pdf www.croiconference.org/sites/default/files/posters-2017/449LB_Emu.pdf |
|
|
·|û¡GÙçÙç10147414 µoªí®É¶¡:2018/8/18 ¤W¤È 11:05:55²Ä 419 ½g¦^À³
|
¤Ñ©R¤j ·PÁ«ùÄò´£¨Ñ¸ê®Æ¡I½Ð°Ý±z¤âÃ䦳TMB355·íªìPhase3¸ÕÅ窺¸ê®Æ¶Ü¡H¥]¬A¯f¤H¿©¯fI´ºµ¥¡C¤£µM±Í¤H¯u±o¦A§ä®É¶¡¨ìªþªñÂå¾Ç¤¤¤ß¹Ï®ÑÀ]§ä·s^®æÄõÂå¾Ç´Á¥Z°µ¤ñ¸û¤F...¤£ª¾¦ó®É¯à¦¨¦æ⋯⋯ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/18 ¤W¤È 08:31:26²Ä 418 ½g¦^À³
|
to ÙçÙç¤j www.cbsnews.com/news/fda-offers-pfizers-hiv-drug-selzentry-new-life-for-all-the-good-it-will-do/ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/17 ¤U¤È 07:54:56²Ä 417 ½g¦^À³
|
to ÙçÙç¤j, content.equisolve.net/cytodyn/media/288c99cb56808c695d4dbf5b9ec8e1bd.pdf |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/17 ¤W¤È 07:42:23²Ä 416 ½g¦^À³
|
¨È·àªºCEO ³Å«iCarl Firth: ¦b¥þ²y«e¤Q¤jÃļtªü´µ¯S±¶§Q±d¡]AstraZeneca¡^¤u§@ªñ¤Q¦~¡A¤S¶i¤J¬üªLÃÒ¨é¾á¥ô¨È¬wÂåÀø²£·~§ë¸êÁ`ºÊªñ¤T¦~¡A³Å«i«Ü²M·¡·sÃĸꥻ¥«³õªº¥ÍºA°_¸¨¡C ¡X¡X¡X¡X¡X¡X¡X¡X- ¤£¥u³Å«i¡A¨È·à±d¥|¦ì³Ð¿ì¤H¤¤¡A¦³¤T¦ì¬Ò¥X¨©óªü´µ¯S±¶§Q±d¡A´¿¦¨¥\±À°Ê®ð³ÝÃĪ«Symbicort¡Bºë¯«¯fÃĪ«Seroquel¡B§ÜÁx©T¾JÃĪ«Crestor¡B¼ìºÅÃĪ«Nexiumµ¥©ú¬PºZ¾PÃĤW¥«¡C ³o¨Ç·sÃIJ£·~¦Ñ±N²`ª¾¡A¦b³o¤@¦æ½×^¶¯¤£¬O®³¨ìÃÄÃÒ¡A¦Ó¬O¦¨¥\¾P°â¨ì¥þ²y¥«³õ¡C¡u¦b¤é¡B´ä¡B¥xµ¥¨È¬w°ê®a¦³«Ü¦h¬ãµoÀu²§ªº¬ì¾Ç®a¡A«o¯Ê¥F±N·sÃÄ°Ó·~¤Æªº¤H¤~¡C¡v¦³¸gÅç¡B¦³¸êª÷¡A³Å«i«H¤ßº¡º¡¡AY·sÃĶ¶§Q®³¨ìÃÄÃÒ¡A¥¼¨Ó¨È·à±d¤]±N´§x¥xÆW·sÃĤ½¥qµL¤O¸gÀ窺¥«³õ¦æ¾P¡C ¡X¡X¡X¡X¡X¡X ¥L³zÅS¡Aªñ¨Ó¤]¦³¥~¸êªk¤H³z¹L¥L¤F¸Ñ¥xÆW¥»¤g·sÃĤ½¥qªº§ë¸ê¾÷·|¡A¦ý©M¥xÆW¥»¤g¤½¥q¬Û¤ñ¡A¨È·à±dÅã±o¡u®e©ö¡v³\¦h¡G¡u°ê»Ú§ë¸êªÌ¬Ý§ÚÌ¡A¬Ý¨ìªº¬O¤@ӹ椦³°ê»Ú¸gÅç¡B»P¤jÃļt¦³±j¯P³sµ²¡C§Ú̦b¥L̲´¤¤¬O¤@®a°ê»Ú·sÃĤ½¥q¡C¡v ¡X¡X¡X¡X¡X ¥v¤WºÀɪº¥~¸ê·sÃĪѨȷà±d¡]ASLAN¡^¡AÄv±o¼Ð¥[Åv§¡»ù¤»¤Q¤K¡D¤E¤G¤¸¡A§C©ó¤½¥qì¥ý¹w´Á¤K¤Q¤K¤¸ªñ¨â¦¨¤§ÃСA©ó2017¦~¤»¤ë¤@¤é¥¿¦¡¦b¥x±¾µP¤WÂd¡C ¦³·s¥[©Y²H°¨¿ü¡B¸ó°ê¤jÃļtÀq§J¡]Merck¡^µ¥ª¾¦W¤jªÑªF¥[«ù¡A¤S´¿®³¤U¤G¡³¤@¤»¦~«×¨È¬w³Ì¨Î¥Í§Þ¤½¥q¤j¼ú. ¡X¡X¡X ¨È·à±dªºÁ`³¡³]¦b·s¥[©Y¡A¦ý·í¦aªÑ¥«¼ö¤¤°l³v¸ê²£ªÑ¤Îª÷¿ÄªÑ¡A´X¥GµL¦PÃþ¤½¥q±¾µP¡F»´äªÑ¥««h¬OÀò§QªùÂen¨D°ª¡F¦ÓY¦b¥þ²y¥Í§Þ·sÃľݥx¬ü°ê¨º´µ¹F§J±¾µP¡A¦bÅb¸s¤§¤¤§óÃø¥H¥YÅã¡F¦¹®É¡Aªñ¦~¤j¤O¹ªÀy¥Í§ÞÂåÃÄ¡B§ë¸ê¤H¿³P«k«k¡BÁ{§É¹ê¤OÀu¨qªº¥xÆW¡A´N¦¨¤Fº¿ï¡C ³o¦¸¨Ó¥x±¾µP¡A³Å«i¦ª¾¹CÀ¸³W«h¤£¦P¡C¡uÂd¶R¤¤¤ßn¨D«Ü¦h¸ê®Æ»P²Ó¸`¡A½T«O§A¬O¤@®a¦n¤½¥q¡A¡v³Å«i»¡¡A¡u¦ý¬ü°êÃÒºÞ·|§óÃö¤ß¤½¥q¦³¨S¦³¾A®É´¦ÅS¸ê°T¡C¡v ¦¹¥~¡A§ë¸êªÌ¹ï·sÃĤ½¥qªºµû¦ô¤]¯Ê¥F³¹ªk¡A¡u«Ü¦h§ë¸êªÌ¥u¬ÝªÑ»ù¡A¨Ò¦p¤¤Q¤¸«K©y¡B¤G¦Ê¤¸¤Ó¶Q¡A¦ý¤£¬ÝªÑ²¼¼Æ¶q»P¥«È¡C¡v¥L«ü¥X¡A³oºØ§ë¸ê¤èªk¤]³\¦³¯q©óµu´Á³ø¹S¡A¦ý«o¤£¯àªø´Á¾Þ§@¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤U¤È 04:58:35²Ä 415 ½g¦^À³
|
·s¥[©Y¬F©²°òª÷¦¨¬°¨È·à±dªº³Ì¤jªÑªF. ¥un¦³¿ú³~¡A¤£©È¨S¦³¿ú! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤U¤È 04:20:53²Ä 414 ½g¦^À³
|
·s¥[©Y²H°¨¿ü(·s¥[©Y100%ªº°ê®a°òª÷)¦¬Áʬù30%ªº¨È·à±d¬ü°êADR 12,660,000¬ü¤¸. ¥Ø«e²H°¨¿ü¨È·à±d6497 ,«ùªÑ¥Ñ6%¼W¥[¨ì10%(16»õ¸ê¥»ÃB) ²H°¨¿ü±±ªÑ¨p¤H¦³¤½¥q¦b²Ä¤G©u«×¦¬ÁʤFASLAN PHARMACEUTICALS ADR REP 5ªº·sªÑ¥÷¡A»ùȬù12,660,000¬ü¤¸¡C 约 30% ªºASLA ADR. ¡X¡X¡X ²H°¨¿ü±±ªÑ¨p¤H¦³¤½¥q¡A²ºÙ²H°¨¿ü±±ªÑ©Î²H°¨¿ü¡A¬O¤@®a·s¥[©Yªº§ë¸ê¤½¥q¡A·s¥[©Y¬F©²°]¬F³¡¹ï¨ä¾Ö¦³100%ªºªÑÅv¡C¥Ñ©ó¨ä¦Û¦¨¥ß°_¨ì2004¦~9¤ë´Á¶¡±q¥¼¤½¥¬¹L°]°È³øªí¡A¦]¦¹³Q»{¬°¬O·s¥[©Y³Ì¯«¯µªº¥ø·~¤§¤@¡C ºû°ò¦Ê¬ì www.temasek.com.sg/en/index.html ¡X¡X¡X¡X¡X- ²H°¨¿ü±±ªÑ¨p¤H¦³¤½¥q¦b²Ä¤G©u«×¦¬ÁʤFASLAN PHARMACEUTICALS ADR REP 5ªº·sªÑ¥÷¡A»ùȬù12,660,000¬ü¤¸¡C Platinum Investment Management Ltd.¦b²Ä¤G©u«×¦¬ÁʤFASLAN PHARMACEUTICALS ADR REP 5ªº·sªÑ¥÷¡A»ùȬù2,532,000¬ü¤¸¡C ³Ì«á¡AMYDA Advisors LLC¦b²Ä¤G©u«×¦¬ÁʤFASLAN PHARMACEUTICALS ADR REP 5ªº·s¾¦ì¡A»ùȬù195,000¬ü¤¸¡C 1.41¢HªºªÑ²¼¥Ø«e¥Ñ¾÷ºc§ë¸êªÌ©M¹ï¨R°òª÷¾Ö¦³¡C Temasek Holdings Private Ltd acquired a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter worth about $12,660,000. Platinum Investment Management Ltd. acquired a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter worth about $2,532,000. Finally, MYDA Advisors LLC acquired a new position in ASLAN PHARMACEUTICALS ADR REP 5 during the second quarter worth approximately $195,000. 1.41% of the stock is currently owned by institutional investors and hedge funds. www.fairfieldcurrent.com/2018/08/15/zacks-investment-research-upgrades-aslan-pharmaceuticals-adr-rep-5-asln-to-buy.html ¡´¨È·à±dªºÀuÂI¤£³ÓªTÁ|¡G 1. Merckªº Alnair Investment(7%)------------------¡´°ê»Ú¤j¼tª½±µ¤JªÑ 2. ·s¥[©Y²H°¨¿ü°òª÷¤Uªº BV Healthcare II(6%)-------¡´¥ý¶i°ê®a¬F©²°òª÷ª½±µ¤JªÑ 3. ¬ãµo¹Î¶¤°}®e°í±j¡A³£¨Ó¦Û°ê»Ú¤jÃļt---------------¡´AstraZeneca, GSK & Novartis.... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/16 ¤U¤È 03:44:05²Ä 413 ½g¦^À³
|
«¼C¤j«e½ú»P²³·à¤Í ·PÁ«¼C¤j¥H«eªº¤À¨É Åý¤p§Ì¦b¾Ç²ß¤¤¦¨ªø ·à¤l·|¨Ï¥Î¨ºÓ¾÷¨î¥[³tÃÄ«~¼f¬d·íµMÃÄ¥H¤½¥q¨Ñ§i¬°¥D, ¤£¹LÁA¸Ñ¬ÛÃöªk³W¤]¯à²¤ª¾¤@¤G A ·sÃĬdÅçµn°O¥[³t®Öã¾÷¨î¡i103.12.12 ³¡±Â¹¦r²Ä1031412602¸¹¤½§i¡j ¬°º¡¨¬°ê¤HÂåÀø¢¤Á»Ý¨D¡A¦b¬ì¾ÇÃÒ¾Úªº¤ä«ù¤U¡A¥H¿ï¾Ü´À¥NÀø®Ä«ü¼Ð¡]surrogate endpoint¡^¤§¤è¦¡¡AÁYµuÃÄ«~¬ãµo¤§®Éµ{¡A¨Ï±oÃĪ«¥i´£¦¤W¥«¡A ¯Sq©w·sÃĬdÅçµn°O¥[³t®Öã¡]accelerated approval¡^¾÷¨î¡C ¾A¥Î¹ï¶H¡G²Å¦X¥H¤U¦U¶µÄÝÃĨƪk²Ä¤C±ø©w¸q¤§·sÃĦV TFDA ¥Ó½Ðµû¦ô«á¡A»{©w¦C¤J¾A¥ÎªÌ ÃÄ«~«ÅºÙ¾AÀ³¯gÀ³²Å¦X¤U¦C±¡§Î¤§¤@¡G ¾AÀ³¯g¬°§Ú°êªºÄY«¯e¯f¡A¥B¸Ó¾AÀ³¯g¨ã¦³Á{§É¤WªºÀu¶Õ¡A¥iº¡¨¬§Ú°êÂåÀø¢¤Á»Ý¨D¡A¥B¨ãÂåÀø¤W¥DnÀu¶Õ¡]major advance¡^ ¾AÀ³¯g¨ãÂåÀø¢¤Á»Ý¨D¡A¥B¦b¤Q¤jÂåÃÄ¥ý¶i°ê¤§¥ô¤@°ê¤w¨ú±o¨uÃÄ»{©w¡]Orphan drug designation¡^ ¾AÀ³¯g¨ãÂåÀø¢¤Á»Ý¨D¡A¥B©ó°ê¤º«DÄݨu¨£¯e¯fÃĪ«¡A»s³y©Î¿é¤J§Ú°ê½T¦³§xÃøªÌ B Ó¤H»{¬°©t¨àÃĨϥΠ¥[³t®Öã¡]accelerated approval ) ©Î conditional approval ( ¥ý®ÖÃÒ¦b¸É°µ¤T´Á, ¤T´Á·|¥Ñ¨ä¥L¤¤¤j«¬¥Í§Þ¤½¥q¨Ó°µ) ªº¾÷·|³Ì¤j ·à¤l¤G´Á¼Æ¾Ú¥XÄl¦pªG¤£¿ùªº¸Ü´N¥i´£¥X¥Ó½Ð ¨Ì¾Ú²Îp¨ì2008¦~¬°¤î¡A¬ü°ê©|¥¼¥X²{¨Ì¥[³t®Öã¨î«×¨ú±oÃÄÃÒ«á³QºM¾PªºÃÄ«~ (°Ñ¦Ò: ±´°Q¬ü°êÄY«¯e¯f¥ÎÃÄ«P¶ipµe (¤W) ¥[³t®Öãaccelerated approval ) C ¨ä¥L¦³Ãö©t¨àÃĪk³W»P²{ª¬¥i°Ñ¦Ò¥H¤U¸ê°T ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0p2bex6j78djq6n0 ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0pcb6rc71fafw3m2&PageNO=1 ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤U¤È 12:24:55²Ä 412 ½g¦^À³
|
to ÙçÙç¤j content.equisolve.net/cytodyn/media/9bb625fefc4872db42ac65d15afea2ae.pdf |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤W¤È 11:27:31²Ä 411 ½g¦^À³
|
viiv ,Fostemsavir 3´ÁÁ{§Éªº¿zÀ˱ø¥óMDR¤¤ ¬¡©ÊÃĪ«OSS<=4 ¡]2 classsx2 fully-active ) Must have ≤ 2 classes with at least 1 but no more than 2 fully-active antiretrovirals remaining which can be effectively combined to form a viable new regimen, based on current and/or documented historical resistance testing and tolerability and safety Antiretroviral-experienced with documented historical or baseline resistance, intolerability, and/or contraindications to antiretrovirals in at least three classes Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients Study Type : Interventional (Clinical Trial) Actual Enrollment : 367 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 Actual Study Start Date : February 23, 2015 Actual Primary Completion Date : August 18, 2016 Estimated Study Completion Date : April 15, 2020 clinicaltrials.gov/ct2/show/study/NCT02362503?show_locs=Y#contacts ©Ò¥H©t¨àÃĸê®æªº¥«³õ¤¤¡A¥un¤£¦PÃĪ«ªº¤À¤l¡A¦p¤p¤À¤lVs¡D¤j¤À¤l¡A¬Ò¥i¨ú±oÃĵýªº¾÷·|¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤W¤È 11:09:22²Ä 410 ½g¦^À³
|
¤@¡BÃö©ó©t¨àÃÄ ©t¨àÃĬO°w¹ï¨u¨£¯e¯f©Î¯f¯gªºÃĪ«²£«~¡C³q¹L1983¦~ªº©t¨àÃĪk³q¹L¬ü°êªk«ß¹ï©t¨àÃĪº¶}µo¶i¦æ¤F¸gÀÙ¤Wªº¿EÀy¡C°ê®a¨u¨£¯e¯f²Õ´¡]NORD¡^¦b»s©w¸Óªk®×¤è±µo´§¤F«n§@¥Î¡A¥Ø«e¦ôp¦³3000¸U¬ü°ê¤H±w¦³7,000ºØ¨u¨£¯e¯f¡C¦b1983¦~ªk®×¤§«e¡A§åã¤F38ºØ©t¨àÃÄ¡C¬ü°ê³Ìªìªº©t¨àÃĪk®×ªº¦¨¥\¨Ï¨ä¦b¨ä¥L¥Dn¥«³õ±o¨ì±Ä¥Î¡A¨ä¤¤³ÌµÛ¦Wªº¬O1993¦~ªº¤é¥»©M2000¦~ªº¼Ú·ù¡C ¨u¨£¯e¯f±wªÌ¤H¸s¦bªk«ß¤¤³Q©w¸q¬°¡G ¡E¬ü°ê¡G<200,000¦W±wªÌ¡]10,000¤H¤¤<6.37¡A°ò©ó¬ü°ê3.14»õ¤H¤f¡^¡E¼Ú·ù¡G10,000¤H¤¤<5¤H¡]<250,000¦W±wªÌ¡A°ò©ó¼Ú·ù¤H¤f514¦Ì¡^ ¡E¤é¥»¡G<50,000¦W±wªÌ¡]®Ú¾Ú¤é¥»¤H¤f128m¡A<10,000¤À¤§4¡^ ªk«ß³W©wªº°]°È¿EÀy±¹¬I¥]¬A¡G ¥«³õ±Æ¥L©Ê ¡E¬ü°ê¡G7¦~ªº§åãÀç¾P±MÀçÅv;ª`·N¡G¤j¦h¼Æ©t¨àÃĨ㦳¶W¹L7¦~ªº½Æ¤è±M§Q¡C ¥«³õ¿W¥e©Êªý¤î¡§¬Û¦PÃĪ«¡¨ªº«²Õ²£«~¡C¡¥*****¤£¦PÃĪ«¤´¥i¦b¬Û¦Pªº¥«³õ¤W¥«******** ¨Ò¦p¡C Fabrazyme¡]Genzyme¡A²{¬°Sanofi¡^»PReplagal¡]Transkaryotic¡A²{¬°Shire¡^¡C¦pªGÁ{§É¤WÀu¶V¡]¥\®Ä/°Æ§@¥Îªº²V¦X¡^¡A¥i¥H±À½¡§¬Û¦PÃĪ«¡¨±Æ°£¡C¨Ò¦p¡C Rebif±À½¤FAvonexªº©t¨àÃıMÀçÅv¡]2002¦~3¤ë7¤é¡^ ¡E¼Ú·ù¡G10¦~ªº§åãÀç¾P±MÀçÅv °§C¬ãµo¦¨¥» ¡E¬ü°ê¡G¬ãµo¦¨¥»50¢Hªºµ|¦¬©è§K ¡E¬ü°ê¡G²Ä¤@¶¥¬q¦Ü²Ä¤T¶¥¬qÁ{§É¸ÕÅ窺¬ãµo¸ê§U¡]2008-12°]¦~¨C¦~3000¸U¬ü¤¸¡^¡E¬ü°ê¡G§K°£¥Î¤á¶O¥Î¡]FFDCA²Ä526¸`¡G¤½¥qWW¦¬¤J<5000¸U¬ü¤¸¡^ info.evaluategroup.com/rs/607-YGS-364/images/EPOD17.pdf ¤G¡BTMB-Bispecific ¡A¦ó¤j¤@³Õ¤h©Ò°µ °Ñ¦Ò¤åÄm Huang Y., et al. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell 2016, 165; 1621. ¦³¹êÅç«Ç¤¤ªº¦UºØHIV¯f¬r§í¨î剤ªº§ÜÃĩʮįà¤ñ¸û¡A¤Wºô§ä´N¦³. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤W¤È 10:53:59²Ä 409 ½g¦^À³
|
An orphan drug is a pharmaceutical product aimed at rare diseases or disorders. The development of orphan drugs has been financially incentivised through US law via the Orphan Drug Act of 1983. The National Organization for Rare Disorders (NORD), which was instrumental in establishing the Act, currently estimates 30 million Americans suffer from 7,000 rare diseases. Prior to the 1983 Act, 38 orphan drugs were approved. The success of the original Orphan Drug Act in the US led to it being adopted in other key markets, most notably in Japan in 1993 and in the European Union in 2000. Rare Disease Patient Populations are Defined in Law as: ¡E USA: <200,000 patients (<6.37 in 10,000, based on US population of 314m) ¡E EU: <5 in 10,000 (<250,000 patients, based on EU population of 514m) ¡E Japan: <50,000 patients (<4 in 10,000 based on Japan population of 128m) Financial Incentives by Law Include: Market Exclusivity ¡E USA: 7 Years of marketing exclusivity from approval; Note: Majority of orphan drugs have a compound patent beyond 7 years. The market exclusivity blocks ¡¥same drug¡¦ recombinant products. E.g. Fabrazyme (Genzyme, now Sanofi) vs. Replagal (Transkaryotic, now Shire).¡¥Same drug¡¦ exclusion can be overturned if clinically superior (mix of efficacy/ side effects). E.g. Rebif overturned Avonex¡¦s orphan drug exclusivity (7 MAR 2002) ¡E EU: 10 Years of marketing exclusivity from approval Reduced R&D Costs ¡E USA: 50% Tax Credit on R&D Cost ¡E USA: R&D Grants for Phase I to Phase III Clinical Trials ($30m for each of fiscal years 2008-12) ¡E USA: User fees waived (FFDCA Section 526: Company WW Revenues <$50m) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤W¤È 09:05:02²Ä 408 ½g¦^À³
|
«¼C¤j, ¨È·à±d ¤@¡BASLAN001 ÁxºÞÀù2 缐,FDA ©t ¨àÃĵý. FDA ¨ú±o2´Á120¤H(60:60)¼Ï¶sÁ{§É ,¥Dn«ü¼ÐORR/PFS FDA ¨ú±o2´Á68¤H,³æÁu OPEN LABEL ¼Ï¶sÁ{§É ,¥Dn«ü¼ÐORR ¥H¤W¥Dn«ü¼Ð¹LÃö(P<0.05 or ¤¤°êORR¤@©w% ),´N¤¹³\¥Ó½ÐÃĵý. FDA ³¡¤À¦pMBC ªºIBRANCE ¥Î¤G´Á¥Ó½Ð¥[³t¼f¬d¡A2015¦~®Ö·ÇÃĵý,2018¦~3´ÁÁ{§É¸ÕÅ秹¦¨. ¡X¡XASLAN001 ÁxºÞÀù 2½u,3´ÁÁ{§É¥t¥[350¦W,2/3´Á¦@470¤HªºÁ{§É¡AÁÙ¬On°µ.¡X- ±N³°Äò¥Ó½Ð FDA Àu´f 1 Fast Track 2 Break Through Therapy 3 Accelerated Approval 4 Priority Review ¥Ñ2014¦~ªº³ø¾É¥iª¾:°e¥ó¥Ó½Ð¬ü°êFDAÃĵý¥ª¥k¡A¥ç¥Ó½Ð§Ö³t¼f査¡BÀu¥ý¼f¬d¡C ¦ÓBTD¥¿±`¤]¬O¥H2´ÁÁ{§É¸ÕÅç¸ê®Æ¥Ó½Ð. ¡X¡X¡X- ´¼Àº¯ØŦÀùÃĪ«PEP02¡]§Y±ÂÅv¼t°ÓMerrimackªºMM-398¡^¡A¹wp¥»¤ë»P¬ü°êFDA·¾³q¡A±ÂÅv¼t°ÓMerrimack³W¹º9¤ë°e¥ó¥Ó½Ð¬ü°êFDAÃÄÃÒ¡A§Æ±æ³z¹L§Ö³t¼f¬d©ÎÀu¥ý¼f¬d¤è¦¡¡A·m¦b¦~©³¨ú±oÃÄÃÒ¡Cªk¤H¹w¦ô¡AYMM-398¶¶§Q¦b¤µ¦~¨ú±oÃÄÃÒ.... ·sÃÄ°e¼f¡@¥x¼t¨u¯f¥ÎÃÄ¿ú´º¦n Áp¦X³ø¡þ2014.07.09¡þ°OªÌ©P¤p¥P¡þ¥x¥_³ø¾É www.tfrd.org.tw/tfrd/library_d/content/id/960 ¤G¡BASLAN001 GÀùÀù1 缐,FDA ©t ¨àÃĵý «¼C¤j ½Ð°Ý±z6¦~«e§ë¸ê4147®É ¡AÀ³¸Ó¤]µLBTD⋯¥|¶µÀu´f¡A¦p¦ó¤U§ë¸ê¨Mµ¦? 1 Fast Track 2 Break Through Therapy 3 Accelerated Approval 4 Priority Review |
|
|
·|û¡G«¼CµL¾W10030199 µoªí®É¶¡:2018/8/16 ¤W¤È 08:27:08²Ä 407 ½g¦^À³
|
2018.08.16 ¥Ñ©ó¤w¹LµÛ¤s¶³³¥Åbªº¥Í¬¡¡A°h¥X¦¿´ò¤[¨o¡A¨S¦³¨º»ò¥Î¥\¤F¡C ´X¦ìºô¤Í¡A³£¬O§V¤O¾\Ū§ä¸ê®Æ¤§¤¤¡A ©Ò¥H¡A ¸Û¤ß&µê¤ß ½Ð±Ð¤@¤U¡G (¤Ñ©R¡B¥xÁÞ¡B¡B¡B) FDA ¦³¥|¶µ±`¨£ªºÀu´f/ªÖ©w/¼úÀy : 1 Fast Track 2 Break Through Therapy 3 Accelerated Approval 4 Priority Review ¨È·à±d¡A¤À§O¦³¨º´XÓÃÄ«~ trial ¡A¨ú±o¨º´X¶µªº Àu´f©O ? §Ú¦³¤W¨È·à±dªº¾ú¥v«°T¬d¡A ¨S¦³¬Ý¨ì¡C ©Ò¥H½Ð±Ð¤@¤U¡C ·PÁ ! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/16 ¤W¤È 07:54:11²Ä 406 ½g¦^À³
|
¤Þ¥Î²q·Q¤j¶K³ø&¤ß±o ·s¾÷Â઺¬ã¨s¤j¦h¨Ó¦Û¤@¤p¸sªº³Õ¤h¤p¤½¥q¼Æ¦~¡Ð¼Æ10¦~ªº®É¶¡¬ã¨s¡A¨Ó¦Û¤jÃļtªº·s¾÷Âà¤Ö. ¡X¦p¥xÆW¤¤¬ã°|ÁÞ¤À¤lªº¬ã¨s´N¥@¬ÉÄݤ@ÄݤG. ¤jÃļt¬°¼W¥[²£«~½u©Ò¥H¥|³B§ä´M¤Wz¤p¤½¥qªº¬ãµoµ²ªG¡A¦Ó¥Î±ÂÅv¤è¦¡¨Ó¨ú±oÁ{§É¡B¤Î¥þ²y¾P°âÅv. ¤p¤½¥q´N¬O¨S¿ú¥i¿NÁ{§É¡B¦æ¾P©Ò¥H±ÂÅvµ¹¤j¼t¡C ©Ò¥H¾Ú²Îp¦X§@¥æ©ö®×¤¤¡A¦³93%ÄÝ©ó±ÂÅv¼Ò¦¡. ¡X¡X- ¡X¡X¡X¡X¡X¡X¡X¡X ·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/16 ¤W¤È 07:29:22²Ä 975 ½g¦^À³ ·sÃĤ½¥q§ä¥X¸ô ®ü¥~¶Ò¸êÉq 2018¦~08¤ë16¤é 04:10 ¤u°Ó®É³ø ¤å¡þ½²²Qªâ www.chinatimes.com/newspapers/20180816000610-260210 ¶Ô·~²³«H¥Í§ÞÂåÀø²£·~t³d¤H¸·¦¨¥þ¤]Æ[¹î¨ì¡A¨Ã¤£¬O¥þ³¡·sÃĤ½¥q³£·|¨ì®ü¥~¡Au®ü¥~±¾µPªº¤½¥q¤j³¡¤À³£°µ¨ì²Ä¤T´ÁÁ{§É¹êÅç¡A¦]¦¹¡A¤Ï¦Ó¬O¬°§Ú°êª§¥ú¡A¦P®É¤]¥i¥HÀ°¦£§Ú°êÁÈ¥~¶×¡C ¸·¦¨¥þ¤ÀªR¡A¥Í§Þ»sÃĤ½¥qªºµo®i¡A³q±`¥i³z¹L±ÂÅv¡B¨ÖÁÊ»P¦X¸ê¤TºØ¦X§@¥æ©ö¼Ò¦¡¨Ó´M¨D«´¾÷¡AÀò¨ú³Ð·sªº¬ãµo¸ê·½¡A±À°Ê²£«~¶i¤J¥«³õ¡C®Ú¾ÚDeloitte½Õ¬d¡A¥Ø«e¥þ²y¥«³õ¤Wªº¦X§@¥æ©ö®×¨Ò¤¤¡A¦³93¢HÄÝ©ó±ÂÅv¼Ò¦¡¡B6¢H¬O¨ÖÁÊ¡A¦Ó¦X¸ê¶È¥e1¢H¡F»OÆWªº±ÂÅv®×¼Æ¶q¥¿¼W¥[¤¤¡A³vº¥ªï¤W°ê»ÚÁͶաC¸·¦¨¥þ«Øij¡A¥ø·~»Ý¥ýÂç²M¦Û¨¤½¥q¥¼¨Ó¤¦~ªºÀç¹B¤è¦V¤Î¾ãÅé°]°È³W¹º¡A¦A®Ú¾Ú¤½¥q¥þ±ªºÀç¹B¦Ò¶q¡A¤~¯à¶i¤@¨B§ä¨ì¾A·í¼Ðªº»P¦X§@¹Ù¦ñ¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/15 ¤U¤È 10:16:22²Ä 405 ½g¦^À³
|
¤G½uÁxºÞÀù®Ú¥»¨S¦³®Ö㪺ÃÄ¥i¥Î ,³oºØ°Æ§@¥Î§Cªº¼Ð¹vÃĤ@¦ý³Q¤¤°ê»P¬ü°êFDA®Öã,·|³Q¦C¤J¤G½uÁxºÞÀù¼Ð·Ç¥ÎÃÄ Ó¤H¬ã§P¤¤°ê¦³¾÷·|¦b2019¤U¥b¦~®ÖãÃÄÃÒ ¦]¬°¤¤°ê¦bÁ{§É¼f¬d»PÃÄÃÒ¼f®Ö°µ¤F¤j´T«×§ï®æ¥[¤W©t¨àÃÄ»PµLÃÄ¥i¥Î±¡ªp¤U¼f¬d³t«×·|«Ü§Ö ¬ü°êFDA¦³¾÷·|¦b2020¤W¥b¦~®ÖãÃÄÃÒ (²z¥Ñ©t¨àÃÄ»PµLÃÄ¥i¥Î±¡ªp¤U¼f¬d³t«×·|«Ü§Ö) ¥H¤WÓ¤H¤À¨É ¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤U¤È 05:02:20²Ä 404 ½g¦^À³
|
1. FDA ¥Î166¤Hªº¤G´ÁÁ{§É®Ö·ÇMBC her2¡Ð, www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000SumR.pdf ¤W¥«²Ä¤G¦~¬ü°ê½æ20»õ¬ü¤¸ ½Ö説120¤Hªº¤G½uÁxºÞÀù¡AY¨úÃĵýÂå¥Í¤£´±¥Î! ¡X¡X¡X¡X JACKY WU10147205 µoªí®É¶¡:2018/8/14 ¤W¤È 01:36:41²Ä 381 ½g¦^À³ ¥xÁÞ¤j¤j¡C ¬Ý¬Ý4147±z´Nª¾¹D©t¨àÃÄ¡A³Ð·sÀøªk¡A§Ö³t¼f¬d®³¨ìÃÄÃÒ¡AÂå¥Í¤£´±½T«HÃĮijB¤èñ¶}¤£¥X¨Ó¡Aªì´Án¥Î¸Õªº¡Aµ¥±wªÌÀËÅç¼Æ¾Ú¥X¨Ó¡A¦p½T»{¦³®Ä¤~·|Ä~Äò¶}¥ß³B¤èÅÒ¡A¥i¬O4147¥Ø¼Ð¬OµLÃÄ¥iÂå¡]¹ï©Ò¦³¾÷Âà§ÜÃÄ©Ê¡^¡A¥«³õ³Ì¤p¡A³£¤w¸gGG¤F¡A¤£n¤Ó¼ÖÆ[¤F¡AÂå¥Í·|¬Û«H120¤H¼Ï¶s¸ÕÅçµ²ªG¡A©^ÄU¤j¤j¤T´ÁÁ{§É¬O¤@¤À¿ú ¤@¤À³f¡A¦Ó¥B³o¨Ç¯f¨Ã«Dµ´¯g¡An¥´¤J¥«³õ¨Ã«DµL¥i¨ú¥N¡A¨äÀ禬¦p¤Ñ©R¤j©Ò¨¥¤W¦Ê»õ¡A¯uªº«ÜÃø¡A´Nºâ¯à¹F¨ì90´X%ªºÀ禬³£¸¨¤Jt³d¦æ¾Pªº¤jÃļt¡A·à¤l¯à®³¦h¤Ö¡A°Ñ¦Ò¤¤¸Î»¡ªk¡A¥L̤]°Ý¹L°ê¥~¤jÃļt¡A´N¬O¦]¬°³o¨Ç¤j¼t¶}µ¹¤¤¸Î¤À¼í«Ü§C¡A©Ò¥H¤~·|±ÂÅv¤pÃļt¡A©Ò¥H¤j¼t¤À¼í§C¥u¯àÁÈÃÄ«~¥Í²£¥N¤u¶O¡A¤pÃļt¤À¼í°ªÃĽ椣¥X¥h¡Aµ²ªG¬O¤@¼ËµLªkÁȤj¿ú¡A©Ò¥H³£GG¤F¡A©^ÄU¤£n¤Ó¼ÖÆ[ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤U¤È 04:16:23²Ä 403 ½g¦^À³
|
To :ªì¶i¤J·sÃÄ»â°ìªº§ë¸êªÌ: ¤Þ¥Î«¼C¤jªº´£¿ô ¡¥======================= µ½·N´£¿ô±z¡A§ë¸ên¶q¤O¦Ó¬°¡C ©Ò¿×¶q¤O¡A¤@«h¥]¬A¦Û¤vªº°]¤O¡C¤@«h¥]¬A¦Û¤vªº¥\¤O¡C´`§Çº¥ªñ¡A¾Ç¤£÷aµ¥¡C ²z°] & §ë¸ê¡A¬Oȱo²¦¥Í²×¥Í×½mªº¥\½Ò¡C ´`§Ç¡@: ©w¦s ¡÷ ©w®ÉÃB°òª÷ ¡÷ ©w¦s¬J©ÀªÑ¥x¿n¥x¶ì¤¤µØ¹q«H ¡÷ ¦¨ªøÁZÀuªÑµØºÓ ¡÷ ?? ¡÷ °ªÀô´`ªÑ«n¨È¬ì°ê¥¨¡@ ¡÷¡@¡÷¡@ ·sÃÄÃþªÑ¡C ·sÃÄÃþªÑ¤w¬O²`¤ô°Ï¡A°ª§Q¼í&°ª·ÀI¡A¨Ã¤£«Øij ªì¶¥§ë¸ê¤H ¡A¥S¥xÀ³¦h¥[·r°u¡C ¶q¤O ¦Ó¬°¡C ¤£¯à¾aµÛ¡@ºô¸ô½×¾Â¡A¤u°Ó¸gÀÙ¤é³ø¡B²Ä¥|¥x¡B°Ý°Ý«¼C¡B¡Bµ¥¡A´N¶TµM±q¨Æ§ë¸ê¤]¡C no-armed ¤W¾Ô³õ ! ªþ±a¤´¬Oµ½·N¤@´£¡A¥H§Ú¤k¨à¬°¨Ò¡Aª÷¿Ä¬ÛÃö¬ì¨t²Ä¤@¾Ç©²²Ä¤@§ÓÄ@¡A貦·~¡F¥B¦h¦~¨Ó¹ï·sÃÄÃþªÑ¦ÕÀá¥Ø¬V ¡÷ ¦b¦¹Àô¹Ò¤U¡A§Ú¤´¬OÅý¦o̧ë¸ê¡G©w®ÉÃB°òª÷¡B¥x¶ì¡B¡Bµ¥©w¦s·§©ÀªÑ¡C¡@¡@«Ý¥\¤O°ö²`«á¡@¡÷¡@¦A¶i¤J¡@²`¤ô°Ï¡C ¡¦=================================== ¦b¬ü°ê·sÃĬO§ë¸ê¾÷ºc¤~´±§ë¸êªº¼Ðªº¡A´²¤á¤Ö¡C ·ÀI¬Û·í¤j¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤U¤È 04:07:18²Ä 402 ½g¦^À³
|
¨È·àÁÙ¦b¿N¿ú¶¥¬q¡A¨S¤H¦b¬Ýeps. , ¨È·à¦b¬ÝÁ{§É¼Æ¾Ú. ASLAN001 ¯à§_¨ú±oÁx¹DÀù¤G缐Ãĵý ASLAN003¦åÀùªº±ÂÅv»ùÈ ASLAN003 ¤¤««×²§¦ì©Ê¥Ö½§ª¢¡Bý³Ýªº¦Ê»õ¬ü¤¸ªºÁ{§É¶i«×¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2018/8/15 ¤U¤È 03:56:53²Ä 401 ½g¦^À³
|
Hi ¤Ñ©R www.fairfieldcurrent.com/2018/08/14/aslan-pharmaceuticals-adr-rep-5-asln-receives-average-recommendation-of-buy-from-analysts.html ¬°¤°»ò Zacks Investment Research ·|¹w´ú the company will post ($0.34) earnings per share for the current quarter?? ¬O¤°»ò³y¦¨¦¹±À´ú? PS. ¤j³¡¤À°ê¥~§ë¸ê¾÷ºc¹w´Á ASLAN ADR target $12 ¥ª¥k¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤U¤È 12:44:32²Ä 400 ½g¦^À³
|
·sÃĪº¥»¹Ú¤ñ±`µo¥Í¦b®³¨ìÃĵý¡A¤W¥«¶}½æªº²Ä¤@©u¤º¡C ¤W¥««á´N¥Ñ¥¼¨Ó¥»¯q¤ñ¼vÅTªÑ»ù! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤U¤È 12:07:22²Ä 399 ½g¦^À³
|
ª©¤Wªº«¼C¤j,¥i¥H©ê6¦~ªº4174·sÃÄªÑ 40¦h¤¸©ê¨ì¥Ø«e240¤¸. ¬O§Úªº¾Ç²ß¹ï¶H. ¥Lªº¦W¨¥n®³Ãĵý¬ÝFDAªºÀ°¦£¦³¦h²` BTD/©t¨àÃÄ(§Ö³t¼f¬d).... ¦p¤µ¯à¥Î2´Á¼Æ¦r¥h¥Ó½ÐFDAÃĵýªºASLAN001. ¼ç¦b»ùȤΪø©ê»ùÈ,¦p¦ó? |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/8/15 ¤W¤È 11:25:29²Ä 398 ½g¦^À³
|
¨È·à±d ¦³±æ«ì´_«H¥Î¥æ©ö ²Ä2©u°]³ø¥XÄl¡A¾Ú²Îp¥x²î¡]2208¡^¡B¤é³Ó¥Í¡]2547¡^µ¥9ÀÉӪѡA²Ä2©u¨CªÑ²bȦ^¨ì²¼±10¤¸¥H¤W¡A¦³±æ«ì´_«H¥Î¥æ©ö¡F¥t¤]¦³¶§©ú¡]2609¡^¡Bªø¶é¬ì¡]8038¡^µ¥7Àɲbȱ¼¨ì²¼±¥H¤U¡A®£¾D¨ú®ø«H¥Î¥æ©ö¡C ±©ÃÒ¥æ©Ò±j½Õ¡A±N¨Ì¾Ú¡u¦³»ùÃÒ¨é±o¬°¿Ä¸ê¿Ä¨é¼Ð·Ç¡v²Ä4±ø¤Î¡uÃÒ¨é°Ó¿ì²z¦³»ùÃÒ¨é¶R½æ¿Ä¸ê¿Ä¨é·~°È¾Þ§@¿ìªk¡v²Ä22±ø¤Î²Ä23±ø³W©w¡A¼f®Ö¤W¥«¤½¥q¤½§i¨Ã¥Ó³ø²Ä2©u°]°È³ø§i¨CªÑ²bȸê®Æ¡A¦A¹ï¥~«Å¥¬²Å¦X¼È°±»P«ì´_¿Ä¸ê¿Ä¨é¥æ©ö½Õ¾ã¦W³æ¡C ÃÒ¥æ©Ò¹wp¤U©P¤G¡]21¡^¤é«Å¥¬³Ì«á½T©w¦W³æ¡A¨Ã©ó¹j¤é©P¤T¥¿¦¡¹ï¥~¹ê¬I¡C¦Ü©ó¤WÂdªÑ²¼±¡ªp¤]»P¤W¥«ªÑ²¼¤@¼Ë¡C³Ì«á¥i¯à«ì´_¤Î¨ú®ø«H¥Î¥æ©ö¦W³æ¡A±N¥HÃÒ¥æ©Ò¤ÎÂd¶R¤¤¤ß¤½§i¬°·Ç¡C ¤W¥«Âd¤½¥q²Ä3©u°]³ø¤w©ó¬Q¤éºI¤î¤½§i¡A¾Ú²Îp¡A¤jªF¡B¥x²î¡B¤é³Ó¥Í¡B¥¿¼w¡BøÊÀsÄË¡Bõ©T¡B¥x«n-KY¡B¤¬»õ¡B¨È·à±d-KYµ¥9ÀÉӪѡA¨CªÑ²bȧ¡¦^¤É¦Ü²¼±10¤¸¥H¤W¡C ¨ä¤¤¡A¤jªF¡Bõ©Tµ¥§¡¦]²Ä2©u¥ÑÁ«Âà¬Õ¡A±a°Ê¨CªÑ²bȦ^¤É¡A¨ä¤¤¡A³Ì¨üÃöª`ªº¬O¡A¤jªF²Ä2©u¨CªÑ¤jÁÈ15.3¤¸¡A¨CªÑ²bȱq²Ä1©uªº6.57¤¸¡A¼É½Ä¦Ü21.11¤¸¡F¥x²î«h¦]¿ì²z²{ª÷´î¸ê«á¡A²bȱq²Ä1©u©³ªº7.38¤¸¡A¤j´T¼u¤É¦Ü20.56¤¸¡C ¦¹¥~¡A¨ì²Ä2©u©³¤î¡Ai¥ú¡B¶§©ú¡BÃh¯S¡B¥Ã©ý¡B¤ÓªY¡Bªø¶é¬ì¡BµØÁâøʵ¥7ÀÉӪѡA¨CªÑ²bȦ]²Ä2©uÁ«·lµ¥¦]¯À¡AP¶^¸¨¦Ü²¼±10¤¸¥H¤U¡A¤]±Á{¾D¨ú®ø«H¥Î¥æ©öªº©R¹B¡C ¦pªG¦¨¯u¡A³o¼Ëéw·àªº¦¨¥æ¶q±N·|¾ãÓ¤j¤j´£°ª¡A¦³¶q¤~¦³»ù¡A·Pı¦¨¯u´N¬O¤@Ó¤j§Q¦h! ¤j®a¥i¥H°Ñ¦Ò¬Ý¬Ý! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/15 ¤W¤È 11:11:52²Ä 397 ½g¦^À³
|
·à¤l«á¦³´©§L: ·à¤l±ÂÅvBMS¨È¬w°ÏÅv§Q Àu¤Æ°]°Èª¬ªp BRISTOL-MYERS SQUIBB 2016¦~ 8¤ë ¦V¨È·à±d¦¬ÁÊ ASLAN002 (BMS777607) ¨È¬w°ÏÅv§Q ASLAN002 ¬°RON ¤Î cMET ¨üÅé¹TÓi»Ä¿E酶ªº±j®Ä§í¨î¾¯ ¨È·à±d¤w¦¬¨ú 1,000 ¸U¬ü¤¸Ã±¬ùª÷ ( ¤w¤J³U) ¥¼¨Ó¦A¦¬¨ú¹O 5,000 ¸U¬ü¤§¨½µ{ª÷ ( ª÷ÃB¤ñ¬ü°êADR ÁÙ¦h) ¥¼¨Ó¦A¦¬¨ú¥H ASLAN002 ¥þ²y¾P°âª÷ÃB©Ò´£¨úªºÅv§Qª÷ ( ¤ñ²v¦h¤Ö¨S¦³¤½§G) ©Ò¦³¶}µo»P°Ó«~¤Æªº¶O¥Î«h¥Ñ BMS t¾á¡C ( ¤jÃļtªá¿ú¶}µo ) BMS ¦¬ÁÊ ASLAN002 Àu¤Æ·à¤lªº°]°Èª¬ªp www.aslanpharma.com/app/uploads/2016/08/160810-Press-release-BMS-reacquires-ASLAN002-%E4%B8%AD%E6%96%87%E7%89%88.pdf ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤W¤È 10:53:55²Ä 396 ½g¦^À³
|
¤Å·N! ¤Å¥²! ¤Å©T! ¤Å§Ú! ¾P°â¼Æ¦r«n©Ê= 3´ÁÁ{§É¸Ñª¼PȹL¤£¹LÃö(´N¹³¯E¹©/°ò¨È¸Ñª¼PÈ¥¼¹LÃö¤§ºG¯P!) ¼vÅT¾P°âªº¦]¯ÀÀH®É¦bÅÜ. ªÑ»ù¤ÏÀ³¾P°â¦¨¿¦¬Û·íµL±¡! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤W¤È 09:56:24²Ä 395 ½g¦^À³
|
ASLAN001³o¬O¥Î2´ÁÁ{§É¼Æ¾Ú¨ú¬ü°êN=120¤H¤Î¤¤°êÃĵýªºN=68¤HÁ{§É. ¬O©t¨àÃĨɧֳt¼f¬d. ¦b¥xÆW¥Ø«e¬O°ß¤@¥Î2´ÁÁ{§É¼Æ¾Ú¾Ú¨ú¬ü°êÃĵýªº¼Ð¹v¥ÎÃÄ. ----------- ¤µ¦~©³¨ú±o¤¤°ê¼Ï¯Ã(¥i¥Ó½ÐÃĵý)68¤H ,³æÁu,open label ,ÁxºÞÀù2½u¥Dn«ü¼ÐORR. ©ú¦~¤¤«e¨ú±o¬ü°êFDA¼Ï¯Ã(¥i¥Ó½ÐÃĵý)120¤H,¤ºÞÀù¥Dn«ü¼ÐORR¤ÎPFS. ªÑ»ùÁÙ¦b¶W§CÂI. ¤½¥q¤G缐ÁxºÞÀù¥«³õ14»õ¬ü¤¸,Yº¯³z²v50%,¤]¦³7»õ¬ü¤¸. ¤W¥««áªÑ»ù¥«Èx3¿=21»õ¬ü¤¸.¡X¡X¬Û·í©ó¥Ø«eè¤W¥«41xx ¹wp2020¦~¨ú±oÃĵý. ³oºØ¼Ð¹vÃĪ« PK ¤ÆÀøÃĪ« ©ó¤G缐ÁxºÞÀù 1b Á{®ÉªºORR 20%(arq087 N=29 &aslan001 N=15vs. 2%~3%(³æÃĤÆÀø,¤åÄm) MPFS 6Ó¤ë (arq087) vs. 1.8~2.6Ó¤ë¡]³æÃĤÆÀø¤åÄm) ¼Ï¯Ã¹LÃö¾÷²v¬Û·í°ª |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤W¤È 07:48:35²Ä 394 ½g¦^À³
|
´¼Àº2011¦~°µ§¹¯ØŦÀù2½u2´ÁÁ{§É«áªº3´ÁÁ{§É¤Î¼Ú¬w¡Ï¥xÆW¦a°Ï¾P°â±ÂÅv¦X¬ù¤@2.2»õ¬ü¤¸. ¥Ø«eªÑ»ù136, ¥«È200»õ¥x¹ô, ªÑ»ù³Ì°ª355¤¸¡X-2014¦~5¤ë«Å¥¬3´ÁÁ{§É¤@¤@¦w¯à±o ¥Dn«ü¼Ðos ¹L関. ©M¹ï·Ó²ÕPKMOS6.1¤ëVs.4.2¤ë¼W¥[1.9¤ë, PÈ<0.014 ªÑ»ù2011¦~11¤ë¦¬©³60¤¸(ñ±ÂÅv¦X¬ù) ´Á¶¡º¦6¿. ¨È·à±dASLAN001 ,¤µ¦~¤¸¤ë¥ç§¹¦¨3´ÁÁ{§É¤Î¥þ²y¾P°â±ÂÅv, ¤µ¦~©³¨ú±o¤¤°ê¼Ï¯Ã(¥i¥Ó½ÐÃĵý)68¤H ,³æÁu,open label ,ÁxºÞÀù2½u¥Dn«ü¼ÐORR. ©ú¦~¤¤«e¨ú±o¬ü°êFDA¼Ï¯Ã(¥i¥Ó½ÐÃĵý)120¤H,¤ºÞÀù¥Dn«ü¼ÐORR¤ÎPFS. ªÑ»ùÁÙ¦b¶W§CÂI. ¤½¥q¤G缐ÁxºÞÀù¥«³õ14»õ¬ü¤¸,Yº¯³z²v50%,¤]¦³7»õ¬ü¤¸. ¤W¥««áªÑ»ù¥«Èx3¿=21»õ¬ü¤¸.¡X¡X¬Û·í©ó¥Ø«eè¤W¥«41xx ¹wp2020¦~¨ú±oÃĵý. ³oºØ¼Ð¹vÃĪ« PK ¤ÆÀøÃĪ« ©ó¤G缐ÁxºÞÀù 1b Á{®ÉªºORR 20%(arq087 N=29 &aslan001 N=15vs. 2%~3%(³æÃĤÆÀø,¤åÄm) ORR 6Ó¤ë (arq087) vs. 1.8~2.6Ó¤ë¡]³æÃĤÆÀø¤åÄm) ¼Ï¯Ã¹LÃö¾÷²v¬Û·í°ª. ªÑ»ùÁÙ¬On¦³¤j¤H¥h·ÓÅU¤~¤ñ¸û²Å¦X¸Ó¦³»ùÈ¡A亜·à±d¶WÈ´NºCºCµ¥¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/15 ¤W¤È 06:56:45²Ä 393 ½g¦^À³
|
²§¦ì©Ê¥Ö½§ª¢¤§¤¶²Ð tw.news.yahoo.com/²§¦ì©Ê¥Ö½§ª¢Äo¤Sµh-Âå®v«Øij-«O«ù¥Ö½§°®Àê-070000188.html ³\¦h¤H¥H¬°²§¦ì©Ê¥Ö½§ª¢¬O¥®¨à±MÄݯe¯f¡A¦ý¹ï©ó30¦h·³ªº¤pªL¨Ó»¡¡A««×²§¦ì©Ê¥Ö½§ª¢Äñ¨¦h¦~¡A©{¦p¤@³õ´c¹Ú¡C¥~ªí¯gª¬¦³¦p°®Å~¡A¥Ö½§ªx¥X¬õ¯l¡A¯gª¬ÄY«®É¡A³sÁy³¡¦Ù½§³£ªø¥X¬õ´³¡B¥Ö®h¡A¥¨Äo¥[¤W¯kµh¡AÅý¥Lªñ´X¦~¨ÓµLªk¦n¦nºÎı¥ð®§¡A¤]¤£¤Ó´±¥~¥X¡B»P¤H¤¬°Ê¡C ¤¤¤sÂå¾Ç¤j¾Çªþ³]Âå°|¥Ö½§¬ì¥DªvÂå®v¿à¬f¦p«ü¥X¡A¤j³¡¤À²§¦ì©Ê¥Ö½§ª¢±wªÌ¬°2·³¥H¤Uªº¥®¨à¡A®ð·Å¤@°ª¥þ¨¬y¦½¡A´N·|ªø¥X¬õ¯l¡A¤p¤â¤@§ì´N¯}¥Ö¡Bº¯¦å¡F¤£¹L¡A¤´¦³2¦¨ªº²§¦ì©Ê¥Ö½§ª¢±wªÌ¬°¦¨¦~¤H¡C°·«O¸ê®ÆÅã¥Ü¡A¥xÆW¨C¦~¬ù¦³15¸U¦W20¦Ü49·³¦¨¤H¦]²§¦ì©Ê¥Ö½§ª¢¦Ó´N¶E¡AÁ{§ÉÆ[¹î¡A¨C4¦W¦¨¤H±wªÌ¤¤¡A´N¦³1¤H¬Oªø¤j¤§«á¤~µo§@¡C ¿à¬f¦p»¡©ú¡A´X¥G¨CÓ¤H³£Å¥¹L²§¦ì©Ê¥Ö½§ª¢¡A¦ýÁ`»{¬°³o¨Ã«DÄY«ªº¥Ö½§¯e¯f¡C¨Æ¹ê¤W¡A²§¦ì©Ê¥Ö½§ª¢¥i¤À¬°»´¡B¤¤¡B«µ¥3¯Å¡A¦pªG¨ì¤F¤¤««×¡A±wªÌ·|¦]ªø´Á·kÄo¦Ó¥¢¯v¡A¥B¥Ö½§¯gª¬¥O¤HÃø³ô¡BÃø¨ü¡A¼vÅTªÀ¥æ¡B¨D¾Ç¡B¥Í¬¡¤Î¤u§@µ¥¤H»Ú¤¬°Ê¡C ¡uÄo¡v¬O²§¦ì©Ê¥Ö½§ª¢ªº¯S¼x¤§¤@¡A±wªÌµo§@®É¥Ö½§©_ÄoµL¤ñ¡A·k§ì«á¥Ö½§·|¶}©l¯}¥Ö¡B±¼®h¡B¬yÁw¡A¤§«áµ²¯m¡B¼W¥Í«p¥Ö¡A¦Ó¥~Æ[§e²{¬õ¶Â¦â¡C°£¤FÄo¤§¥~¡A²§¦ì©Ê¥Ö½§ª¢¦¨¤H±wªÌªº¥t¤@Ó§xÂZ´N¬OµLªkÂ_®Ú¡A¥BµL¹wĵªº¤ÏÂеo§@¡Aª¬ªp¦n®É¡A¥Ö½§¯gª¬¥i¯à¥u¬O°®Àê¡A¤@¥¹´_µo¡A¥Ö½§¯f¨_µo¬õ¡A¥B¦ñÀH·¥«×Äo·P¡C ¿à¬f¦p¸ÑÄÀ¡AºC©Ê¤ÏÂеo§@ªº¥Ö½§µoª¢¡B¦Ù½§¼@ÄoÅý¤H¤ÏÂзk§ì¡BÀY³¡¨âÀU©M¥|ªÏ¥X²{¬õ¯l¡BÓ¤H¤Î®a±Ú¦³¹L±ÓÅé½è¡A¥un²Å¦X¤Wz¯gª¬¡A´N¥i½T¶E¬°²§¦ì©Ê¥Ö½§ª¢¡C»´«×¯gª¬³z¹LÃĪ«¤Î¥~¥ÎÃÄ»I´N¥i±±¨î¯f±¡¡A¦pªG¬O¤¤««×¡A«h¥²¶·×´_¥Ö½§«Ì»Ù¡A¨Ã§í¨î§K¬Ì¹L«×¬¡¤Æ¡A¤¤««×²§¦ì©Ê¥Ö½§ª¢µ´«D¥u¬O³æ¯Âªº¥Ö½§°ÝÃD¡C ³Ìªñ¤Ñ¼ö¡B·Å«×°ª¡A¤@°Ê´N¥þ¨«_¦½¡A®e©ö»¤µo²§¦ì©Ê¥Ö½§ª¢¡A¿à¬f¦p´£¿ô¯f¤Í¡A¥~¥X®É³Ì¦nÄâ±a¤ò¤yÀ¿«ø¦½¤ô¡AÅý¥Ö½§«O«ù°®Àê¡A¦pªG¬°««×¡A«h¥i¦Ò¼{¨Ï¥Î¥Íª«§K¬Ì»s¾¯¡A¨Ö¥Î¥~¥ÎÃþ©T¾J¡A´N¯à¤j´T´î»´ÄY«µ{«×¡C §ó¦h NOWnews ¤µ¤é·s»D³ø¾É |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤U¤È 06:13:04²Ä 392 ½g¦^À³
|
Dupilumab ¤w¤½§G¤W¥««áªº²Ä5©u¾P°âª÷ÃB¡C¥Ø«e¨C©u¦¨ªø5000¸U¬ü¤¸¾P°â. §é²{²v3.6% ²Ä7¦~¾P°â°ª峄50»õ¬ü¤¸,12¦~ªº§é²{È300»õ¬ü¤¸. . 1 2 3 4 5 6 7 8 9 10 11 12 3.6% 1.036 1.073296 1.111934656 1.151964304 1.193435019 1.236398679 1.280909032 1.327021757 1.37479454 1.424287143 1.475561481 1.528681694 2.7 10.2 18.2 26.2 34.2 42.2 50 50 40 40 40 40 2.6 9.5 16.4 22.7 28.7 34.1 39.0 37.7 29.1 28.1 27.1 26.2 sum 301.2 ------------------------------------- ªvÀø¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ ¾P°â·~ÁZ Dupixent Approval History FDA approved: Yes (First approved March 28th, 2017) Brand name: Dupixent Generic name: dupilumab ¾P°âÃB :¦Ê¸U¬ü¤¸ 2017¡CQ2 US 28 2017Q3 US 89 2017Q4 US 139 ¥þ¦~¦Xp US 256 ¡X¡X¡X¡X¡X¡X- 2018, Q1 us 117 out of US14 ¦Xp 131 2018 , Q2 US¡A181 ou of US28 ¦Xp 209 ¥b¦~²Öp340 ¦Ê¸U¬ü¤¸¡]¤W¥««á²Ä¥|~¤©u) ¤W¥«²Ä¤@¦~²Öp387¦Ê¸U¬ü¤¸ ¥Ø«e¬ü°ê°Ï¨C©u¬ù¥H·s¼W50¦Ê¸U¬ü¤¸ªº¾P°âÃB¼W¥[¤¤¡C ¹wp40~50»õ¬ü¤¸ªº¾P°â°ª®p. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤U¤È 05:22:45²Ä 391 ½g¦^À³
|
Dupilumab FDA 2017¦~3¤ë®Ö凖¤W¥«. ¤W¥««e¤@¦~¡A¥«³õ´N¹w´Á¾P°âª÷ÃB¥i¹F50»õ¬ü¤¸¡C 2013,3,28 ¤@2017,7,15¡A´Á¶¡ªÑ»ù¶}¦p¤jº¦,¥«È¼W¥[140»õ¬ü¤¸¡C ¥«³õ¤w§iª¾ªvÀø¤¤¡B««×²Ä¤@ӼйvÃĪ«ªº¥«È¡C ASLAN004 ¥\¯à©Mdupilumab ¬Û·í¡A¥Î¶q´î¥b¡A¥´°w¨C¥|¶g¥´¤@°w¡CªvÀø4Ó¤ë¿Å¶q¥Dn«ü¼Ð! ¥[¤W¬ü°êý³Ý30¬ü¤¸¥«³õ¡B¥þ²y¶W¹L100»õ¬ü¤¸¡B¬Û·í¤jªº²Ä¤GӼйvÃĪ«ASLAN004nÁ{§É¤F. 700¤Hªº¤T´ÁÁ{§É¥un¤@¦~¥i¨ú¥Dn«ü¼Ð¡C±q3´ÁÁ{§É¶}©l¨ì¨úµý¥un2¦~¥b¡C ¥»¹Ú¤ñ¦ó®É¶}©l¡H ¡X¡X¡X¡X¡X- ¦³¤Fdupilumab¼Æ¾Ú¡ASanofi¡ARegeneronªº¾P°âÃB¥i¯à¹F¨ì¼ç¦bªº$ 5B¡]50»õ¬ü¤¸À禬¹w¦ô) §@ªÌ¡GCarly Helfand | 2016¦~4¤ë4¤é¤W¤È9:15 ¤@¨Ç¤ÀªR®v¹w´úRegeneron¡]$ REGN¡^©MSanofi¡]$ SNY¡^Ô¿ïÀã¯lªvÀøÃĪ«dupilumab³Ì²×¥i¯à·|Àò±o¶W¹L50»õ¬ü¤¸ªº¦~«×¾P°âÃB¡C¶g¤¡A¨â¤HÁÚ¥X¤F¤@¨B¡A¨Ï³o¨Ç¹w´ú¦¨¬°²{¹ê¡C Dupilumab¦b¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢±wªÌªº¨â¶µIII´Á¸ÕÅ礤¦W¦C«eT¡A¸Ó¤½¥qªí¥Ü¡A»P¦w¼¢¾¯¬Û¤ñ¡AÅãµÛ²M°£¥Ö½§¡A´î¤Öæ±Äo¡A´£°ª¥Í¬¡½è¶q©M¤ß²z°·±d¡C²{¦b¡A»sÃÄ°Ó±N³o¨Çµ²ªG¯Ç¤J¥LÌp¹º¦b¤µ¦~²Ä¤T©u«×´£¥æªººÊºÞ¤è®×¤¤¡C ¦pªGÀò±o§åã¡Adupilumab - ³o¤w¸g©Ó¾á¤FFDAªº¡§¬ð¯}¡¨ªº¼ÐÅÒ - ±N¬O¦b¦P¯Å¨®§K¬ÌÀøªkªº²Ä¤@Ó¶i¤J¥«³õ¡A¨Ã§@¬°ÁÉ¿ÕµáR¡®d¥D¥ô®J§Q¨È´µ¿A¾|¥§¦b¤@¥÷Án©ú¤¤«ü¥X¡A²{¦b¦³¡§µL§å㪺¬ü°ê¥þ¨ªvÀø¡§¹ï©ó³oÓ±wªÌ¦À¡A¡§±j½Õ¤F©úÅ㥼º¡¨¬ªºÂåÀø»Ý¨D¡C¡¨ ¥Ø«eÀã¯l±wªÌªº¿ï¾Ü¥]¬A§K¬Ì§í»s¾¯¡A¦pÀôÌUµß¯À - ¥i¥H¼W¥[¦MÀI·P¬V©MÀù¯gªº·ÀI - ©M§½³¡Ãþ©T¾J¡A¨ä¦Û¨ªº¼ç¦b°Æ§@¥Î¥]¬A¥Ö½§ÅÜÁ¡¡C Áɿյỡ¡A¥Ø«e¡A¤j¦h¼Æ¯SÀ³©Ê¥Öª¢±wªÌ³£¦b¹p¹F¤U¸¦æ¡C¸Ó¯f¯g¼vÅT¤F¬ü°ê¬ù700¸U¦Ü800¸U¦¨¦~¤H¡A¸Ó¤½¥q¦ôp¥Ø«e¥u¦³160¸U¤H³Q¶EÂ_©MªvÀø¡C ¦Ò¼{¨ì©Ò¦³¦]¯À¡A¤ÀªR®v»{¬°dupilumab¨C¦~ªº¦¬¤J¶W¹L25»õ¬ü¤¸ - ¨ä¤¤¤@¨Ç¹w´ú¨C¦~ªº¦¬¤J°ª¹F40»õ¬ü¤¸©Î50»õ¬ü¤¸¡C ¡§³o¨Çµ²ªG¥i¯àµ¹AD±wªÌ±a¨Ó·sªº§Æ±æ¡A¨ä¤¤³\¦h±wªÌ¦h¦~¨Ó¤@ª½¾D¨üµhW¡A¡¨Zerhouni»¡¡C Sanofi©MRegeneron±N¡§§V¤OºÉ§Ö¬°±wªÌ´£¨Ñ³oºØ³Ð·sÀøªk¡C¡¨ Sanofi / Regeneron¹Î¶¤¨Ã¨S¦³°±¯d¦bdupilumab¤W¡C¤µ¦~¦¨Ç®ÉÔ¡ARegeneronº®u¬ì¾Ç©xGeorge YancopoulosºÙ¸ÓÃĪ«¬°¡§¥O¤HÃø¥H¸m«Hªº¼Wªø¾÷·|¡AµL½×¬O¾AÀ³¯gÁÙ¬O¨ä¥L¾AÀ³ÃÒ¡¨ - ¨Ò¦pý³Ý¡A¨ä¤¤dupilumab¤w¸g¹L´ú¸Õ¡C Yancopoulos§i¶D§ë¸êªÌ¡A¡§§ÚÌ»{¬°³o¥i¯à¬O¤@ºØ«D±`¤£¦Pªº¹L±Ó¬ÛÃö¯e¯fªº«nÃĪ«¡C¡¨ With dupilumab data, Sanofi, Regeneron gear up for potential $5B in sales by Carly Helfand | Apr 4, 2016 9:15am Some analysts are predicting Regeneron ($REGN) and Sanofi¡¦s ($SNY) candidate eczema treatment, dupilumab, could wind up capturing annual sales of more than $5 billion. And Friday, the pair took a step toward making those projections a reality. Dupilumab came up big in two Phase III trials of patients with moderate-to-severe atopic dermatitis, the companies said, significantly clearing skin, reducing itching, and upping quality of life and mental health over placebo. Now, the drugmakers will put those results into a regulatory package they plan to submit in the third quarter of this year. If approved, dupilumab--which already bears the FDA¡¦s breakthrough tag--would be the first in its class of immunotherapies to hit the market, and as Sanofi R&D chief Elias Zerhouni pointed out in a statement, right now there are no approved systemic therapies in the U.S. for this patient pool, underscoring the clear unmet medical need. Current options for eczema patients include immunosuppressants such as cyclosporine--which can increase the risk of dangerous infections and cancer--and topical steroids, whose own set of potential side effects includes skin-thinning. And right now, most atopic dermatitis patients are flying under the radar, Sanofi said; the condition affects about 7 million to 8 million adults in the U.S., and the company estimates only 1.6 million of them are currently diagnosed and treated. All things considered, analysts see dupilumab racking up more than $2.5 billion a year--with some among them forecasting an annual haul of up to $4 billion or $5 billion. These results may bring new hope to AD patients, many of whom have suffered for years, Zerhouni said. Sanofi and Regeneron will work to bring this innovative therapy to patients as quickly as possible. The Sanofi/Regeneron team isn¡¦t stopping there on dupilumab. Earlier thi |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/8/14 ¤U¤È 02:44:03²Ä 390 ½g¦^À³
|
¤µ¤Ñéw·àªºªÑ»ù¨«¶Õ¬Ý°_¨Ó¬O¦³¤ÏÀ³¦¬®×ªº§Q¦h¤F¡A¤£¹LÁÙ¬On¬ÝÄw½X¡A¦pªG¹³¬üªL³oºØ³ßÅw¹j¤é¨Rªº¨é°Ó«Ü¦h¡A¨º¬Ý¨Ó¥i¯à´N¤@¤é¦æ±¡¤F¡A§Æ±æQ4éw·à¯à±aµ¹§Ú̧ó¦hªº¦n®ø®§! |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/8/14 ¤U¤È 12:59:03²Ä 389 ½g¦^À³
|
«u§r¡A ¶}¶}ª±¯º¡A§O¦b·Nªº¡A Ây¤H¥u¬O¥´Ây¶¢®Ì®É¡A ¬Ý¨ì¡u«D¬w·à¡vªºªí²{«Ü´Î¡A ¤£⋯,¬O¡u¨È¬w·à¡v¡A µ¹¥¦Æg¤@¤Uªº |
|
|
·|û¡G¥¿´ä°Q®ü¤H10145796 µoªí®É¶¡:2018/8/14 ¤U¤È 12:34:48²Ä 388 ½g¦^À³
|
¬Ý¨ìÂy¤j¡AÅý§ÚÂ\±o§ó¤ß¦w¤F¡AÁÂÁ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤U¤È 12:18:04²Ä 387 ½g¦^À³
|
·PÁ¡I Ây¤j¡A®É®É´£¿ô ªÑ¥«ªº·ÀI¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤U¤È 12:09:17²Ä 386 ½g¦^À³
|
¦³¤H¨Ó¥´¨È¬w³D! «¢«¢! |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/8/14 ¤U¤È 12:05:50²Ä 385 ½g¦^À³
|
°Ú³é¡ã ¬ü°ê¥P³æ¯uªºÀ~¤H¡A ¦ý¡A©Î³\¡u¶È¡v·í¤é¦³®Ä¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/14 ¤W¤È 08:16:52²Ä 384 ½g¦^À³
|
JACKY WU ¤j¤j ´£¨ìªºmarketingªº½T¬O¥xÆW¥Í§Þ¸û®zªº³¡¥÷¡A¤£¹L¨C®a¤½¥q®Ö¤ßÄvª§¤O³£¤£¦P¡A¥H·à¤l¨Ó»¡½Í§P±ÂÅv¨ÖÁʬãµoµ¦²¤¬O¨ä±j¶µ¡A£¥¦¨¥»¦Ò¶q§ó¬O¨ä±j¶µ¡A§Ú»{¬°·à¤l¬ãµoªº²£«~Äݩ󶥬q©Ê¡A¤T´ÁÁ{§É»P¦æ¾P·|¥Ñ¨ä¥L¥Í§Þ¤½¥q±µ¤â¡AASLAN002¤£¬O¤w¸g±ÂÅvBMS |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤W¤È 08:12:56²Ä 383 ½g¦^À³
|
²§¦ì©Ê¥Ö½§ª¢¤Îý³Ý ªº¥Dn«ü¼Ð¤Î¦¸n«ü¼Ð. ¥Î¤£¨ì¡§¥¿½èÄá¼v¡¨ ,¹³Àù¯gnÆ[¹î¸~½F¤j¤p¡A©Ò¥H¶O¥Î¬Û·í§C¡C clinicaltrials.gov/ct2/show/NCT02277743 ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ªº¤T´ÁÁ{§É¦p¤W |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/14 ¤W¤È 07:47:10²Ä 382 ½g¦^À³
|
§ó¥¿ JACKY WU ¤j¤j |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/14 ¤W¤È 07:40:38²Ä 381 ½g¦^À³
|
JACKY WU ÁÂÁ´£¿ô¥mÀ{¡A§Ú¬Û«H²{¦b¸ê°Tºô¸ô³o»òµo¹FÂ×´I¡A¨CÓ¤H§ë¸ê«e³£·|¿W¥ß«ä¦Òµû¦ô«á¤~°µ¥X¨Mµ¦¡A¥t¥~°·Ä³§A¸ê°T¤À¨Én¦p¤Ñ©R¤j¤@¼Ë¡A¨¥¤§¦³ª«¡A¤j®a¤~·|¬Û«H¡C§Ú¬Û«H¥xÆW¥Í§Þ²£·~¯à¶q±j¡A¤@©w·|´¬Ü¦R®ð |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤W¤È 07:19:59²Ä 380 ½g¦^À³
|
§ó¥¿ ¨CÓÁ{§É750¤H¡A¦@1500¤H¡A ªvÀø费¥Î2¸U¬ü¤¸ÃÄ费(¥|Ó¤ëªvÀøx5000¬ü¤¸)x3¿¡AÀù¯gµ¥¯Å费¥Î¡A¤£¹L9000¸U¬ü¤¸¡C ¨È·à±d¦A¼W资¡A¬O¥Iªº°_¡C ¨º2´ÁÁ{§É°µ§¹¡A½Ð°Ý±ÂÅv费¥i®³¦h¤Ö¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤W¤È 07:06:39²Ä 379 ½g¦^À³
|
JACKY WU¤j¡A ¨È狮¥Ø«e¥«È2»õ¬ü¤¸¥ª¥k¡C 100»õ¬ü¤¸¥«Ô·ªº3´ÁÁ{§É°µ§¹¡C ±ÂÅv¥X¥h¡A°ê»Ú¦æ±¡´N¬O100»õ¬ü¤¸¡C Y3´Á¤£°µ¡A ¨CÓÁ{§É750¤H¡A¦@1500¤H¡A ªvÀø费¥Î2¸U¬ü¤¸ÃÄ费(¥|Ó¤ëªvÀøx5000¬ü¤¸)x3¿¡AÀù¯gµ¥¯Å费¥Î¡A¤£¹L3000¸U¬ü¤¸¡C ¨È·à±d¦A¼W资¡A¬O¥Iªº°_¡C ¨º2´ÁÁ{§É°µ§¹¡A½Ð°Ý±ÂÅv费¥i®³¦h¤Ö¡H ¤£¥Î»¡100»õ¬ü¤¸¡A50%¡A50»õ¬ü¤¸´N¦n¡C ¤À¤@¥b¡A25»õ¬ü¤¸±ÂÅvñ约¡C ¨º¬O¯q¦wªº50¿¡C 1¦~¥i°µ§¹¤@Ó3´ÁÁ{§É¡C ¹ÚÁÙ¦³¦h»·¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/14 ¤W¤È 05:01:13²Ä 378 ½g¦^À³
|
Regeneron Pharmaceuticals, Inc. ¥h¦~®³¨ìÃĵý«á3Ó¥b¤ë¡AªÑ»ù¥«È¤jº¦140¦h»õ¬ü¤¸¡A¤£¬Oº¦°²ªº. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X 1.FDA ®Öã¤é´Á 2017,3¤ë28¤é www.drugs.com/history/dupixent.html Dupixent Approval History FDA approved: Yes (First approved March 28th, 2017) Brand name: Dupixent Generic name: dupilumab Dosage form: Injection Company: Sanofi and Regeneron Pharmaceuticals, Inc. Treatment for: Atopic Dermatitis 2.ªÑ»ù 388¬ü¤¸º¦¨ì517¬ü¤¸(2017/03/28~2017//07/17) finance.yahoo.com/quote/REGN/?p=REGN Dupliumab ¥h¦~FDA 3¤ë®Ö·Ç, ¬ãµo¤½¥qREGENERON ªÑ²¼¥«È3Ó¤ë¤jº¦¬ù140»õ¬ü¤¸. ¨È·à±dASLAN004 ªvÀø ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ªºÀø©MDupliumab ¤ñ¸û,¥\¯à®t¤£¦h¡A¥ÎÃħóªø®Ä. dupliumab 2¶g¥´¤@¦¸°w. aslan004 4¶g¥´¤@¦¸°w. ¥|Ӥ몺ªvÀø. °Æ§@¥Î§ó§C ¥t¥~ý³Ý¤µ¦~©³n®³Ãĵý30»õ¬ü¤¸ªº¥«³õ(º¯³z²v50%pºâ)¡A³o¬O²Ä¤@Ӽйv药¡A¤j®a¬Ý¬Ý2Ó¾AÀ³µý ¦b¬ü°ê´Nn½æ80»õ¬ü¤¸¡A欧¬w±ß¤@¦~¤W¥«¡A¥þ²y¯à§_¦~½æ100»õ¬ü¤¸¡A7¦~«á°ªûß¾P°â¡I |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/14 ¤W¤È 01:36:41²Ä 377 ½g¦^À³
|
¥xÁÞ¤j¤j¡C ¬Ý¬Ý4147±z´Nª¾¹D©t¨àÃÄ¡A³Ð·sÀøªk¡A§Ö³t¼f¬d®³¨ìÃÄÃÒ¡AÂå¥Í¤£´±½T«HÃĮijB¤èñ¶}¤£¥X¨Ó¡Aªì´Án¥Î¸Õªº¡Aµ¥±wªÌÀËÅç¼Æ¾Ú¥X¨Ó¡A¦p½T»{¦³®Ä¤~·|Ä~Äò¶}¥ß³B¤èÅÒ¡A¥i¬O4147¥Ø¼Ð¬OµLÃÄ¥iÂå¡]¹ï©Ò¦³¾÷Âà§ÜÃÄ©Ê¡^¡A¥«³õ³Ì¤p¡A³£¤w¸gGG¤F¡A¤£n¤Ó¼ÖÆ[¤F¡AÂå¥Í·|¬Û«H120¤H¼Ï¶s¸ÕÅçµ²ªG¡A©^ÄU¤j¤j¤T´ÁÁ{§É¬O¤@¤À¿ú ¤@¤À³f¡A¦Ó¥B³o¨Ç¯f¨Ã«Dµ´¯g¡An¥´¤J¥«³õ¨Ã«DµL¥i¨ú¥N¡A¨äÀ禬¦p¤Ñ©R¤j©Ò¨¥¤W¦Ê»õ¡A¯uªº«ÜÃø¡A´Nºâ¯à¹F¨ì90´X%ªºÀ禬³£¸¨¤Jt³d¦æ¾Pªº¤jÃļt¡A·à¤l¯à®³¦h¤Ö¡A°Ñ¦Ò¤¤¸Î»¡ªk¡A¥L̤]°Ý¹L°ê¥~¤jÃļt¡A´N¬O¦]¬°³o¨Ç¤j¼t¶}µ¹¤¤¸Î¤À¼í«Ü§C¡A©Ò¥H¤~·|±ÂÅv¤pÃļt¡A©Ò¥H¤j¼t¤À¼í§C¥u¯àÁÈÃÄ«~¥Í²£¥N¤u¶O¡A¤pÃļt¤À¼í°ªÃĽ椣¥X¥h¡Aµ²ªG¬O¤@¼ËµLªkÁȤj¿ú¡A©Ò¥H³£GG¤F¡A©^ÄU¤£n¤Ó¼ÖÆ[ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/14 ¤W¤È 12:32:45²Ä 376 ½g¦^À³
|
·à¤l¼Ï¯Ã¸ÕÅç¥u»Ý120¤H¡A´Nºâ¥þ³¡¦b¬ü°ê°µÁ{§É¡A¨CÓ¤H¤Q¸U¤¸¤]¤£¶W¹L1200¸U¬ü¤¸ ¤¤°ê¼Ï¯Ã¥u¦¬68¤H§ó¬Ù¡A³o¨âӼϯøÕÅç·à¤l³£¦³¯à¤O¿W¥ß§¹¦¨¡C ¤U±³o«h³o¹ï¯E¹©·à¤l»P¨ä¥L¥Í§Þ¤½¥q¬O¦n®ø®§¡CFDA in Brief: FDA advances efforts to help modernize oncology drug¡C ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/14 ¤W¤È 12:11:38²Ä 375 ½g¦^À³
|
¨S¦³À禬¨C¦~¿N10´X»õ¡A´NºâÃĪ«2´Á¦¨¥\¡A¤T´ÁÁÙn¿N´X¤Q»õ¬üª÷¡A°²¦p¤G´Á«á±ÂÅv¤jÃļt¡A¥L±µ¤âÁÙn¿N´X¤Q»õ¬üª÷¡A¨º§A·Q®³¨ì¤À¼í¦³¦h¤Ö¡Aµ´¹ï¤£¬O©Mt³d¤T´ÁÁ{§ÉÃļt¤@¤H¤@¥b¡A¦U¦ì¤j¤j¤d¸U¤£n¤Ó¼ÖÆ[¤F¡A¤@¯ë¦æ±¡¦b10%¥H¤U¡A¦©°£©Ò¦³¬ãµo¶O¥Î¤Î¶}µoªÌ±ÂÅvÅv§Qª÷¡A³Ñ¤Uªº¤£¦h¡A³Ì«á¥u¦³À°¤j¼t¥N¤uÁȨú·LÁ¡§Q¼í¡A¶È¦¹¦Ó¤w¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/13 ¤U¤È 11:42:44²Ä 374 ½g¦^À³
|
¨È·à±d¬ãµoªº²§¦ì©Ê¥Ö½§ª¢¥«³õ³W¼Ò ·j´M:Atopic dermatitis market ®É¶¡³]©w¤@¦~¤º¡A²Ä¤@«h¸ê°T ¨Ì¾Ú¦~³øÁÙ¦³¤TÓ¾AÀ³¯g³W¹º¶i¤JÁ{§É¡Apipeline ¶V¨Ó¶V¦h¡AªÑªFªº·ÀI´N·|°§C¡A·à¤l¬ãµoªºÃij£¬O§C¦¨¥»©Î§K¶OÀò±o¡A ´Nºâ¬ãµo¥¢±Ñ¡A·ÀI¤]¬O°§C¨ì³Ì¤p¡A¬ãµo¦¨¥\¤F¡A¤j®a¤À¨É¦¨ªG¡C¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/13 ¤U¤È 11:05:39²Ä 373 ½g¦^À³
|
A¨È·à±d¬ãµoªºÁx¹DÀù¥«³õ³W¼Ò: ¨Ì¾Ú¤½¥qªk»¡·|¸ê°T: 14»õ¬ü¤¸ (¤G½u¨S¦³®Ö㪺ÃÄ §ó¨S¦³¼Ð¹vÃÄ ) B¨È·à±d¬ãµoªºGÀù¥«³õ³W¼Ò: ( ¬°Àù¬O¤jÃÄ) ·j´M: Gastric Cancer Treatment Market to Expand Rapidly to $4.4 Billion by 2024 C ¨È·à±d¬ãµoªº«æ©Ê°©ÀH©Ê¥Õ¦å¯f ( ¦~½Æ¦X¦¨ªø²v°ªªºÃÄ) AML¥«³õ³W¼Ò ( Global Acute Myeloid Leukemia Market US$ XX Billion by 2023) ·j´M: acute myeloid leukemia market size ( ®É¶¡³]©w1¦~¤º §ä²Ä¤T«h¸ê°T) D ¨È·à±d¬ãµoªº²§¦ì©Ê¥Ö½§ª¢ ( ¥þ²y¶W¹L 2 »õ¦W¯f±w²`¨ü¨äÂZ) ®ð³Ý¤H¤f¼Æ¤]«Ü¤j ) ¥H¤WÓ¤H¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤U¤È 10:38:40²Ä 372 ½g¦^À³
|
¨È·àADR¤jº¦¦^8.39¬ü¤¸/ªÑ °ª©ó¤µ¤Ñ¥xªÑ40.6¥x¹ô /ªÑ 27%.·¸»ù finance.yahoo.com/quote/asln/ |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/13 ¤U¤È 09:17:28²Ä 371 ½g¦^À³
|
¦U¦ì¤j¤j¤d¸Un¤p¤ß¡A¥Í§ÞªÑ±q¤µ¤Ñ¶}©l°£¤F¢³¢°¢³¢¶¥~¡A¸É¶^¤F¡A¤£ºÞªÑ²¼¦n¤£¦n¤@°_±þ¡A¤×¨ä¬O¥»¹Ú¤ñ¼Ðªº§ón¤p¤ß¤F¡A¤d¸U¤£n¹³¢³¢°¢³¢¶¤@¼Ë¡A³Q±þªº¹M¥Ò¤£¯d |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤U¤È 05:14:18²Ä 370 ½g¦^À³
|
histock.tw/stock/6497 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤U¤È 04:59:25²Ä 369 ½g¦^À³
|
¸¤H¤j, ±zªº¸ê®Æ¬O¹ïªº,¥~¸ê¶R100±i¡B½æ33±i. ¬üªL°µªº¬Û·íµu. ªk»È¤Ú¾¤ÃÒ¨é¥u¬O¨C¤Ñ20±i¥ª¥kªº¶R. |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/8/13 ¤U¤È 04:04:28²Ä 368 ½g¦^À³
|
¤Ñ©R¤j§A¦n! ½Ð°Ý§A¥~¸ê¶R½æªº¸ê®Æ¦bþÃä±oª¾ªº©O? èè¬Ý¤F¤@¤U¤µ¤Ñ¥~¸ê¶R¶W67±i¡A¤µ¤Ñ¶R¶W³Ì¦h¬Oªk»È¤Ú¾¤¦Ó½æ¶W³Ì¦hªº¨é°Ó¬O¤@®aµØ«n¥Ã©÷¤¤¥¿¡A³o®a´N¬O8/7©M¬üªL³oÓ°²¥~¸ê¨âÓ¤@°_·Qnª£§@éw·àªºªÑ»ù¡A¦ý¬O³o¨â®a¨é°Ó¤j³£¬O°µµu½u¡A©Ò¥H¥u·|ÅýÄw½X§ó¥[ªº²V¶Ã¡A¥u¬O¤µ¤ÑªÑ»ù¶^´T¤ñ¸û¤j¡A©Ò¥H¤~·Qn¤ÀªR¤@¤U¡C ÁÂÁÂ! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤U¤È 03:06:59²Ä 367 ½g¦^À³
|
¨È·àµL´Iª¨ª¨¡C ¤ñ¤j½Lªi°Ê¤j¬O¥²µM¡I ¤µ¤Ñ¥~资¶R100±i¡A卖30±i¡C «ùÄò¦Y货¤¤¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/8/13 ¤U¤È 02:51:18²Ä 366 ½g¦^À³
|
ı±o¤µ¤Ñ¨È·à±dªº¨«¶Õ®zªº¦³ÂI¸Ø±i¡A¤W§«ô¤½§GGÀù¤@½uªvÀø¤§¥þ²y¤G/¤T´ÁÁ{§É¸ÕÅ窺¤G´ÁÁ{§É¦¬®×¡AÁ`¦@¦¬¤F52Ó¡A쥻¹wp¦¬40Ó¡A¤ñ¹w´Áªº¦h¡A´Nºâ¤£¬O§Q¦hªº®ø®§¡A¤]¬O¥¿¦Vªº¶i®i§a¡Aµ²ªG¤µ¤Ñ¤p¶^¶}¥X¡AªÑ»ù´N¤@¸ô¤U±´¶^¯}40¡A³Ì«á¦¬40.6¡A¤µ¤Ñªº¨«¶Õ¤ñ¸û¥X¥G·N®Æ¤§¥~¡A¤£ª¾¤j®a¦³¬Æ»ò¬Ýªk¶Ü? ÁÙ¬O¥u¬O¤j½L¤£¦n¡A¨È·à±d¥u¬O¸ò¶^µM«á¶^ªº¤ñ¸û¦h³o¼Ë! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤U¤È 02:13:14²Ä 365 ½g¦^À³
|
ÙçÙç¤j, ½Ð°Ý 1.www.medpagetoday.com/publichealthpolicy/medicare/74467 µØ²±¹y - ÂåÀø«OÀI©MÂåÀø¸É§UªA°È¤¤¤ß¡]CMS¡^±N¤¹³\2019¦~ªºMedicare Advantagep¹º¹ïB³¡¤ÀÃĪ«±Ä¥Î¡§¤À¨BªvÀø¡¨¤èªk¡C 2.Pro140 ¤W¥« ¥H¤W¨âӨƥó¹ïTMB355¾P°â¦³¦ó¼vÅT¡H Ävª§¥«³õ¬O°ÊºAªº¡A³sÀsÀYGILEAD ¤]³Q¥é¥ÍÃÄK¡C ¦b¼w°ê3¦X¤@ªºHIV ¤@½u¥é¥ÍÃÄAtripla ,¹s°â¨C¤Ñªá¤@¼Ú¤¸¡C¨C¤ë30¼Ú¤¸. ¦Ó¦b¬ü°ê¹s°â¨C¤ë¤´¦b2700¬ü¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤W¤È 08:25:44²Ä 364 ½g¦^À³
|
www.medpagetoday.com/publichealthpolicy/medicare/74467 µØ²±¹y - ÂåÀø«OÀI©MÂåÀø¸É§UªA°È¤¤¤ß¡]CMS¡^±N¤¹³\2019¦~ªºMedicare Advantagep¹º¹ïB³¡¤ÀÃĪ«±Ä¥Î¡§¤À¨BªvÀø¡¨¤èªk¡C CMSµo§G¤½§i¨Ãµo¥¬¤F¤@¥÷³Æ§Ñ¿ý¡A¸Ô²Ó»¡©ú¤F©P¤G¤U¤ÈªºÅܤơC ¥u¦³¤@Ó°ÝÃD¡C¤À¨BªvÀø¬O¤@ºØ¨Æ¥ý±ÂÅvªº§Î¦¡¡AÂå¥Í½T¹ê«D±`°Q¹½¨Æ¥ý±ÂÅv¡A±N¨äµø¬°ÂZ¶Ã±wªÌ»PÂå¥ÍªºÃö«Y¨Ã³y¦¨¤£¥²nªºt¾á¡C ¦b¤À¨BªvÀø¤¤¡A±wªÌ¥²¶·¹Á¸Õ¥t¤@ºØÃþ¦ü¦ý³q±`¸û«K©yªºÃĪ«¤~¯à¶}¥X§ó©ù¶QªºÃĪ«¡C CMSºÞ²zûSeema Verma¦b¹q¸Ü·|ij¤W§i¶D°OªÌ¡A³oºØ·s¤èªk±N¡§½T«O±wªÌº¥ý±µ¨ü³ÌÀu¿ïªºÃĪ«ªvÀø¡C¡¨ ¦o¸É¥R»¡¡Ap¹ºªº·s¿ï¾ÜÁÙ±N¦bB³¡¤À©MD³¡¤ÀÃĪ«¤§¶¡³Ð³y¤@Ó¡§¤½¥ªºÄvª§Àô¹Ò¡¨¡A¨Ïp¹º¯à°÷¬°±wªÌ´£¨Ñ§ó¦nªº¥æ©ö¡C B³¡¤ÀÃĪ«³q±`§ó©ù¶Q¨Ã¥B³q±`¥]¬A¥Íª«»s¾¯¡C¥¦Ì³q±`¥Ñ¨ä¿ì¤½«ÇªºÂå¥ÍºÞ²z¡A¦ÓD³¡¤ÀÃĪ«¬O¦bÃĩбµ¨ü¨Ã¦Û§ÚºÞ²zªºÃĪ«¡C Verma¸ÑÄÀ»¡¡A¦b¹L¥h¡AÄvª§¥i¯à¦]¬°B³¡¤ÀÃĪ«ÄÝ©ó¤@ºØºÖ§Q¦Ó¨äÄvª§¹ï¤âÄÝ©ó³æ¿WªºD³¡¤Àp¹º¦Ó¨ü¨ìªýê¡C ®Ú¾Ú³oºØ·s¤èªk¡ACMS±N¤¹³\p¹º¡§¥æ¤eºÞ²z¡¨³o¨ÇÃĪ«¡C ¡§¦]¦¹¡A¦pªG¤@¶µp¹º¦P®ÉºÞ²zB³¡¤ÀºÖ§Q©MD³¡¤ÀºÖ§Q¡A¥¦Ì°ò¥»¤W......»Ýn¥ý¨Ï¥Î¸û§C¦¨¥»ªºÃĪ«¡A¡¨¦o»¡¡C ¸Ó¾÷ºcªí¥Ü¡AÂåÀø«OÀIÀu¶Õp¹º¤¤ªºB³¡¤ÀÃĪ«¤ä¥X¨C¦~Á`p¬ù120»õ¬ü¤¸¡C·s»D¬Éªº¥t¤@¦W©xûªí¥Ü¡A¦b¨pÀ糡ªù¡A¤À¨BªvÀø¤w±NÃĪ«¤ä¥X´î¤Ö¤F15¢H-20¢H¡C ¤@Ó¤p²Õ¼y¯¬¤Fp¹º¤¤ªºÅܤơC ¡§§ÚÌÆg½à¬F©²Ãöª`°§CÃÄ«~»ù®æ©M¼W¥[¥Íª«¥é»sÃĪº¨Ï¥Î¡A¡¨¥i«ùÄòRx©w»ù¹B°Ê¦b¤@¥÷·s»DÁn©ú¤¤ªí¥Ü¡C ¡§§ÚÌ´Á«Ý¬Ý¨ì³oÓp¹ºªº§ó¦h²Ó¸`¡A§Ú̱N»P¬F©²©M¨ä¥L§Q¯q¬ÛÃö¤è¦X§@¡A¦b§ïµ½»ù®æ½Í§P©Mºû«ùÂåÀø«OÀI¨ü¯q¤HÀò±oÃĪ«ªº¾A·í³~®|¤§¶¡¨ú±o¥²nªº¥¿Å¡C¡¨ ¥¿¦p¹w´Áªº¨º¼Ë¡AÂå¾Ç¬É¹ïCMSp¹ºªºÅܤƧó¥[ÃhºÃ¡C ¬ü°êÀù¯g¨ó·|/Àù¯g¦æ°Êºôµ¸Á`µô§J¨½´µ¡Pº~´Ë»¡¡A¸Ó¾÷ºc·sªº¤À¨BªvÀø¤èªkªº²Ó¸`±N¨M©w¨ä¹ïÀù¯g±wªÌªº¼vÅT¡C º~´Ë¦b¤@¥÷·s»D½Z¤¤»¡¡G¡§³q¹LÀù¯gªvÀø¤w¸g¨¬°÷§xÃø¤F - Àù¯g±wªÌ¤£À³¸Ó³Q¢º¥ý¹ï¤@ºØ¤wª¾¤£¯à¬°¥LÌ°_§@¥ÎªºÃĪ«¡¨¥ý¥¢±Ñ¡§¡C ¥L±j½Õ¤F¡§§Ö³t¡A©ö©ó²z¸Ñªº¤W¶Dµ{§Ç¡¨ªº«n©Ê¡A¨Ã´°«P¸Ó¾÷ºc CMS: Medicare Advantage Plans Can Require Step Therapy ¡XInsurers can impose this form of prior authorization for Part B drugs next yea by Shannon Firth, Washington Correspondent, MedPage Today August 08, 2018 WASHINGTON -- The Centers for Medicare and Medicaid Services (CMS) will allow Medicare Advantage plans in 2019 to apply a step therapy approach to Part B drugs. CMS made the announcement and issued a memo detailing the changes on Tuesday afternoon. advertisement There¡¦s just one problem. Step therapy is a form of prior authorization and physicians really, really hate prior authorization, viewing it as disrupting the patient-physician relationship and creating an unnecessary burden. In step therapy, patients must attempt another similar but typically less expensive medication before they can be prescribed a pricier one. CMS Administrator Seema Verma told reporters on a conference call that the new approach would ensur[e] that patients receive the most preferred drug therapy first. The new option for plans would also create a level playing field between Part B and Part D drugs, enabling plans to negotiate better deals for patients, she added. Part B drugs are typically more expensive and often include biologic agents. They are typically administered by physicians in their office, whereas Part D drugs are those picked up at a pharmacy and self-administered. advertisement In the past, competition may have been stymied by having a Part B drug under one benefit and its competitor under a separate Part D plan, Verma explained. Under this new approach CMS would allow plans to cross-manage these medications. So, if a plan is managing both the Part B benefit and the Part D benefit, they can essentially... require the lower cost drug to be used first, she said. The agency said Part B drug spending in Medicare Advantage plans totals about $12 billion annually. Another official on the press call said that, in the private sector, step therapy has cut drug spending by 15%-20%. One group celebrated the planned change. We applaud the Administration¡¦s focus on bringing down drug prices and increasing access |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤W¤È 04:11:27²Ä 363 ½g¦^À³
|
ÙçÙç¤j¡A Ó¤HµLªk预¦ôTROGAEZO ªº¥¼¨Ó¾P°â¶q¡C ²Ä349½g¬O¥Ø«eªÑ»ù¤Uªº¼Ð·Ç¾P¶q¡A¨Ã¤£¬OÓ¤H预¦ô¥¼¨Óªº¥|¦~«áªº°ªûß¾P¶q¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤W¤È 04:02:15²Ä 362 ½g¦^À³
|
¥t¥~¤@Ó·s¤p¤À¤lÃĪ«(·s¾÷Âà:§@¥Î©ó¯f¬rªºENV gp120 ªý¤î¶i¤JT CELL §í¨î¾¯) FOSTEMSAVIR ,©M TMB355 ¡A¤¬¬°¤T´ÁÁ{§Éªº聨¦X¥ÎÃĪÌ. 24¶g¤T´ÁÁ{§Éµ²ªG¤w2017/11/28 ¤½§G. (¬OÄ~TMB365 «á²Ä¤T¥N TMB-Bispecific Âù¼Ð¹v (TMB355+gp120 ¡§¤¤ªº¥t¤@¼Ð¹v¡¨¡C) ¡X¡X¡X¡X¡X 13/19 participants used ibalizumab i-base.info/htb/32869 Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results 28 November 2017. Related: Conference reports, Antiretrovirals, EACS 16 Milan 2017. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤W¤È 03:20:41²Ä 361 ½g¦^À³
|
ÙçÙç¤j¡A ¤@¡B°²³]¨ä¥L¤£ÅܬO ¼Æ¾Ç¼Ò¦¡ªº败µ§¡C ¤G¡BPRO140 ¥i¥H¦b®a¦Û¦æ¥´针ªºHIV CCR5 §Y±N°e¥ó¥Ó½Ð药µý¡C ¤T¡A¥»¯q¤ñ15¿ªºªÑ»ùªÅ¶¡vs·ÀI |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/13 ¤W¤È 03:11:49²Ä 360 ½g¦^À³
|
ÙçÙç¤j¡A |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/12 ¤U¤È 11:02:23²Ä 359 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d¤ä¥IArray1.28»õ¬ü¤¸¨ú±o¥þ²y°Ó«~¤Æ»P¦A±ÂÅvÅv§Q¡A³o¥Nªí¤½¥q¹ïASLAN001ªº«H¤ß¡C¦Ü©ó¦A±ÂÅv®É»Ý¦A¤ä¥I¦Ê¤À¤§50±ÂÅvª÷µ¹Array¬O¦³±ø¥óªº¡A¦b¦³¨Ç¯S©w±¡ªp¤U¬O¤£¥Î¤ä¥Iªº¡Añ¬ùª÷¤]¬O¶W¹L¯S©wª÷ÃBªº³¡¥÷¤~»Ýµ¹¦Ê¤À¤§50¡C¥i¥H°Ñ¦Ò¦~³ø¦³¸Ô²Ó»¡©ú¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/12 ¤U¤È 10:52:03²Ä 358 ½g¦^À³
|
¤Å·N! ¤Å¥²! ¤Å©T! ¤Å§Ú! §ë¸ê¦W¨¥! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/12 ¤U¤È 10:18:24²Ä 357 ½g¦^À³
|
ÙçÙç¤j, Selzentry Maraviroc ¨C¦~¨C¤H²bÀ禬¬ù= ¥§¡¹s°â1540x12x80%=14784¬ü¤¸ 2017 ¬ü°ê Ðä¾P°â8600¸U¬ü¤¸/14784¬ü¤¸=¬ù5817¤H¦~ªº¨Ï¥ÎªÌ. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- www.goodrx.com/selzentry Walmart 60 tablets of Selzentry 300mg PRICE USD1548 ----- ------------------------INDICATIONS AND USAGE---------------------------- SELZENTRY is a CCR5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only CCR5-tropic HIV- 1detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents (1). Tropism and treatment history should guide the use of SELZENTRY (1). ---------------DOSAGE AND ADMINISTRATION--------------------- When given with strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except tipranavir/ritonavir), delavirdine (2, 7.1) 150 mg twice daily With NRTIs, tipranavir/ritonavir, nevirapine, and other drugs that are not strong CYP3A inhibitors or CYP3A inducers (2, 7.1) 300 mg twice daily With CYP3A inducers including efavirenz (without a strong CYP3A inhibitor) (2, 7.1) 600 mg twice daily www.accessdata.fda.gov/drugsatfda_docs/label/2007/022128lbl.pdf |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/12 ¤U¤È 10:02:25²Ä 356 ½g¦^À³
|
ÙçÙç¤j, 関©óTROGAEZO ªº¤T´ÁÁ{§ÉN=40¤H, ¬¡©ÊÃĪ« oss=0 (FDA ¤£¤¹³\TROGARZO³æ¿W¨Ï¥Î) ¬¡©ÊÃĪ« oss=1 ,¥i¯à¬OCCR5/MVC 20%//8/40,©Î FUZEON30% 12/40 ,¤w¦³§ÜÃÄ©Ê ©Ò¥H¥¼¨ÓCCR5(ZELZENTRY)//FUZEON ¯uªº¬OOSS <=2 ªº³Ì¤jÄvª§ªÌ. ¦ý¨p¤H«OÀI¤½¥q(¤½«Op¹º¸ò¶i??)·|¥ý®Ö©w«K©y»ù®æÀu¥ý¨Ï¥Î.¬O°ÝÃD¡I CCR5 ªºMVC (ZELZENTRY)2017¦~¬ü°êÁÙ¾P°â6600¸U^Âé(8600¸U¬ü¤¸).,¥þ²y1.28»õ^Âé. ¸ê®Æ¨Ó·½: GSK 2017°]³ø www.gsk.com/media/4629/fy-2017-results-announcement.pdf P.45 ¡X¡X¡X¡X¡X¡X- FDA¡XLABEL ¨ü¸ÕªÌ¸g¾ú¤F¤j¶qªvÀø¸gÅç¡G53¢Hªº°Ñ»PªÌ¦b¸ÕÅç¤J²Õ«e±µ¨ü¤F10ºØ©Î§ó¦h§Ü°fÂà¿ý¯f¬rÃĪ«ªºªvÀø; ¥ÎNRTIªvÀø98¢H¡A¥ÎPIªvÀø98¢H¡A¥ÎNNRTIªvÀø80¢H¡A¥ÎINSTIsªvÀø78¢H¡A¥Îgp41¿Ä¦X§í»s¾¯ªvÀø30¢H¡A¥ÎCCR5¦@¦P¨üÅé«ú§Ü¾¯ªvÀø20¢H¡C The subjects were heavily treatment-experienced: 53% of participants had been treated with 10 or more antiretroviral drugs prior to trial enrollment; 98% percent had been treated with NRTIs, 98% with PIs, 80% with NNRTIs, 78% with INSTIs, 30% with gp41 fusion inhibitors, and 20% with CCR5 co-receptor antagonists. www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/12 ¤U¤È 09:09:14²Ä 355 ½g¦^À³
|
ÙçÙç¤j, ¡¯²Ä¤@Ó°ÝÃD¤ñ¸û²³æ¡A±zNo. 349½gºâ¦¡¤¤¦³¨Ç°Ñ¼Æ±Í¤HµLªk°Ñ³z¡AÁÙ±æ¦h«üÂI°g¬z¡C ¢I¡u²Ä¤@¦~¹wp¾P°â¤H¼Æ¡G¥§¡5633x20%=1126¤H¤@¦~¡C1126/6=¨C¤ë·s¼W188¤H¡C1126x12=13519¤H¤ë¡v º¦~¹w¦ô¤H¼Æ1126¤H¡A¬°¦ó°£¥H6=¨C¤ë·s¼W¤H¼Æ¡H µM«á¬°¦óÁÙn±Nº¦~¹w¦ô¤H¼Æ1126¦A¼¤W12Ó¤ë¡H ©Ò±o¤§¼ÆÈ¥Nªí·N¸q¬°¦ó¡H Ans. ²Ä¤@¦~¥§¡1126¤H/¤ë ¡A¥þ¦~Á`¨Ï¥Î¤H¼Æ=1126x12Ó¤ë=13,512¤H¡Ð¤ë °²³]¨C¤ë増¶q¤H¼Æ¬°d , ¤@¦~Á`¨Ï¥Î¶q=(d+12d)x12/2=13512 (±è«¬¤½¦¡) d=173¤H. *188¤H¬O¿à¤Hºâªk. 173x110%(¤¤Â_¤H¼Æ½Õ¾ã,10%¤¤Â_²vºâ)=190¤H¡A¨C¤ë·s¼W190¤H.¡A¾ã¦~¥§¡¨C¤ë1126¤H¨Ï¥Î. ²Ä¥|¦~, ¨C¤ë¥§¡5633¤H¨Ï¥Î,¤~¦³ 8.8¸U¬ü¤¸/¦~x5633=4.957»õ¬ü¤¸ªº¦~¦¬¤J. ¡¯²Ä¤GÓ°ÝÃD¨ä¹ê¬O°w¹ï±zNo. 350½g´£¥Xªº¤ÀªR ANS. ¦ô¬ü°êMDR25,000¤H¡A¦ôp¤@¦~¤º»Ý¸Ó·sÃĪº±wªÌ¬ù¥e¥b¼Æ¥ª¥k¡A¥Ø¼Ð¤H¼Æ¬ù1.2¦Ü1.3¸U ¦Ü¶·´«ÃĤHªº¬¡©ÊÃĪ«OSS <=4 (¤T´ÁÁ{§É40¤Hªº°ò½u¸ê®Æ)¦û¦h¤Ö¤ñ²v?Ó¤H¤£ª¾¡C ±zY¦³¬ü°êªº²Îp¸ê®Æ¡A½Ð§iª¾. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X MDRªº©w¸qn¨ÌFDA®Ö㪺LABEL¬°凖. PATIENT INFORMATION TROGARZOTM (tro-gar-zo) (ibalizumab-uiyk) injection TROGARZO is a prescription medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults who: ¡E have received several anti-HIV-1 regimens in the past, and ¡E have HIV-1 virus that is resistant to many antiretroviral medicines, and ¡E who are failing their current antiretroviral therapy HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). , ¥t¥~ ®Ú¾Ú¤T´ÁÁ{§Éªº©Û¶Ò±ø¥ó ,NRTI, NNRTI, and PI,¦U¤@ºØHIV§í¨î¾¯²£¥Í§ÜÃÄ©Ê¡A´N¥i°Ñ¥[Á{§É¡C ¦ý¤@¯ë¶·´«3¦¸ÃÄ¡A¨C¦¸3ºØHIV§Ü°fÂà¿ý¯f¬rÃĪ«ªºÂû§À°sÀøªk,¦@¯Ó¥Î10ºØ¡C ¦Ó¤w¤W¥«5¤j¾÷Âà¦@¬ù30ºØ³æÃÄ.©Ò¥HMDR±wªÌ³Ì°ª¦³20ºØ¬¡©ÊÃĪ«¥i¥Î¡C ¤T´ÁÁ{§É©Û¶Ò±ø¥ó¦p¤U: ¡X¡X¡X¡X ³q¹L§ÜÃÄ©Ê´ú¸Õ´ú¶q¡A°O¿ý¤F¨Ó¦Û¤TÃþ§Ü°fÂà¿ý¯f¬rÃĪ«¡]NRTI, NNRTI, and P¡^¤¤ªº¨C¤@ºØ¾÷Â઺¦Ü¤Ö¤@ºØ§Ü°fÂà¿ý¯f¬rÃĪ«¨ã§ÜÃÄ©Ê¡C ¡X¡X- documented resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications (NRTI, NNRTI, and PI) as measured by resistance testing. ¡X¡X 14 CLINICAL STUDIES Trial TMB-301: Trial TMB-301 was a single arm, multicenter clinical trial conducted in 40 heavily treatment-experienced HIV-infected subjects with multidrug resistant HIV-1. ¡X¡X- documented resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications (NRTI, NNRTI, and PI) as measured by resistance testing. ¡X¡X¡X¡X Subjects must have been treated with antiretrovirals for at least 6 months and be failing or had recently failed (i.e., in the last 8 weeks) therapy. www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf ¡X¡X¡X¡X¡X¡X¡X- fuzeonè¥X¨Ó ¨º®ÉÔaids¯à¥ÎªºÃĤ£¨ì²{¦b¤@¥b ¤S¬O°ß¤@¤@Ó·s¾÷¨îÃÄ ©Ò¥H·í®ÉÔ½æ±o¦n¥¿±` ¦ý¦]¬°n¨C¤Ñ·b¨â°w ¤@¦~·b360°w «á´Á¤@°ï¤£¥Î §ÜÃÄ©Ê´N¥X¨Ó ANS.¤Wz¬O¿ù»~¸ÑŪFUZEON,2006¦~Q4¡A¥§¡¨C¤ë½æ8600¦h¤H¡C ¦]¬° 2006/2007¦~ FDA ®Öã3¤j·sÃÄ,¨ú¥N¤FFUZEON. Integrase Inhibitor RAL(¶W±jªº´O¦X酶§í¨î¾¯),·s¾÷Âà¡A¥Î¶q¾¯¶q¤p¡A¤W¥««á¤j½æ. PI¡X-DRV Entry Inhibitor//CCR5¡XMVC FUZEON ¥_¬ü¦a°Ï(¬ü°ê&¥[®³¤j)¦~¾P°â¶q(KITS)¾ã²z 2003 (3¤ë©³FDA ®Öã¤W¥«) 19,400 KITS (¨C¤H¨C¤ë¤@Kit ²~) 2004 58,900 KITS 2005 72,000 KITS 2006 79,700 KITS(¾P°â°ª®p) 2007 72,700 KITS 2008 36,000 KITS 2009 20,000 KITS 2010 16,100 KITS ¡X¡X- |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/12 ¤W¤È 09:07:36²Ä 354 ½g¦^À³
|
¨È·àªºGÀù¤@缐¤G´Án=52¤HÁ{§É¹êÅç¸ê®Æ¥¼¨ÓnÃöª` 1.¥h°£HER2 ,IHC+3 «á A.HER1 ,IHC+3 ªº¤ñ²v¦³¦h°ª? ToGA¡X- HER2,IHC+3 ¤ñ²v256/584=43.8% B.¥LªºORR ¯à§_¦p¶PÀù¥丅oGA ¹F47.3% ? ¦Ó¹ï·Ó²Õ¦bORR34.5%¥ª¥k ? HR·ÀI¤ñ 34.5%/47.3%=0.73 ¡X¡X¡X¡X¡X¡X¡X¡X www.slideshare.net/mobile/jtcancercenter/grothey-gi-malignancies-11111 p.80 P.78 ¶PÀù¥ªº¤@½uGÀù丅oGA , 3´ÁÁ{§É¡A,¿zÀË her2+ , ¹êÅç²ÕN=294¤H, ORR 47.3% ¹ï·Ó²ÕN=290¤H¡AORR 34.5% P=0.0017 ORR ©M¹ï·Ó²Õ, HR·ÀI¤ñ·U§C·U¦n¡C HER1,IHC+3 ¤ñ²v·U°ª·U¦n¡C ©Ò¦³ªº»ùȨ̵Mn¬Ý¤T´ÁÁ{§É350¤H¡A¥Dn«ü¼ÐOS , ¥Ñ2´Á52¤H¡A¥t¥[298¤Hªº2/3´ÁÁ{§É¡A¹wp45Ó¤ë¡A247¤H¸ê®Æ¦¨¼ô¡A¥i¸Ñª¼ Overall Survival (OS) - Phase 3 part [ Time Frame: When 247 OS events have occured. 247 OS is estimated to occur after approximately 45 months ] Phase 3 part: Overall Survival (OS) defined as the time from randomization until death by any cause. Any subject not known to have died at the time of the analysis will be censored based on the last recorded date on which the subject was known to be alive. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/8/12 ¤W¤È 08:26:30²Ä 353 ½g¦^À³
|
ªÑ²¼¥«³õ´N¬O¥u¦³³g¸ò©È¨â¦r,¦Ñ·àªº²{¤µ¦ì¶¥À³¸Ó¬On³g©Î©È ?·à¤Í̪º½TÀ³¦n¥Í«ä¶q~~Ó¤Hı±oGÀù¼Æ¾Ú¦b¤@´Áªº¼Æ¾Ú¤w¦³«ü¥X¤£¿ùªº¤è¦V,·à¤ÍÌ¥i¼f·Vµû¦ô~~ ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,¦Û¤vn¹ï¦Û¤vªº§ë¸êt³d~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/12 ¤W¤È 04:44:53²Ä 352 ½g¦^À³
|
¨È·à¦~ªì¦Y¤UASLAN001¥þ²y¤T´ÁÁ{§É¤Î°Ó·~¤Æ¦X¬ù¡C ¦X¬ù¤¤ª`°O¡AY2¦~内¨È·à¥t±ÂÅv给¤U´å¡A则n¤À¤@¥b给¤W´åªº¬ãµo¤½¥q¡C ¦]¦¹¦U¦ì¤j¤j¡A2019¦~12¤ë31¤é«eÀ³¬Ý¤£¨ìASLAN001ªº¤U´å±ÂÅv¡C ©Ò¥H¤j®aÀ³Ãöª`ªº¨È·à±ÂÅv¬OASLAN003 ¦åÀù±ÂÅv¡C ¤ÎASLAN004 ¤¤««×²§¦ì©Ê¥Ö½§ª¢¡Bý³Ýªº¥þ²y100»õ¬ü¤¸±ÂÅv¤j¼@¡C ¥t¥~§ë¸ê³Ì©È¤@¨¥°ó¡C ¤Å·N¡B¤Å¥²¡A¤Å©T¡A¤Å§Ú¡I ¯uªº¤@ÂI¤£°²¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/12 ¤W¤È 04:21:44²Ä 351 ½g¦^À³
|
¬ü¤¤¨â°ê¶T©ö¤j¾Ô¤é¯q¿E¯P¡A§ë¸ê¤H¯É¯ÉÁY¤â¡A±N¡u¤¤°ê¹Ú¡v«Å¶Ç¥´¦^쫬¡A¨Ã¤Þµo¤@¨t¦Ct±®ÄÀ³¡A¥þ²yªÑ¥«»P¸gÀÙÅܱo¸ÞÃÔ¦hÅÜ»P°ÊÀú¤£¦w¡A°]°T¸³¨ÆªøÁª÷ªe¦bÁy®Ñ¤Wªí¥Ü¡A¥xªÑ¶i¤J1¸UÂI¥H¤W¡A¤w¶i¤J²Ä15Ó¤ë¡AY¨S¦³°ò¥»±¤ä¼µ¡A¦Ñ¦±Y½L¤F¡C¦ý²{¦b¥xªÑ³o¤]¬O³ÌÃø¾Þ§@ªº®É¨è¡C ³o2Ó¤ë¡A¤j¦h¼Æªº§ë¸ê¤H³£½ß¿ú¡A¦ý¬OÁª÷ªeªí¥Ü¡A§ë¸ê³Ì¤W¼¤ßªk¡G¤Å·N¡B¤Å¥²¡B¤Å©T¡B¤Å§Ú¡C Áª÷ªe¦bÁy®Ñ¥Ü¡A¤j¦h¼Æ¾Ç²z³£¦³¹Bºâ¤½¦¡¡A¤]·|¦³¼Ð·Çµª®×¡A§Y¨Ï¹³¸gÀپǤ]·|°²³]¨Ñµ¹»Ý¨D¡A°²³]¤@¤Áª¬ªp¤£Åܪº±¡ªp¤U¥h±À«Ø¼Ò«¬¡A°ß¿W§ë¸ê¾Ç¨S¦³¼Ð·Çµª®×¡A§ë¸ê¬O¤@¤Á±¡ªp³£·|ÅÜ¡A¨CÓ¤H¦pªG¥Î¥DÆ[·N©À·Q¨Ó¾r¶¿³oÓ¥«³õ¡A¤@©wÅܦ¨¿é®a¡A³o¤]¬O¤j¦h¼Æ¸gÀپǮa§ë¸êªÑ²¼®e©ö½ß¿úªºÃöÁä©Ò¦b¡C ´N¥H°ê¥¨¬°¨Ò¡A«Ü¦h¤H°Ý§Ú¡A°ê¥¨°]³ø¼Æ¦r¨º»ò¦n¡A¬°¤°»òªÑ»ù¶^³o»òºG¡H§Ú説ªÑ»ù¶]¦b°ò¥»±«e±¡A¥ý«eªÑ»ù¤jº¦¬O¦b¤ÏÀ³²{¦bªº¼Æ¦r¡A²{¦bªÑ»ù¤j¶^¡A¥i¯à¬O¦b¤ÏÀ³¥¼¨Ó³Q°Ê¤¸¥óªºªi°Ê¡A¨ä¹ê¸³¨Æªø³¯®õ»Ê¤°»ò³£¤£¥Î»¡¡C ¥xªÑ¶i¤J1¸UÂI¥H¤W¡A¤w¶i¤J²Ä15Ó¤ë¡AY¨S¦³°ò¥»±¤ä¼µ¡A¦Ñ¦±Y½L¤F¡C¦ý²{¦b¥xªÑ¦b11000ÂI¤W¤U¤w¸g¥b¦~¦h¡A¦ý¬O³o¤]¬O³ÌÃø¾Þ§@ªº®É¨è¡C ³o2Ó¤ë¡A¤j¦h¼Æ¤H³£½ß¿ú¡A¦]¬°¥ý«eº¦±o«Ü¶}¤ßªºÓªÑºG¶^¡A²{¦b·|º¦ªº¡A³£¬O¥H«e¤£·|º¦ªº¡A³o¬OªÑ¥«¦b«¾ãµ²ºc¡A¦b¬Ý¤¤¬ü¶T©ö¼¯À¿ªº¤U¤@Ó½Õ¾ã¡AªÑ¥«¥¿¦b醖ÆC¤U¤@Ó¦^¦XªºÅܤơA¨S¦³¼Ð·Çµª®×¡A³o¥¿¬OªÑ¥«³Ì°g¤H¤§³B¡A§Ú¸g±`¥H³o¤KÓ¦r¨Ó«jÀy¦~»´ªº§ë¸êªB¤Í¡G¤Å·N¡A¤Å¥²¡A¤Å©T¡A¤Å§Ú¡I¡]°]¸g¤¤¤ß¡þ¥x¥_³ø¾É¡^ ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ³Q°Ê °êx´º®ð´`ÀôªÑ , ªÑ»ù=¥¼¨Ó2¦~¤½¥q²bÈ ¥Ø«e²bÈ100¤¸¡A¥[¤µ©ú2¦~¼W¥[²bȦô200¤¸=300¤¸. ²bÈx1.5¿(¥DÆ[µû»ù) 300x1.5¿, ¶W¹L450¤¸ªº°ê¥¨,¥Ø«e¬Ý¨Ó¬O·ÀI ¤§«e¾Ù°T¡B¿ûÅK¡B·s药¥ç¥i¦p¦¹µû¦ô |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤U¤È 11:33:18²Ä 350 ½g¦^À³
|
·s¼Wªº³B¤èÅҼƶq¤Ö¡Aì¦]«D±`¦h¡A¨Ã«D³æ¤@ªº«O»Ùñ约Âл\²v¡A¦æ¬F°µ·~4~6¶g¦p¦¹Â²³æ Ó¤H©Òª¾¥i¯àì¦]¦p¤U¡G ¤@¡A«OÀI¤ä¥I§x¹Ò www.genetinfo.com/investment/featured/item/18622.html ¬ü°êMedicare ,¤j°ÃÄ»ù¤èªk,¬Ù¤U¨Óªº¿ú¦^õX¤@¥bµ¹¯f±w.(¦Û¥IÃB¤j´î) 1¡B¶}©ñ³B¤èÃĪ«Ä³»ù: 2¡B¤Þ¶iº¥¶i¦¡ªvÀø(step therPY):±q«K©yªºÃĶ}©l¨Ï¥Î. ¦¹Ãþ¦b¨p¤H«OÀI¤w¦æ¤§¦³¦~. (Ãø©Ç è¤W¥«ªºHIV³J¥Õ½èÃÄ ,¦³¨Ç¤w¶}¥ß³B¤èÅÒ¦ý«OÀI®Ö¤£¤U¨Ó????,!!!!! ¤×¨ä¦bMDRªì´Áªº¯f±w ¦³10¦hºØ«K©yªº¤p¤À¤lÃÄ¥i¨Ï¥Î,n½ü¨ì¶W¶Qªº³J¥Õ½èÃÄ, ¦b¨p¤H«OÀI¥inµ¥«Ü¤[,²{¦b¤½«OMedicare//Medicaid¤]¦p¦¹, ///!!!! ) ¤G¡B±wªÌ§x¹Ò 1.¨C¤G¶g¤W¤@¦¸Âå°|ªº§Ü©Ú HIV¶§©ÊªºªvÀø¦b¬ü°ê¼s§i¬O±j½Õ¡§¥¿±`¡A¬¡ÅD¡A¬y°Ê(µLµh).¥un«ö³W©wªA¤fªAÃĪ«§Y¥i¡C¡]µù1) ¦Ó·sHIV³J¥Õ½èÃĬO¨C¤G¶g¬Ý¤@¦¸Âå¥Í¡A¥´¤@¦¸°w¡C¡]¤×¨ä¬On¶}¨®1~2¤p®É¥H¤WªÌ/½ë,¡X¬ü°ê鄕¤U¬O¦a¼s¤Hµ}) ¤fªAÃĪ«¯f¬r±±¨î¥¿±`«á4-6Ó¤ë¥h¤@½ëÂå°| vs. 2¶g¤@¦¸ (Àù¯g±wªÌ¤]§Æ±æ¦b®a¦Û¤v¥´°w) ¥H¤Wµ¹±wªÌ«Ü¤jªº¥Í¬¡§ïÅÜ, 2.2011¦~ ·s»D: 2´ÁÁ{§É©Û¶Ò§xÃø °Ñ»P¹êÅç¦ý¥u¦¬¨ì¤@ÓӮתº¤¤°êÂåÃĤj¾ÇªþÂå·P¬V¬ì¥D¥ôÂå®v¤ý¥ô½å«o¤£³o»ò¼ÖÆ[¡A¥L«ü¥X¡A·R´þ¯f±w¤E¦¨¤³£¦bªù¶E¥H¤fªAÃĪ«ªvÀø¡A¥u¦³¤¢H¦í°|¡A³oÓ·sÃĶ·°t¦X¨Ï¥Î쥻ªºªvÀøÃĪ«¡A¨Ã©w´Á¦^Âå°|ÀR¯ßª`®g¡A¥ú¬O¦¬®×´N«Ü§xÃø¡A¥¼¨Ó¯f±w°t¦X«×¬O¤@¤j°ÝÃD¡C www.canews.com/News_Center/News_2011/News_release_2011_1213001_01_05.html ¤T¡AÃĪ«Ävª§§x¹Ò ¤T´Á40¤HÁ{§É¡A¬Ò¬O§Ö¨SÃĪÌ(OSS ¬¡©ÊÃĪ«<4 ºØ)¨Ó°Ñ¥[¡C ¬¡©ÊÃĪ«OSS=0,N= 5¤H,(FDAn¨D¦Ü¤Ö OSS=1 Áp¦X,¥ÎÃÄ,¦]¦¹³o¨Ç¤H¤£¬O¥Ø¼Ð«È¤á) ¡§OSS=1, N=12 ¤H ¡¨OSS=2, N=18¤H ¡§OSS=3 , N=3¤H ¡¥¡¦OSS=4, N=2¤H www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf TABLE 6. °ÝÃD¬OMDRªÌ, ªºOSS½d³ò ¬O 0 ~20, MDR ±wªÌ¦³¬¡©ÊÃĪ«0~20ºØ¡A (¦p¸g3¦¸´«ÃÄ¡A¬ù¥Î±¼10ºØHIV¡A«áÁÙ¦³20ºØ¬¡©ÊHIV§í¨îÃĪ«ªÌ,¬Ò¥iºÙ¬°MDR±wªÌ) ¡X¡X¡X ¡X¡X¡X¡X¡X- µù:1 ·íµM¡A³oºØµ¦²¤ªº°ÝÃD¦b©ó¡A¥¿¦b»â¾É¬Û¹ï¥¿±`¡A¬¡ÅD¡A¬y°Ê¡]µLµh¡H¡^¥Í¬¡ªº¦ã´þ¯f¯f¬r¶§©ÊªÌ¤£¤Ó¥i¯à¦P·N¨C¤Ñ¨â¦¸ªº¥Í¬¡½è¶q¨îFuzeon. The problem with this strategy, of course, is that HIV-positive people who are leading relatively normal, active, mobile (pain free?) lives are unlikely to agree to the quality of life constraints twice daily Fuzeon www.treatmentactiongroup.org/tagline/2004/march/fuzeon-fizzles |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤U¤È 08:01:52²Ä 349 ½g¦^À³
|
·sÃħë¸ê¤ß±o: ¯E¹©¤@§Ð¡A¾ÇÃÀ¤£ºë¡A©ê¤W¤S©ê¤U. ¡X¡X-¤Ó·Q«H¤½¥q»¡ªk¡A50~60%¦³®Ä¡A¥i¥H¥ý¥´¼Æ°w¨Ó¿zÀËMBC°Ñ»PªÌ....«á¨ÓMBC°ï¤£¥XMBC¤T´ÁÁ{§É. ¦ý¾Ç¨ì Á{§É¼Æ¾Ú PȪº«n©Ê.//FDAªº»{¦P©Ê ¤¤¸Î ¤@§Ð¡A¦]¥ý¬ã¨sFUZEON, ÁA¸Ñ ¾P°â¼Æ¾Ú«n©Ê¡A ¬ü°ê3Ӥ몺¾P°âÃB´N©wªÑ»ù¥Í¦º. ¡§¦]¬°¤W¥««e¦æ销¤Hû¤w¸g±µÄ²Âå¥Í¤@¦~¤F¡C¡¨ ¤µ¦~5¤ë15¤é TH¤½¥q«Å§G½æ100¤H¡A¥t¦³250¤H«Ý¶}³B¤èÅҮɡA´N¨M©w¥ýÂ÷¶}¡C ¡X¡X-¦]¬° FUZEON ¤]¬O2003¦~5¤ë¤¤¦¯(½æ45¤Ñ)¡A½æ¥X2600¤H¡C¡X¡X(¤@¾ã¦~ªº¾P°â¦¨ÁZ) 2003¦~7~9¤ë¡A¨C¤ë·s¼W500¤H,¤£¦p¤Wz2600¤Hªº¼W¥[³t²v¡AªÑ»ù¤j¶^ ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦³¤Ó¦h¦]¯À³y¦¨¾P°â¼Æ¾Ú¤£¨Î. Y¦Û¤v§äì¦]¸ÑÄÀ¡A¦Ó¦Û»{¬°¥¼¨Ó·|Åܦn. ªÑ»ù±`¬O¤£¯d±¡! ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ºâµ¹¤j¤jÌ¬Ý ¤@¤ä¥Ø«e¥«È20»õ¬ü¤¸,ªºè¤W¥«ªº·sÃĪÑ. ¬On·f°t4¦~«á8»õ¬ü¤¸ªº¥þ²y¾P°â°ª®pÃB ¬ü°êÁ`¾Pª÷ÃB5633¤Hx8.8/10,000=4.957 »õ ¬ü¤¸ ¼Ú¬wÁ`¾Pª÷ÃB5633¤Hx5.4/10,000=3.041»õ¬ü¤¸ Y¹ê»Ú¨C¤ë·s¼W³B¤èÅÒÂ÷¼Ð·Ç¾P°â«Ü»·. ¤p¤ßªÑ»ù×¥¿.!!! ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥|¦~¾P°â°ª®p,§é²{²v 8% 1.08^4=1.36 20x1.36=27.2 »õ¬ü¤¸.(¥|¦~«áÉ]È) 15¿¥»¯q¤ñ(¦PÃþÀsÀY2015¦~ªñ´Á°ª®p¾P°â¦~ªº¥»¯q¤ñ) finance.yahoo.com/quote/GILD?ltr=1 µ|«á¯Â¯q=27.2/15=1.813»õ¬ü¤¸ µ|«e 1.813/79%=2.3»õ¬ü¤¸ 2.3x30.6=70.4»õ¥x¹ô ¤ò§Q=70.4+6»õºÞ¾P¬ã¶O¥Î=76.4»õ ¤À¼í«á¥xÆWÀç·~ÃB=76.4/60%(¤ò§Q²v)=127»õ¥x¹ô¡X-¤À¼í52% ¤À¼í«e127/0.52=244¥x¹ô =8 »õ¬ü¤¸.¡X¡X¥þ²y²b¾P°â(¼Ú¡Ï¬ü) ²bÃÄ»ù ¬ü°ê8.8¸U¬ü¤¸ ¼Ú¬w5.4¸U¬ü¤¸ ¡X¡X¡X¡X ¥§¡7.1¸U¬ü¤¸. 8»õ¬ü¤¸/7.1¸U¬ü¤¸=11267¤H¤@¦~ 11267/2=5633¤H(¼Ú¡B¬ü¦U¦~¾P5633¤H) ¬ü°êÁ`¾Pª÷ÃB5633¤Hx8.8/10,000=4.957 »õ ¬ü¤¸ ¼Ú¬wÁ`¾Pª÷ÃB5633¤Hx5.4/10,000=3.041»õ¬ü¤¸ ¡X¡X- ²Ä¤@¦~¹wp¾P°â¤H¼Æ ¥§¡5633x20%=1126¤H¤@¦~ 1126/6=¨C¤ë·s¼W188¤H 1126x12=13519¤H¤ë ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¥§¡5633x30%=1660¤H¤@¦~ 1660/6=¨C¤ë·s¼W277¤H 1660x12=19,920¤H-¤ë ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¹ê»Ú¾P°â=Q1 ?) Q2 ? Q3 ? Q4 ? ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦Xp ? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/11 ¤U¤È 04:43:41²Ä 348 ½g¦^À³
|
¤Ñ©R¤jªº»¡ªk§¹¥þ¥¿½T ·à¤lGÀù¨Ã¤£¬O°w¹ïHer2+ ICH +3 ©Ò¥H»P¶PÀù¥§¹¥þ¨S¦³Ävª§Ãö«Y¡C ·à¤l¤@½uGÀù¬O°w¹ïHer1¡BHer2¦@¦Pªí²{ ICH¤£¬O+3 ªº¯f±w¡C¾A¥Î¯f±w¤H¤f¼Æ°ª¹F¦Ê¤À¤§40¡AGÀù¥H¥þ²y¥«³õ¨Ó¬Ý¬O¤jÃÄ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤U¤È 04:35:08²Ä 347 ½g¦^À³
|
·sÃħë¸ê ¤@¡BÁ{§É¶¥¬q~¨ú±oÃĵý www.phycos.com.tw/articles/139 ·sÃĶ}µo¦bÁ{§É¶¥¬q¤§¦¨¥\²v ¤G¡B¨ú±oÃÄÃҫ᪺¾P°â ¥u¯à参¦Ò¤w¦s¦bªºÃĪ«°µ¬ã¨s. ¬ü°ê·sÃĪѬO¦¨¼ô¥«³õ. ·sÃĤW¥«3Ó¤ë´Nª¾¡A©¹«á10¦~ªº·~ÁZ¡C ªÑ»ù¤ÏÀ³«Ü§Ö¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X FUZEON 2003¦~, 3¤ë29¤é¤W¥« , ¬O½æªº¤£¦p¹w´ÁªºÃÄ ¤W¥«®É¹w¦ô½æ10»õ¬ü¤¸¡A4¦~«á¥þ²y¾P°â³Ì°ª2.68»õ¬ü¤¸. ¤W¥««e¹w¦ô²Ä¤@¦~«e9Ó¤ë(2003,4~12¤ë),¥Ø¼Ð¾P°â1.2»õ¬ü¤¸¡A³Ì«á2004¦~¶È¾P°â0.36»õ¬ü¤¸. ¹F¦¨²v¶È30%. ªÑ»ù³Ì°ª¬ù54¬ü¤¸/ªÑ(2003/07/15),¥«È12»õ¬ü¤¸. 2003¦~,7¤ë15¤é, 54¬ü¤¸/ªÑ¶}©l°_¶^¡A9¤ë©³¦¬ 25¬ü¤¸. 2004¦~¤¸¤ë ¶^¨ì18¬ü¤¸/ªÑ, ¥«È剰3.6»õ¬ü¤¸. www.treatmentactiongroup.org/tagline/2004/march/fuzeon-fizzles img.tapuz.co.il/forums/17412423.pdf FUZEON ¥þ²y²bÀ禬 (¦Ê¸U¬ü¤¸) 2003 13.1 17.6 ¦Xp 36.3 2004 24.0 35.5 34.2 39.8 ¦Xp 135.2 2005 42.5 53.9 48.9 62.9 ¦Xp 208.2 2006 55.4 57.2 63.0 73.3 ¦Xp 249.0 2007 64.3 62.1 73.9 66.5 ¦Xp 266.8 ¡X¡X¡X¡X¡X¡X- ¬ü¥[¦a°ÏFUZEON ²bÀ禬(¦Ê¸U¬ü¤¸) 2003 Q2 4.3 Q3 10.7 Q4 13.3 ¦Xp 28.3 2004 Q1 16.0 Q2 24.4 Q3 21.1 Q4 24.2 ¦Xp 85.7 2005 Q1 23.3 Q2 25.2 Q3 28.4 Q4 35.8 ¦Xp 112.7 2006 Q1 27.4 Q2 31.1 Q3 33.5 Q4 42.2 ¦Xp 134.2 2007 Q1 29.3 Q2 32.9 Q3 30.6 Q4 31.5 ¦Xp 124.3 79700/12=6641/¦~¤@¤H FUZEON ¾P°âÃB°ª峯 (¬ü¥[¦a°Ï) FUZEON ¥_¬ü¦a°Ï(¬ü°ê&¥[®³¤j)¦~¾P°â¶q(KITS)¾ã²z 2003 (3¤ë©³FDA ®Öã¤W¥«) 19,400 KITS (¨C¤H¨C¤ë¤@Kit /60 ²~) 2004 58,900 KITS 2005 72,000 KITS 2006 79,700 KITS(¾P°â°ª®p) 2007 72,700 KITS 2008 36,000 KITS 2009 20,000 KITS 2010 16,100 KITS *¼Ú¬w¤Î¨ä¥L°ê®a¥¼²Îp¡C *¸ê®Æ¨Ó·½ºô¸ô³ø¾É *¦±ß¯f¤H¦U¥´°w¤@¦¸¡C ¤Wzª÷额¦¨5¿*30%§Y¬°²b§Q¡A欧¬wºC15Ó |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/8/11 ¤U¤È 04:06:32²Ä 346 ½g¦^À³
|
¤Ñ¤j,ÁÂÁ±z~~ASL001¥iª½¶¡±µ«ÊÂê¥|ºØHer®a±Úªº¸~½F³~®|,¬G¦³¥i»P¶PÀù¥Ävª§ªº¬Ýªk,³o¼Ë¬Ý¨Ó¥i»P¨äÁp¦X¥ÎÃÄ»¡¤£©w¤]¬O¤@Ó¤è¦V~~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤U¤È 03:40:28²Ä 345 ½g¦^À³
|
¥þ²y¶W¹L10Ó¤½¥q¦b°µ¶PÀù¥ªº¥é¥ÍÃÄ.¦³2-3Ó¤w®Öã¤W¥«. ¨È·à±d¤£¶i¥hHER2+,IHC+3 ³o¶PÀù¥¥«³õ¬O¬Û·í©ú´¼ªº§à¾Ü¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤U¤È 03:29:16²Ä 344 ½g¦^À³
|
ASLAN001 GÀù¤G´ÁÁ{§É±Æ°£½d³ò¦p¤U, ¦]±Æ°£ HER-2 ,IHC +3,¬GµLªk»P¶PÀù¥¬Û¤ñ. clinicaltrials.gov/ct2/show/NCT03130790 Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) ¼Ð·Ç ¤J¿ï¼Ð·Ç - ²Ä2¶¥¬q ¡X¡X ¨ã¦³²Õ´¾ÇÃҹꪺ¤£¥i¾Þ§@ªºG©ÎGEJÀù¯gªº§½³¡±ß´Á¡X¡X¡X- ¡X¡X¡X¡X- ¨ã¦³IHCÃÒ¾Úªº¨ü¸ÕªÌ¨Ï¥Î·í¦a¹êÅç«Ç¤¤ªº¼Ð·Ç¼Ð·Çªí¹FHER1¡]¤ô¥¬°+©Î++©Î+++¡^©MHER-2¡]¤ô¥¬°+©Î++¡^¡C³q¹LIHC½T©w¨ã¦³HER-2¹L¶qªí¹F¤ô¥ªº¨ü¸ÕªÌ¡A¨ü¸ÕªÌ³q¹LIHC½T»{HER2 2+¡A³q¹LFISH½T»{HER2°ò¦]ÂX¼W¡A¦ý»P¦±§´¯]³æ§Ü*¬Û¥Ù¬Þ¡C *¦³Ãö¦±§´¯]³æ§Ü¬ÛÃö¸T§Ò¯gªº¸Ô²Ó«H®§¡A½Ð°Ñ¾\¥]¸Ë»¡©ú®Ñ©Î¬ü°êªvÀø«ü«n¡C ¡X¡X¡X¡X¡X¡X¡X HER -2 (¡Ï¡Ï¡Ï)= IHC ¡Ï3 , ¬O³Q±Æ°£ ±Æ°£¼Ð·Ç¡G HER-2¹L¶qªí¹Fªº¨ü¸ÕªÌ³q¹LIHC½T©wªº+++¤ô¥©Î¨ü¸ÕªÌ³q¹LIHC½T»{HER2 2+¡AHER2°ò¦]ÂX¼W³q¹L¤¤¤ß¹êÅç«Ç¤¤ªºº·¥úì¦ìÂø¥æ¡]FISH¡^½T»{¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X Exclusion Criteria: Subject with HER-2 over expression at level of +++ determined by IHC or subject confirmed HER2 2+ by IHC with HER2 gene amplification confirmed by Fluorescence in situ hybridization (FISH) in the central lab. Criteria Inclusion Criteria - Phase 2 Part Subjects ¡X¡Xi¡X- Subjects with tumors with IHC evidence of expression of HER1 (at level of + or ++ or +++) and HER-2 (at level of +, or ++) using standard criteria in the local lab. Subjects with HER-2 over expression at level of +++ determined by IHC and subject confirmed HER2 2+ by IHC with HER2 gene amplification confirmed by FISH but has contradiction to trastuzumab*. *For details of contraindication related to trastuzumab, refer to package insert or US treatment guideline. ¡X¡X¡X¡X¡X¡X Exclusion Criteria: Subject with HER-2 over expression at level of +++ determined by IHC or subject confirmed HER2 2+ by IHC with HER2 gene amplification confirmed by Fluorescence in situ hybridization (FISH) in the central lab. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/8/11 ¤U¤È 03:13:34²Ä 343 ½g¦^À³
|
¤Ñ¤j,¤£¦n·N«ä,À³¬OHER1/ HER2 Co Expressing¤~¹ï,ÁÙ¬O¥i»P¶PÀù¥¤@¸ûªøµuù(ªk»¡·|¸ê®Æ²Ä11¶)~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤U¤È 02:46:57²Ä 342 ½g¦^À³
|
ASLAN001 ¤G/¤T´ÁGÀùÁ{§É ¤£¥]§t¶PÀù¥³Ì¦³®Äªº HER2+¡AIHC+3¡A ¤wÁ׶}贺Àù¥GÀù³Ì¥Dn¥«³õ¡C ©t¤j¡A½Ð¸Ô¨£±z¶KªºÁ{§É¿zÀË¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/8/11 ¤U¤È 02:37:59²Ä 341 ½g¦^À³
|
¤Ñ©R¤j, ²{¶¥¬q2´Áªº¤H¼Æ·íµMµLªk¸ò3´Áªº¶PÀù¥(ù¤óÃļt)¬Û¤ñ,¦ýY¦³Àu²§ªº¤G´Áªì¨B¼Æ¾Ú¬O¥i§l¤Þ¤j¼t¦X§@(Y¨S¦³¤º³¡µû¦ô¹LªºÁ{§É¼Æ¾Úªº¤è¦V,µM«ç·|¬O¥t¤@ӼϯøÕÅç),¶i¦Óµ¹¶PÀù¥(À£¤O, ¤]¥i¸ò¤@´ÁMBCµo®iªº¤è¦V¤@¼Ë,¬J¥i¸ò¤j¼tÄvª§¤]¥i¦X§@~~~µM±q¤@´ÁORR-40%¨Ó¬Ý, À³¨ã¦³»P¶PÀù¥¤@¸ûªøµuªº¼ç¤O~~ ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤W¤È 10:38:08²Ä 340 ½g¦^À³
|
www.slideshare.net/mobile/jtcancercenter/grothey-gi-malignancies-11111 p.80 ¶PÀù¥ªº¤@½uGÀù丅oGA , 3´ÁÁ{§É¡A,¿zÀË her2+ , ¹êÅç²ÕN=294¤H, ORR 47.3% ¹ï·Ó²ÕN=290¤H¡AORR 34.5% P=0.0017 PȦbN °Ñ¥[¤H¼Æ·U¦h¡A¦P様ªºHR¤ñ¤U¡APȶV¤p. ¨È·à2´Á¤~52¤H¡APȰѦҥÎ. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/8/11 ¤W¤È 10:27:14²Ä 339 ½g¦^À³
|
¤£¨£±o³á~~~ªì¨B¼Æ¾Ú3Ӥ몺«ü¼Ð¬O¸~½F³Ìªøª½®|ªº§ïÅܲv,¥B¬OHER1/HER¿z¿ï¹Lªº¯f±w...³Ó²vÀ³¬O»á°ª... ¥H¤W¨Ñ°Ñ¦Ò~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/11 ¤W¤È 10:11:14²Ä 338 ½g¦^À³
|
¨È·à±dASLAN001 ¤@缐GÀù2´ÁÁ{§É N=52(26:26) ¹êÅç²Õ ORR 40% ¹ï·Ó²Õ ORR 30% PÈ 45%.¤£·|¹LÃö ¡X¡X¡X¡X- ASLAN001 GÀùÁÙ¬O±o¬ÝN=352¤H¡Aªº¥¼¨Ó¤T´ÁÁ{§ÉOS ¥Dn«ü¼Ð. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/8/11 ¤W¤È 09:02:34²Ä 337 ½g¦^À³
|
Æ[¹î201806ªk»¡·|¸ê®Æ²Ä18¶-GÀù-ORR40%,DCR100%-³o¤£´N¬O¥P¤H«ü¸ô¶Ü ? ªk»¡·|³sµ²: mops.twse.com.tw/nas/STR/649720180531M001.pdf GÀùFDA¸ÕÅç³sµ²: clinicaltrials.gov/ct2/show/NCT03130790?cond=varlitinib&rank=5 ¥H¤W¨Ñ°Ñ¦Ò~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤U¤È 06:32:30²Ä 336 ½g¦^À³
|
GÀù¤G´ÁÁ{§Én=52 §¹¦¨¦¬®×¤§¤½§i 1.¨Æ¹êµo¥Í¤é:107/08/10 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ:¥»¤½¥q¬ãµo¤¤¤§varlitinib (ASLAN001)§¹¦¨§@¬°HER1/HER2¦@¦Pªí²{±ß´Á ©ÎÂಾ©ÊGÀù¤@½uªvÀø¥þ²y¤G/¤T´ÁÁ{§É¸ÕÅ礧¤G´Á¦¬®×¡A¦@©Û¶Ò52¦W¨ü¸ÕªÌ¡CÁ{§É¸Õ Åç½s¸¹001-012¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡Gvarlitinib (ASLAN001) ¤G¡B¥Î³~¡GGÀù ¤T¡B¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤G/¤T´ÁÁ{§É¸ÕÅç ¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)¡B´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G¤w±Ò°Ê¤G/¤T´ÁÁ{§É¸ÕÅç¡C (¤G)¡B¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î¡C (¤T)¡B¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î¡C (¥|)¡B¤w§ë¤J¤§¬ãµo¶O¥Î¡G°ò©ó°Ó·~¾÷±K»P«O±K¨ó©w¤£¤©´¦ÅS¡C ¤¡B±N¦A¶i¦æ¤§¤U¤@¶¥¬q¬ãµo¡G (¤@)¡B¹wp§¹¦¨®É¶¡¡G¤G/¤T´ÁÁ{§É¸ÕÅ礧¤G´Á¸ÕÅçªì¨BÁ{§É¼Æ¾Ú¹wp©ó2018¦~²Ä¥|©u ¤½§G¡C (¤G)¡B¹wpÀ³t¾á¤§¸q°È¡G¤£¾A¥Î¡C ¤»¡B¥«³õ²{ªp¡GGÀù¥Ø«e¦b¥þ²yÀù¯gµo¯f²v¤¤±Æ¦W²Ä¥|¡A¬O¥þ²yÀù¯g¬ÛÃö¦º¤`ªº²Ä¤G ¤j±`¨£ì¦]¡A¤]¬O¨È¬w³Ì±`¨£ªºÀù¯gÃþ«¬¤§¤@¡CGÀùªº¾ãÅé¦s¬¡´Á¤¤¦ì¼Æ¬°11.1Ó¤ë ¡A¤¦~¦s¬¡²v¤Ö©ó20%¡C¥Ø«e²Ä¤@½uHER1/HER2¦@¦Pªí²{GÀù©|µL®Ö㤧¼Ð¹vÀøªk¡C °Ñ¦Ò¸ê®Æ:www.ncbi.nlm.nih.gov/pmc/articles/PMC4768187/ www.ncbi.nlm.nih.gov/pmc/articles/PMC5808709/ www.ncbi.nlm.nih.gov/pmc/articles/PMC4000485/ ¤C¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë ¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤W¤È 11:03:16²Ä 335 ½g¦^À³
|
2018¦~¤¸¤ë ASLAN001 ¤T´ÁÁ{§É&¥þ²y¾P°â±ÂÅv§¹²¦. ñ¬ùª÷2200¸U ùµ{ª÷1»õ¬üª÷ ¾P°â¤À¼í?10~12%? ------------ ÁʶRªÌ:¨È·à±d |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/8/10 ¤W¤È 10:53:35²Ä 334 ½g¦^À³
|
¤£ª¾¤j®a¬O§_ÁÙ°O±o¡A¥h¦~¦~©³¥ª¥kªk»¡·|¤W¦³»¡2018·|¦³®ü¥~±ÂÅvªºµo¥Í¡A¤£¹L¦bQ2ªº©u³øªºÂ²³ø¤W±¨Ã¥¼´£¤Î¡A¤£ª¾¬O°ò©ó«O±Kªºì«h¤£¯à¤½¶}¡AÁÙ¬O®Éµ{¦³©Ò©µÌX©O? ÆZ´Á«Ý¥h¦~¦~©³»¡ªº®ü¥~±ÂÅv¡A¦pªG¦³µo¥Í±N¥i¥H¹ï²{¦bªº°]°È¦³¤j¤jªº§U¯q¡A¹ïªÑ»ù©Ô©ï§ó¤£¦b¸Ü¤U¤F! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤W¤È 10:01:11²Ä 333 ½g¦^À³
|
¡´¨È·à±dªºÀuÂI¤£³ÓªTÁ|¡G 1. Merckªº Alnair Investment(7%)------------------¡´°ê»Ú¤j¼tª½±µ¤JªÑ 2. ·s¥[©Y²H°¨¿ü°òª÷¤Uªº BV Healthcare II(6%)-------¡´¥ý¶i°ê®a¬F©²°òª÷ª½±µ¤JªÑ 3. ¬ãµo¹Î¶¤°}®e°í±j¡A³£¨Ó¦Û°ê»Ú¤jÃļt---------------¡´AstraZeneca, GSK & Novartis.... 4. BMS(¥²ªv§´)©ó2016/08¶R¦^ASLAN002(PD1¤§¥~ªº¥t¤@§K¬ÌÀˬdÂI§í¨î¾¯,RON)ªº¥þ²yÅv§Q (ñ¬ùª÷1,000¸U¬üª÷ + ¨½µ{ª÷¤j©ó5,000¸U¬üª÷¤À10¦~»{¦C + ¤@©w¤ñ¨Òªº¾P°â¤À¼í)---¡´¥Ø«e¤½¥q²{ª÷>20E¡A¥i¥Î¦Ü2019¦~¡I 5. ASLAN003(DHODH)p53ªº»¤¾É¾¯¡A¥Ø«e°w¹ïsolid tumor & AMLªº¬ãµo---¡´2018Q2~Q3±ÂÅv¥i´Á¡I 6. ASLAN004¬°°w¹ï®ð³Ý¤Î¯S©w¸~½FÃþ«¬ªºIL4/IL13³æ®è§ÜÅé----¡´¹w¦ô¾P°âÃB¹O60»õ¬ü¤¸ 7. ASLAN005 «YÂê©wRON¤§³æ®è§ÜÅé¡A§K¬ÌÀˬdÂI§í¨î¾¯----¡´PD1¤§¥~¥tÅPÁÑ®|¡I 8. ¥HModybody§Þ³Nºc«Ø¿W¦³¬ãµo·sÃÄ¡A¨È·à±dÂê©w3¶µ·s¿o¸~½F§K¬Ì¼Ð¹v¶i¦æ¬ãµo(ASLAN006,007,008) ¤Þ¥Î¦Ñ´¤jªº¤Þ¨¥. ASLAN 004 ¤W´å¬OCSL ¿D¬w¬ãµo¤½¥q. ¤T´ÁÁ{§É&¦æ销¤½¥q¥¼ª¾? ¥²¬O¤¤¡B¤jÃļt, 3¦~¤º¦¸n¥I²{ª÷20»õ¬ü¤¸ªºÃļt. |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/10 ¤W¤È 09:53:24²Ä 332 ½g¦^À³
|
©Ò¿×¤Ñ®É¦a§Q¤H©M¡AÃÄ«~¦æ¾P·íµMÃÄ«~¤£¯à¤Ó®t¡A¦A·f°t¤jÃļt¦æ¾P¤è¥i¯à¦¨¥\¡A°£«D¥«³õ¤W¬YºØ¯e¯f¥u¦³¥x¼t°ß¤@¢°¤äÃÄ¡A¨ºÀH«K¤@Ó¤H³£¥i½æªº«Ü¦n¡A¦p¥«³õ¤WÁÙ¦³¿ï¾Ü¡A¥x¼tÃÄn¥´¤J¥«³õ¤ñµn¤ÑÁÙÃø |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤W¤È 09:07:03²Ä 331 ½g¦^À³
|
Dupilumab ¨C©u¦¨ªø5000¸U¬ü¤¸¾P°â. §é²{²v3.6% ²Ä7¦~¾P°â°ª峄50»õ¬ü¤¸,12¦~ªº§é²{È300»õ¬ü¤¸. ñ¬ùª÷+ùµ{ª÷:20»õ¬ü¤¸ 10%¤À¼í=30»õ¬ü¤¸. ¾P°â¤½¥q 300»õ¬ü¤¸*30%²b§Q=90»õ ¦©°£-20»õ(ñ¬ùª÷+ùµ{ª÷)=70»õ ¬üª÷.---²b§Q(²b²{ª÷) 1 2 3 4 5 6 7 8 9 10 11 12 3.6% 1.036 1.073296 1.111934656 1.151964304 1.193435019 1.236398679 1.280909032 1.327021757 1.37479454 1.424287143 1.475561481 1.528681694 2.7 10.2 18.2 26.2 34.2 42.2 50 50 40 40 40 40 2.6 9.5 16.4 22.7 28.7 34.1 39.0 37.7 29.1 28.1 27.1 26.2 sum 301.2 ------------------------------------- ªvÀø¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ ¾P°â·~ÁZ Dupixent Approval History FDA approved: Yes (First approved March 28th, 2017) Brand name: Dupixent Generic name: dupilumab ¾P°âÃB :¦Ê¸U¬ü¤¸ 2017¡CQ2 US 28 2017Q3 US 89 2017Q4 US 139 ¥þ¦~¦Xp US 256 ¡X¡X¡X¡X¡X¡X- 2018, Q1 us 117 out of US14 ¦Xp 131 2018 , Q2 US¡A181 ou of US28 ¦Xp 209 ¥b¦~²Öp340 ¦Ê¸U¬ü¤¸¡]¤W¥««á²Ä¥|~¤©u) ¤W¥«²Ä¤@¦~²Öp387¦Ê¸U¬ü¤¸ ¥Ø«e¬ü°ê°Ï¨C©u¬ù¥H·s¼W50¦Ê¸U¬ü¤¸ªº¾P°âÃB¼W¥[¤¤¡C ¹wp40~50»õ¬ü¤¸ªº¾P°â°ª®p. files.shareholder.com/downloads/REGN/6360252393x0x983112/67E0E219-BCC3-45ED-9FD0-C5F1CF08B0C6/REGN_News_2018_8_2_General_Releases.pdf |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤W¤È 06:04:03²Ä 330 ½g¦^À³
|
¨Ñ给¡B»Ý¨D¨M©w¦¨±Ñ¡I¡I¡I¡I ¥xÆW©ú¤é²£·~10¦~¦¨ºG·~¡I Áª÷ªe¹ÄªÑ»ù¶^¨ì´í³£¤£³Ñ 2018¦~08¤ë09¤é 00:51 ¤¤®É¹q¤l³ø §f©Óõ ...°ê¤º¤Ó¶§¯àÀsÀY¼tZ}¡]6244¡^²Ä2©u¸ê²£´î·l8.23»õ¡BÁ«·l20.74»õ¤¸«á¡AZ}¸³¨Æªø±iªÃ¿Å´N°{Ã㸳®y¡Aµ²§ô¤F¥L¦b¤Ó¶§¯à¹q¦À²£·~ªºÅå©_¤§®È¡A¹ï¦¹¡A°]«H¶Ç´C¸³¨ÆªøÁª÷ªe¦bÁy®Ñªí¥Ü¡A±iªÃ¿Åªº±¾«a¨D¥h¡A¥NªíµÛ¤Ó¶§¯à²£·~±q·í¬õªº©ú¤é²£·~¨«¤F10¦~«á¡A¥u¯à¥Î¡uÁy¦âºG¥Õ¡v¨Ó§Î®e¡C Áª÷ªe«ü¥X¡A¥L±`»P¤§«eZ}ªº¸³¨Æªø¾GºÖ¥Ð¡A¦b¶§©ú¤sªº±¤Ñ¤Î¤j¤Ù¥D®p¸I±¡A¦b10¦h¦~«e¡AZ}ªÑ»ù´¿¸g¼Éº¦¨ì985¤¸¡A¨º®ÉÔÁÙ¦³¯q³qº¦¨ì1205¤¸¤Ñ»ù¡A³¢¶i°]ªº¬R´¹º¦¨ì416¤¸¡A¤Ó¶§¯à²£·~µS¦p¦L¶r¾÷¯ë¡A§l¤Þ¤F¥ø·~ª§¬Û§ë¤J¡C Áª÷ªe·P¹Ä¡A¡u¥xÆWªº¤Ó¶§¯à²£·~³o10¦~ªº¨¯W¤§®È¡A¥u¯à¥ÎÁy¦âºG¥Õ¨Ó§Î®e¡v¡A¥xÆW¤Ó¶§¯à²£·~ªÑ»ù¤j¥¢¦å¡A¡uZ}¤@¸ô±q985¤¸±þ¨ì¥u³Ñ¤U11.85¤¸¡A´N³s¥x¿n¹q¤]¦¨¬°W¥D¡A§ó§O´£¨ä¥L§ë¸ê¤H¦å¥»µLÂk¡A±iªÃ¿ÅÅfµM¨D¥h¡A www.chinatimes.com/realtimenews/20180809000094-260410 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤W¤È 05:56:29²Ä 329 ½g¦^À³
|
¥¼³Qº¡¨¬ÂåÀø»Ý¨D °Ó¾÷¤j ¥ÎLINE¶Ç°e + ¯d¨¥ 2018-08-06 00:00¸gÀÙ¤é³ø °OªÌ¶À¤å©_/¥x¥_³ø¾É ¥¼º¡¨¬ÂåÀø»Ý¨D¨üÆf¥Ø¡A¦¨¿ïÃDÃöÁä¡CµØ¦w«ü¥X¡Aªñ¦~¡u¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D¡v¡]Unmet Medical Need¡^¬O·sÃĶ}µo¤½¥q·¥¤O¶}µoªº»â°ì¡A¦Ó¸Ó¤½¥qªºµ¦²¤§Y¥H¦¹¬°¥D¶b¡A§ä¨ì§Q°ò²£«~¡A·m¶i°ê»Ú¥«³õ¡C ©Ò¿×¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D¤è¦V¦³¤G¡A²Ä¤@ºØ¬O¥Ø«eÁöµM¤w¦³ÃĪ«¡A¦ý¤´¦³«Ü¤j¶i¨BªÅ¶¡¡A¨Ò¦pÀù¯g¡F²Ä¤GºØ¬O§¹¥þ©Î´X¥G¨S¦³ÃĪ«¯àªvÀøªº¯e¯f¡A¥]§t¥ý¤Ñ©Ê¨u¨£¯e¯f¡Bªü¯÷®üÀq¯g¡B¿}§¿¯f¨¬¼ìºÅ¡B¶À´³³¡¯fÅÜ¡B¦¨¤H²§±`¸¨¾vµ¥¡A§¡Äݤ§¡C ¤Wz¶}µo¤è¦V¡AY¯à§ä¨ì¾A¦XªºÀøªk¡A·f°t¨}¦nªºÁ{§É¸ÕÅç³]p¡A°£¤F¯à¤j´T´£¤É²£«~¤W¥«¦¨¥\²v¡A¤]±N¦³§U©ó·sÃĤ½¥q»P°ê»ÚÃļt¶i¦æ·sÃıÂÅv½Í§P¡A¦b¦¹°ò¦¤W¡A¤@Ó¦¨¥\ªº¡u¥¼³Qº¡¨¬ÂåÀø»Ý¨D¡v·sÃĶ}µo®×¡A³q±`¯à¨ú±o¥¨ÃB±ÂÅvª÷¡C ¦b¿}§¿¯f¨¬¼ìºÅ¤è±¡A®Ú¾Úª¾¦W¿}§¿¯fÂå¾Ç´Á¥Z¡]Diabetic Medicine¡^ªº³Ì·s¬ã¨sÅã¥Ü¡A±w¦³¿}§¿¯f¨¬¼ìºÅ±wªÌ¡A¦³°ª¹F±Nªñ23.4%ªº±wªÌ¦b¿©±wªº²Ä¤@¦~´N»Ýn¶i¦æºIªÏ©Î¨ä¥L««Ø¤â³N¡AÄY«ªÌ¬Æ¦Ü¾ÉP¶W¹L15%¥H¤Wªº±wªÌ¦b¤@¦~¤º¦º¤`¡C ®Ú¾Ú²Îp¸ê®ÆÅã¥Ü¡A¿}§¿¯f¨¬¼ìºÅ¯f±w¤H¼Æ°ª¹F6,000¸U¤H¡A84%¯f±w±Á{ºIªÏªvÀøªº¿}§¿¯f¨¬³¡¶Ë¤f¼ìºÅ¡A¬O¥þ²y¶Ë¤fªvÀø¤j¼tªº¹Ú¤Û·sÃļЪº¡A¨C¦~¥þ²y°Ó¾÷¶W¹L¦Ê»õ¬ü¤¸¡AY·sÃĤW¥««á¥«¥e²v¹F10%«h±N¦³10»õ¬ü¤¸¤§°Ó¾÷¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤W¤È 05:41:05²Ä 328 ½g¦^À³
|
Ãö©óHIV药 ²£«~ªºÉóÂà¬O¥i¯àªº¤j°ÝÃD ¥Ø«e3Óªý¤î¯f¬r¶i¤JT细M§í¨î¾¯¬Ò¤£¬O«Ü¦¨¥\¡C CCR5¡AFuzeon,¤Î·s¤W¥«³J¥Õ½è药¡C ¤j®a¤W¥««e预¦ô¬Ò¦³10»õ¬ü¤¸ªº¥«³õ¡A¨ì³Ì«á«e2²£«~¥þ²y°ªûß销°â¬Ò¤£¨ì3»õ¬ü¤¸¡C Roche ¤j¼t¥h½æFuzeon ¤@¼Ë¥¢±Ñ¡C 药«~¤Ó¦h¡A¥²¶··f°t¨ä¥LÉóÂ઺药¡A变¦¨³Ì«á(¥i¯à²Ä10¦¸Âà药)ªº¿ï¾Ü¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/10 ¤W¤È 05:21:07²Ä 327 ½g¦^À³
|
Ãö©óASLAN004,¦æ销¬O¤é«áÁʶR¦¹±M§Qªº¼t°Ó¡A·íµM§Æ±æ±ÂÅvµ¹¤j¼t¡C ³o¬O¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢//ý³Ý ªº°ß¤G¼Ð¹v¡C ¾ãÅ饫³õ-¬ü°ê区´N¦³80¸U¤H(50%渗³z²v¡A¤]¦³40¸U¤H), ¥þ²y¥«³õ§ó¤j¡A领¥ýªº¤½¥qn¥þ®³¬O¤£¥i¯à¡C §_«h¤£·|¥þ²yºÆ¨gªº·m°µ¥é¥Í药¡A ¤@Ó29»õ¨ÅÀù贺Àù¥¡A¥þ²y¶W¹L10®a¦b·m°µ¡C |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/10 ¤W¤È 03:32:47²Ä 326 ½g¦^À³
|
¥H¥Ø«eÁÙ¦b§@¹Úªº¼ÐªºÀ³¸Óµ¥ÃD§÷§Ö¹ê²{®É¡AÃD§÷¹ê²{®ÉÄò©ê¡AªÑ»ù¦º¤`¥æ¤e®É»°§Ö¶]¤d¸U§O¯dÅÊ¡A³oÓ¤èªk´£¨Ñ§ë¸ê¤j¤j°Ñ¦Ò¡A²¦¹Ò·sÃĪѧë¸ê·ÀI¤Ó¤j¤F¡I |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/10 ¤W¤È 03:00:03²Ä 325 ½g¦^À³
|
§ë¸ê¥Í§ÞªÑ¤d¸U¤£n£¸´[±¡Ä@¡A¥ô¦óªº·sÃÄn¶i¤J°ê»Ú¥«³õ¶·¦Ò¼{¥xÆW¥u¬O¤p¼t¡A¦p¦ó±j¹Ü¨ä¥L°ê»Ú¤j¼t©Ò¦û¥«¦û²v¡A¨C¤@®a¤j¼t¨C¦~§ëª`¦bÂå¥Í¨¤W¦h¤Ö¸ê·½¡A¥xÆW¦h½æ1¬ü¤¸³o¨Ç¤j¼t´N¤Ö¤@¬ü¤¸¡A¥LÌ«ç»ò¥i¯à·|¥¥Õ§â¥«³õÅý¥X¨Ó¡A¤@©w·|·¥¤O®«½Ã¥«³õ¡A¾¨¥i¯àµo´§Âå¥Í¼vÅT¤O©è¨î¡A¨ì®ÉÃÄ«~º¯³z²v·|ºC¤S§Cªº¥i¼¦¡AÁöµMÃÄ«~¬O±Ï¤H¡A¦ý¬OÃÄ«~¦æ¾P«o¬O¦å²O²O±þ¼®¾Ô³õ¡A¤£¬OÃÄ«~¯à±Ï¤HÂå¥Í´N·|¶}¥ß³B¤èñ¡A¤£µM³o¨Ç¤jÃļt«ç·|¨C¦~ªá¤j§â»È¤l¦bÂå¥Í¨¤W¡A¤@¥¹¹L´X¦~«á±·sÃÄ¥X¨Ó¡A¥x¼t·sÃĤS·|GG¤F¡I§ë¸ê¤HÀ³¹ï§ë¸ê·sÃÄ·V«ä·ÀI¡A¨C¤@Áû·sÃıq¬ãµo¦Ü°ê¥~¤W¥«°Ê»³¤W¦Ê»õ¬üª÷¡A¦p¦ó¦^¦¬¬ãµo¸êª÷n¦n¦n«ä¦Ò¡A«e¤¤¬ã°|ªø´N´¿¦b¥ßªk°|»¡©ú¤@Áû·sÃĦæ¾P¨S¦³200-300»õ¬ü¤¸¬OµLªk¿ì¨ìªº¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤U¤È 10:59:08²Ä 324 ½g¦^À³
|
°ê»Ú±ÂÅvª÷(ñ¬ùª÷¡Ïùµ{ª÷)=40%¡Ï¾P°â¤À¼í60%)¤@¯ë¬Oµ¥©ó°ª峯¦~ªº¾P°âÃB. YASLAN004 ²§¦ì¥Ö½§ª¢ ¬ü°ê°Ï°ª峯¾P°â¦~: 50»õ¬ü¤¸,(¼Ú¬w°Ï¥t¦ô ,¥i¯à¥´5-6§é) ñ¬ùª÷¡Ïùµ{ª÷=40% ,50x40%= 20»õ¬ü¤¸(ñ¬ù//¤W¥«¥I²M)¡X-(¦ô¨È·à±d¤ÎCSL¦U¤À¤@¥b) ¾P°â¤À¼í =60% , 50x60%=30»õ¬ü¤¸,(¥i¯à10%ªº²b¾P°âÃB)¡X-(¦ô¨È·à±d¤ÎCSL¦U¤À¤@¥b) ³J¥Õ½è¼Ð¹vÃÄ«~¥N¤u¦¨¥»¬°¾P°â²bÃB20%¶]¤£±¼¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤U¤È 10:40:08²Ä 323 ½g¦^À³
|
°ê»Ú±ÂÅvª÷(ñ¬ùª÷¡Ïùµ{ª÷)=40%¡Ï¾P°â¤À¼í60%)¤@¯ë¬Oµ¥©ó°ª峯¦~ªº¾P°âÃB. ¬ü°ê°Ï°ª峯¾P°â50»õ¬ü¤¸(ªvÀø¤¤««×²§¦ì¥Ö½§ª¢ 50¸U¤H, ¬O100»õ¬ü¤¸ªº¥«³õ¡Aº¯³z²v50% ºâ) Regeneron Pharmaceuticals, Inc. ¥h¦~®³¨ìÃĵý«á3Ó¥b¤ë¡AªÑ»ù¥«È¤jº¦140¦h»õ¬ü¤¸¡A¤£¬Oº¦°²ªº. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X 1.FDA ®Öã¤é´Á 2017,3¤ë28¤é www.drugs.com/history/dupixent.html Dupixent Approval History FDA approved: Yes (First approved March 28th, 2017) Brand name: Dupixent Generic name: dupilumab Dosage form: Injection Company: Sanofi and Regeneron Pharmaceuticals, Inc. Treatment for: Atopic Dermatitis 2.ªÑ»ù 388¬ü¤¸º¦¨ì517¬ü¤¸(2017/03/28~2017//07/17) finance.yahoo.com/quote/REGN/?p=REGN Dupliumab ¥h¦~FDA 3¤ë®Ö·Ç, ¬ãµo¤½¥qREGENERON ªÑ²¼¥«È3Ó¤ë¤jº¦¬ù140»õ¬ü¤¸. ¨È·à±dASLAN004 ªvÀø ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ªºÀø©MDupliumab ¤ñ¸û,¥\¯à®t¤£¦h¡A¥ÎÃħóªø®Ä. dupliumab 2¶g¥´¤@¦¸°w. aslan004 4¶g¥´¤@¦¸°w. ¥|Ӥ몺ªvÀø. °Æ§@¥Î§ó§C. ¡X¡X¡X¡X¡X¡X¡X¡X- IMMU-132 ¤@ÓTNBC ¹w¦ô20»õ¬ü¤¸ªº¥þ²y°ª峯¾P°â¡A¹ê»Ú¥þ²y¾P°â±ÂÅv20»õ¬ü¤¸. ¡X¡X IMMU ¤½¥q¦b¤µ¦~ªì´µ·´¤F 20»õ¬ü¤¸ 쥻¤w±ÂÅvªºTNBC , sacituzumab(ADC IMMU-132)¥þ²y¦æ¾P±ÂÅv. ¬ü°êÃÄÃÒ: ¹wp¨ú±o ¤é´Á :2019 /¤¸¤ë/18¤é finance.yahoo.com/quote/IMMU ¬Q¤Ñ¥«È42»õ¬ü¤¸ www.immunomedics.com/wp-content/uploads/2018/02/Corporate-Presentation-February-2018.pdf finance.yahoo.com/news/fda-accepts-biologics-license-application-120000888.html FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer GlobeNewswire¡EJuly 18, 2018 MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (IMMU) (¡§Immunomedics¡¨ or the ¡§Company¡¨), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company¡¦s Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease. The PDUFA target action date is January 18, 2019. If approved, sacituzumab govitecan would be the first and only ADC approved for the treatment of mTNBC. ¡§We are delighted that the FDA has accepted the sacituzumab govitecan BLA for Priority Review,¡¨ commented Michael Pehl, President and Chief Executive Officer. ¡§We will continue to work closely with the regulatory agency as we strive to bring this potential new treatment to mTNBC patients expeditiously.¡¨ The filing is based on Phase 1/2 data of sacituzumab govitecan in mTNBC. About Sacituzumab Govitecan Sacituzumab govitecan, Immunomedics¡¦ most advanced product candidate, is a novel, first-in-class antibody-drug conjugate (ADC). It is currently under review by the U.S. Food and Drug Administration for accelerated approval as a treatment of patients with metastatic triple-negative breast cancer who previously received at least two prior therapies for metastatic disease. If approved, sacituzumab govitecan would be the first and only ADC approved for the treatment of metastatic triple-negative breast cancer. About Immunomedics Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics¡¦ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at immunomedics.com/. The information on its website does not, however, form a part of this press release. |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/9 ¤U¤È 10:28:27²Ä 322 ½g¦^À³
|
¤@¯ë°ê»Ú¤jÃļt¥Ln¤ä¥X½Ð¤jµP·~°È¡B¼s§i¡B¶}¦U¦¡¦U¼Ë¬ã°Q·|¡A©Û«ÝÂå¥Í¦Y³Üª±¼Ö¡i¦pNBAÁ`«axªù²¼¡j¥´¦nÃö«Y¡AÁÙnÃÙ§U¦U¦¡¦U¼ËÂå¾Ç¦~·|¡A¨C¦~nªá¤jµ§¿ú¡A¥LÁÙn®³¢²¢¯%¥H¤W²b§Q¡A«ç»ò¥i¯àµ¹¬ãµo·sÃļt¤Ó¦h¤À¼í¡A¤@¯ë³Ì¦h´N¬O¢°¢¯%(§t»sÃĦ¨¥») |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤U¤È 09:45:48²Ä 321 ½g¦^À³
|
³oºØ1¤H¥Î4Ó¤ë¡A¥´¥|°w¡An=671 ¤H,¤@¦~§¹¦¨¡A ¶O¥Î¤£°ª¡C ¥Dn¥I¤W´åcsl ñ¬ùª÷¡Aùµ{ª÷¶Q ¡X¡X¡X¡X¡X¡X¡X¡X¡X ¨È狮±dªºASLAN004 ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ ¬ü°ê50¸U¦WªvÀø¤¤, Dupilumab¼Ð¹vÃĪ«4Ó¤ëªvÀøªá2¸U¬ü¤¸¡A¬O100»õ¬ü¤¸¥«³õ. º¯³z²v50% , 50»õ¬ü¤¸. ²Ä3´ÁÁ{§É ¥Dn«ü¼Ð¥un1¦~.¨ú±o ®³ÃÄÃÒ ±q3´Á¶}©l2¦~¥b¥ª¥k. clinicaltrials.gov/ct2/show/NCT02277743 Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1) Study Type : Interventional (Clinical Trial) Actual Enrollment : 671 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Study Start Date : October 2014 Actual Primary Completion Date : November 2015 Actual Study Completion Date : February 2016 ¥t¥~ý³Ý ¬ü°ê¥«³õ¬ù60»õ¬ü¤¸¥«È, º¯³z²v50%, 30»õ¬ü¤¸. Dupilumab¼Ð¹vÃĪ« ¹wp¤µ¦~©³¥i¨ú±oý³Ýªº¬ü°êÃĵý. |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/9 ¤U¤È 09:39:14²Ä 320 ½g¦^À³
|
¤Ñ©R¤j¤j ©êºp¤À¨É¤@¤U ¦pªGASLAN 00¢³¤T´Á¦pªGµ¹¤j¼t§@¡A¨º¥x¼t®£©ÈµLªk®³¤@¥b¡A°Ê»³¤T´Ánªá¼Æ¤Q»õ¦Ü¦Ê»õ¬ü¤¸¡A°ê»Ú¤jÃļtµ¹ªº¤À¼í¤@¯ë¥u¯à¢°¢¯%¥ª¥k¡A¦Ó¥B³o¢°¢¯%ÁÙn¤ä¥X»sÃĦ¨¥»¡A³Ñ¤UÀ³¸Ó¤£¦h¤F¡A¥u³Ñ¥´¤u¤u¸ê¦Ó¤w |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤U¤È 09:17:08²Ä 319 ½g¦^À³
|
¤G¡BASLAN 004¥²±ÂÅvµ¹¤¤¡B¤jÃļt 100»õ¬ü¤¸¥H¤Wªº±ÂÅv¡A¥i¯à¤À¼Ú¡B¬ü¡A¤À²§¦ì©Ê¥Ö½§ª¢¤Îý³Ý¤£¦P¾AÀ³µý¡A¤À§O±ÂÅv¡C ¨È·à±d¸ê¥»ÃB¤Ó¤p¡AµLªk3/5¦~¤º¥ICSL 30~50»õ¬ü¤¸²{ª÷¡C¥u¯à¹³´¼Àºªº¨¤¦â¡C°µ§¹2´ÁÁ{§É¡C 3´ÁÁ{§É//¾P°â ¬Ò±ÂÅv¡C ASLAN004ªvÀø ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢¤Î ý³Ý,¬ü°ê¥«³õ50%渗³z²v´N80»õ¬ü¤¸¡C ±ÂÅvª÷(§t销±Â¤À¼í)°ê»Ú¤W¥i°ª¹F80»õ¬ü¤¸¡C ¥[¤W欧¬w¦Xp100»õ¬ü¤¸¥H¤W¡C ©M¤W´åCSL¦U¤À¤@¥b¡C ¬Û·í»¤¤H¡C ªÑ»ù¦p¦ó/¦ó®É¤ÏÀ³¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤U¤È 09:04:18²Ä 318 ½g¦^À³
|
¤@¡B»~·|¤F! ¥L¤£¬O(©tªù¿W¥«) MDRªºÃĪ«Ävª§ªÌ 1~20 ºØÃÄ, ¥un¦³¬¡©ÊªºÃÄ´N¥i§í¨îHIV¯f¬r¡C jerryljw.blogspot.com/2017/07/hiv-mechanism-of-antiretroviral-agents.html?m=1 |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/9 ¤U¤È 08:50:32²Ä 317 ½g¦^À³
|
ÃĽ檺¦n¤£¦n¡A±`±`©MÃÄ¥»¨¨S¦³¤ñµM¬ÛÃö¡A¤£µM°ê»Ú¤jÃļt´N¤£·|¨C¦~ªá¤j§â»È¤l¨ÑÂå¥Íªá¥Î¡A¥xÆW¤pÃļt¦p¦ó¸ò¤HÄvª§¡AÃø§r¡I |
|
|
·|û¡GJACKY WU10147205 µoªí®É¶¡:2018/8/9 ¤U¤È 08:34:17²Ä 316 ½g¦^À³
|
¢³¢°¢³¢¶©tªù¿W¥«ªºÃÄ®³¨ì¬ü°êÃÄÃÒ³£¤w¸gGG¤F¡I¦U¦ì¤p´²¤á¡A¤d¸Un¤p¤ß¡A¤£n¤@´[±¡Ä@»{¬°®³¨ìÃÄÃÒ´N·|¦³´X¤Q»õ¥«³õ¡A¶Ì¶ÌÀ°¤H©ïÃâ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/9 ¤U¤È 05:35:22²Ä 315 ½g¦^À³
|
¤G½uÁx¹DÀùÁp¦X¥|ºØ¤ÆÀøÃÄ¡Aµ²ªG¤´µM¤£²z·Q¡ACape ¤]¥]¬A¦b¸Ì±¡Cmedian progression-free survival of 3.6 months, a median overall survival of 6.4 months, and a response rate of 6% www.karger.com/Article/Abstract/479970 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤U¤È 04:53:34²Ä 314 ½g¦^À³
|
www.genetinfo.com/investment/featured/item/18622.html ¬ü°êMedicare ,¤j°ÃÄ»ù¤èªk,¬Ù¤U¨Óªº¿ú¦^õX¤@¥bµ¹¯f±w.(¦Û¥IÃB¤j´î) ¤@¡B¶}©ñ³B¤èÃĪ«Ä³»ù: ¥é¥ÍÃÄ¥i¤j½æ ¤G¡B¤Þ¶iº¥¶i¦¡ªvÀø(step therPY):±q«K©yªºÃĶ}©l¨Ï¥Î. ¦¹Ãþ¦b¨p¤H«OÀI¤w¦æ¤§¦³¦~. (Ãø©Ç è¤W¥«ªºHIV³J¥Õ½èÃÄ ,¦³¨Ç¤w¶}¥ß³B¤èÅÒ¦ý«OÀI®Ö¤£¤U¨Ó????,!!!!! ¤×¨ä¦bMDRªì´Áªº¯f±w ¦³10¦hºØ«K©yªº¤p¤À¤lÃÄ¥i¨Ï¥Î,n½ü¨ì¶W¶Qªº³J¥Õ½èÃÄ, ¦b¨p¤H«OÀI¥inµ¥«Ü¤[,²{¦b¤½«OMedicare//Medicaid¤]¦p¦¹, ///!!!! ) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤U¤È 03:33:00²Ä 313 ½g¦^À³
|
¯q¦w ¦Xp5000¸U¬ü¤¸ªº±ÂÅv. «Å§G±ÂÅv«áªÑ»ù³Ì°ªº¦¨ì198¤¸¡A¬ù100»õ¥x¹ô. ¬O±ÂÅvª÷ªº6¿¦h. ¨È·à±dªºASLAN004 100»õ¬ü¤¸,¤ÀCSL¤@¥b,³Ñ 50»õ¬ü¤¸ªº±ÂÅv¦¬¤J. ³o½ú¤l¹J¤@¦¸´N°÷¤F. ¦³¶¢¿úªº§ë¸ê¤H¡A´Nµ¥¤@¦¸´N¥i°h¥ð. ¡X¡X¡X¡X- ASLAN004ªvÀø ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢¤Î ý³Ý,¬ü°ê¥«³õ50%渗³z²v´N80»õ¬ü¤¸¡C ±ÂÅvª÷(§t销±Â¤À¼í)°ê»Ú¤W¥i°ª¹F80»õ¬ü¤¸¡C ¥[¤W欧¬w¦Xp100»õ¬ü¤¸¥H¤W¡C ©M¤W´åCSL¦U¤À¤@¥b¡C ¬Û·í»¤¤H¡C ªÑ»ù¦p¦ó/¦ó®É¤ÏÀ³¡H ¡X¡X¡X¡X¡X¡X¡X¡X¡X ¯q¦w¡]6499¡^¨ü´f¤j¤f®|¤ß¾ÉºÞ³N«á¤î¦å¸Ë¸mXPro System¡]IVC-C01¡^¦¨¥\±ÂÅv¡Añ¬ùª÷Ѻª`º©uEPS¬ù9.2¤¸¡A¥¿¦¡ÅE¨Àò§Q¦æ¦C¡C¸³¨Æªø±i¦³¼w¬Q¡]8¡^¤é¦bªk»¡·|¤¤ªí¥Ü¡A¥Í§Þ¥u¬ÝIP¡]´¼°]¡^©MData¡]¼Æ¾Ú¡^¡A¿ïÃD¬OÃöÁä¡A¥Ø«e¤wÂê©w¤ß¦åºÞ¡B°©¬ì¡B¸¡µÄ¤Îªc§¿¬ìµ¥4Ó»â°ì¶i¦æ¦h¨¤¤Æ§ë¸ê¡C ¯q¦w¶}±Ò°ê¤º³Ð·sÂå§÷±ÂÅv°ê»Ú¤j¼t¥ý¨Ò¡A°£¤FIVC-C01¥~¡AºX¤U¸¡µÄÃè¼v¹³²M´·¾¹§÷¡]LAP-A01¡^¡B¸¡µÄÃè¤â³NÁ_¦X¾¹§÷¡]LAP-C0 1¡^¥ç¤w¨ú±o¬ü°êFDA¤W¥«³\¥i¡A¥tÂà§ë¸ê«ùªÑ52.63¢HªºPanther¡A¦Û¦æ¬ãµoªº°©¬ì¥|ªÏ³Ð¶Ë¤º©T©wÂå§÷¡]PUMA System TM¡^¡A¤]¦b6¤é¨ú±o¬ü°êFDA 510¡]k¡^²£«~¤W¥«³\¥i¡A¦b¤T¤j²£«~³£¥i±æ¼W²K¥¼¨Ó±ÂÅv§Q¦h¤U¡A¯q¦w¬Q¤ÑªÑ»ù¸õªÅ©Ô¥X²Ä¥|®Úº¦°±¡A¥H124¤¸§@¦¬¡A³Ð¤U1¦~¦h¨Ó·s°ª¡C ±i¦³¼w¥ý«e§Y±j½ÕÂå§÷²£·~¬O ¡u³sÄò¦w¥´¡v¡A¤£¦P©ó¡u°¸º¸¥þÂS¥´¡A¦ý±`³Q¤T®¶¡vªº·sÃIJ£·~¡Aªí¥ÜÀHµÛ±ÂÅv±Ò°Ê¡A¯q¦w¥Ø«e¬OÂS¤W¦³¤H¡A²{¦b¤½¥q¦A¥´¥X¤@¤ä¦w¥´¡A¥B¦³±ÂÅvª÷°µ«á¬Þ¤U¡A¥¼¨Ó·|§ó´±§ë¸ê¡A§ë¸êªº®×¶q·|¡u¦h¤@ÂI¡v¡A¥B±ÂÅv¶¥¬q·|©¹¸û«á´Á¡A¥Hª§¨ú§ó¦hªº±ÂÅvª÷¡C ¯q¦w¬O¦b3¤ë2¤é«Å¥¬±NXPro System¥HÁ`ÃB5¤d¸U¬ü¤¸±ÂÅvµ¹¥þ²y«e¤¤j¤ß¦åºÞÂå§÷¤j¼tTerumo¡AEPS°^Äm¹F28.9¤¸¡C®Ú¾Ú¦X¬ù¡A2¤d¸U¬ü¤¸¡]¬ù¦X·s¥x¹ô6»õ¤¸¡^ªºÃ±¬ùª÷¡A¯q¦w¨Ì¦X¬ù³W©w¥i¥ß§Y»{¦C¬ù8¦¨¬°¦¬¤J¡A¨ä¾l2¦¨±N¨Ì¾Ú¦X¬ù¸j©wªº¸q°È¡A¦Ü2020¦~3¤ë©³¥H«e¨Ì¦U¸j©w¸q°È§¹¦¨¶i«×»{¦C¡C±i¦³¼wªí¥Ü¡A¥Í§Þ¥u¬ÝIP©MData¡A³Ì§xÃøªº¬O¿ïÃD¡F¦n§Þ³N¤£¤@©w¬O¦n²£«~¡A¦n²£«~¤£¤@©w®³¨ìªk³W»{ÃÒ¡A®³¨ì»{ÃÒ¤]¤£¤@©w½æ±o¥X¥h¡A¯q¦w¹Î¶¤¤w¸g°ö¾i¯à¤O¯à¬Ý¨ì¦nªº®×¤l¡C ¥Ø«e¯q¦w¤wÂê©w¹Î¶¤¤ñ¸û±Mªøªº¤ß¦åºÞ¡B°©¬ì¡B¸¡µÄ¤Îªc§¿¬ì¥|Ó»â°ì°µ¬°µo®i¤è¦V¡C www.chinatimes.com/newspapers/20180309000390-260206 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤W¤È 10:46:17²Ä 312 ½g¦^À³
|
IMMU ¤½¥q¦b¤µ¦~ªì´µ·´¤F 20»õ¬ü¤¸ 쥻¤w±ÂÅvªºTNBC , sacituzumab(ADC IMMU-132)¥þ²y¦æ¾P±ÂÅv. ¬ü°êÃÄÃÒ: ¹wp¨ú±o ¤é´Á :2019 /¤¸¤ë/18¤é finance.yahoo.com/quote/IMMU ¬Q¤Ñ¥«È42»õ¬ü¤¸ www.immunomedics.com/wp-content/uploads/2018/02/Corporate-Presentation-February-2018.pdf finance.yahoo.com/news/fda-accepts-biologics-license-application-120000888.html FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer GlobeNewswire¡EJuly 18, 2018 MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (IMMU) (¡§Immunomedics¡¨ or the ¡§Company¡¨), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company¡¦s Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease. The PDUFA target action date is January 18, 2019. If approved, sacituzumab govitecan would be the first and only ADC approved for the treatment of mTNBC. ¡§We are delighted that the FDA has accepted the sacituzumab govitecan BLA for Priority Review,¡¨ commented Michael Pehl, President and Chief Executive Officer. ¡§We will continue to work closely with the regulatory agency as we strive to bring this potential new treatment to mTNBC patients expeditiously.¡¨ The filing is based on Phase 1/2 data of sacituzumab govitecan in mTNBC. About Sacituzumab Govitecan Sacituzumab govitecan, Immunomedics¡¦ most advanced product candidate, is a novel, first-in-class antibody-drug conjugate (ADC). It is currently under review by the U.S. Food and Drug Administration for accelerated approval as a treatment of patients with metastatic triple-negative breast cancer who previously received at least two prior therapies for metastatic disease. If approved, sacituzumab govitecan would be the first and only ADC approved for the treatment of metastatic triple-negative breast cancer. About Immunomedics Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics¡¦ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at immunomedics.com/. The information on its website does not, however, form a part of this press release. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤W¤È 09:54:03²Ä 311 ½g¦^À³
|
incyte IOD+PD-1 1/2 ´ÁÁ{§É°_©l©ó2014¦~6¤ë. ªÑ»ù°_º¦©ó2013¦~7¤ë. 23¬ü¤¸/ªÑ 2014¦~ 6¤ë ªÑ»ù56¬ü¤¸/ªÑ A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) clinicaltrials.gov/ct2/show/NCT02178722?term=Pembrolizumab+%2B+Epacadostat&draw=3&rank=25 Study Type : Interventional (Clinical Trial) Actual Enrollment : 444 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202) Actual Study Start Date : June 2014 Estimated Primary Completion Date : November 2019 Estimated Study Completion Date : February 2020 ¡X¡X¡X¡X- n¦bªÑ¥«¤¤§ä¨ì¦p¦¹»¤¤Hªº¤jÁ{§É¡A¦ÓªÑ²¼¥«È2.»õ¤¸¬üª÷. «¢«¢«¢! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤W¤È 09:01:30²Ä 310 ½g¦^À³
|
Incyte ªºIDO §í¨î¾¯Epacadostat¡ÏPembrolizumab ,N=706¤H¡Aªº3´ÁÁ{§É2016¦~6¤ë¶}©l,2018¦~4¤ë¸Ñª¼. ªÑ»ù°_º¦ÂI¦b2013¦~7¤ë¡C ³o¤~¬OªÑ²¼ªº¥Í©R.´`Àôªº¶}©l. §AY¦b2016¦~3´ÁÁ{§É¶}©l½æ¡An½æ80¬ü¤¸/ªÑªºINCYTE ,«D2013¦~23¬ü¤¸/ªÑ. ¦Ó¥B¿ù¹L¤@¦¸±q23¬ü¤¸º¦¨ì115¬ü¤¸(2015¦~10¤ë)¡Aªº115/23=5¿º¦´T. ¡X¡X¡X- A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) clinicaltrials.gov/ct2/show/NCT02752074?term=ECHO-301%2FKEYNOTE-252.&rank=1 Study Type : Interventional (Clinical Trial) Actual Enrollment : 706 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) Study Start Date : June 2016 Actual Primary Completion Date : February 28, 2018 Estimated Study Completion Date : April 2019 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤W¤È 08:28:00²Ä 309 ½g¦^À³
|
·sÃĪѻù¤ÏÀ³¥¼¨Ó 3´ÁÁ{§É«e4¦~°_º¦¨ì3´ÁÁ{§Éµ²§ô«e¥b¦~,º¦200»õ¬ü¤¸ªºINCYTE ¤½¥qªÑ²¼¨Ò¤l:¦p¤U ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- finance.yahoo.com/quote/INCY Incyte Corporation (INCY) ¥Dn¤W¥«, 2011¦~ FDA ®Öã Jakafi(R) (ruxolitinib) ¾P°â $346 million in Q2 2018 , ¡X¡X¡X¡X¡X¡X 2017¦~8¤ë1¤éªÑ»ù³Ì°ª¹F137¬ü¤¸/ªÑ,¥«È282»õ¬ü¤¸. www.genetinfo.com/investment/featured/item/9181.html ¡X¬Q¤Ñ¦¬½L 63.6¬ü¤¸/ªÑ ,¥«È135»õ¬ü¤¸, ªÑ»ù¤@¦~¨Ó¥«È¤j¶^53% ¡X¡X¡X¡X ì¦]: ¦]¦³INCYTE ¤½¥qªºIDO §í¨î剤Epacadostat ,©M PD-1 §í¨î剤Pembrolizumab¡BNivolumab¶i¦æ3´Á¦X¨ÖªvÀù¬ÛÃöÀøªk. ¤µ¦~ªº3´ÁÁ{§É¸ÕÅçµ²ªG©M¹ï·Ó²ÕµL²Îp®t²§¡C ¡X¡X¡X¡X¡X¡X¡X¡X- ¦ÓIDO ªºÁ{§É¤ÏÀ³ªÑ»ù±q2013¦~7¤ë23¬ü¤¸(¥«値50»õ¬ü¤¸)°_º¦ 4¦~º¦100¬ü¤¸,¥«Èº¦200»õ¬ü¤¸. ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/9 ¤W¤È 07:37:20²Ä 308 ½g¦^À³
|
ASLAN004ªvÀø ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢¤Î ý³Ý,¬ü°ê¥«³õ50%渗³z²v´N80»õ¬ü¤¸¡C ±ÂÅvª÷(§t销±Â¤À¼í)°ê»Ú¤W¥i°ª¹F80»õ¬ü¤¸¡C ¥[¤W欧¬w¦Xp100»õ¬ü¤¸¥H¤W¡C ©M¤W´åCSL¦U¤À¤@¥b¡C ¬Û·í»¤¤H¡C ªÑ»ù¦p¦ó/¦ó®É¤ÏÀ³¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/8 ¤U¤È 10:26:39²Ä 307 ½g¦^À³
|
©t¨àÃĤj 2018 ¦~¤U¥b¦~¨ú±o varlitinib ¤@½uGÀù¥þ²y¤G´ÁÁ{§É¸ÕÅçªì¨BÁ{§É¼Æ¾Ú 2018 ¦~¤U¥b¦~¨ú±o ASLAN003 ©ó«æ©Ê°©Åè©Ê¥Õ¦å¯f(AML)¤G´ÁÁ{§É¸ÕÅç´Á¤¤¼Æ ³o¨âÓ¾AÀ³¯g¨S¦³´£¨ì¦~©³¤½§i¦Ó¬O¤U¥b¦~ (¤]´N¬O8--12¤ë³£¦³¥i¯à ) «Øij·à¤Í¸gµû¦ô«á¦pªG¬Ý¦n¨È·à±d¬ãµoªºÃĪ«ªº¼ç¤O¥i¥H±Ä¨ú¦u®è«Ý¨ßµ¦²¤,¤£¬Ý¦n´N½æ±¼,¦Û¤vn·í§ë¸ê¨Mµ¦ªº¥D¤H ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,¦Û¤vn·í§ë¸ê¨Mµ¦ªº¥D¤H |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/8/8 ¤U¤È 02:19:18²Ä 306 ½g¦^À³
|
¦Ñ·à±N°_ªº³Ì¤jÃöÁä´N¬O¬Q¤Ñµoªíªº¢ß¢±·~ÁZ»¡©ú,Ó¤Hı±o³Ì«n´N¬O¥H¤U~¦Ü©ó¦³¤H»¡:¤SÁÙ¨S¶}µP©p«ç»òª¾¹DÁ{§É¼Æ¾Ú¦n©Î¤£¦n?ª©¤W³o»ò¦h¤j¤j§V¤O¤À¨É©Òª¾©Ò¾Ç,¬Ý§¹«á¨º©p¦Û¤v«ÈÆ[§PÂ_©O¡H¡@ • ©ó 2018 ¦~¤U¥b¦~¨ú±o varlitinib GÀù¥þ²y¤G´ÁÁ{§É¸ÕÅçªì¨BÁ{§É¼Æ¾Ú • ©ó 2018 ¦~©³¨ú±o varlitinib Áx¹DÀù²Ä¤@½uªvÀø¤§¤@/¤G´ÁÁ{§É¸ÕÅç´Á¤¤¼Æ¾Ú • 2018 ¦~¤U¥b¦~¨ú±o ASLAN003 ©ó«æ©Ê°©Åè©Ê¥Õ¦å¯f(AML)¤G´ÁÁ{§É¸ÕÅç´Á¤¤¼Æ¾Ú • ©ó 2018 ¦~©³¨ú±o varlitinib ©ó¤¤°ê¤§Áx¹DÀù²Ä¤G½uªvÀø¼Ï¯Ã¸ÕÅçªì¨BÁ{§É¼Æ¾Ú • 2019 ¦~¨ú±o varlitinib Áx¹DÀù²Ä¤G½uªvÀø¥þ²y¼Ï¯Ã¸ÕÅç(TREETOPP)ªì¨BÁ{§É¼Æ¾Ú ¥H¤W¨Ñ°Ñ¦Ò,¤Å·í§ë¸ê¨Ì¾Ú¡ã¡ã¡ã |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤U¤È 09:10:32²Ä 305 ½g¦^À³
|
¥Ñ©óASLN001ªºORR+SD 80% ¥H¤W¡A°ª©ó¤ÆÀø组约1¿¡A PFS·|±qÀY赢¨ì§À¡C HR3/5 û{¤F¡C HR¥¿±`1.8/5 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/7 ¤U¤È 08:42:38²Ä 304 ½g¦^À³
|
¤Ñ©R¤j §A°Ý¨ìASLAN0004 °ê»Ú±ÂÅv¦æ±¡ ñ¬ùª÷¡Bùµ{ª÷ ¦h¤Ö¿ú¡H ³o¥i¦Ò˧ڤF! Ó¤H»{³oÁûÃÄè¶}©l¤@´ÁÁ{§É¦Ó¤w, ªº«o¬O¤@Áû¼ç¤OªºÃÄ, ®Ú¾Ú106¦~³ø·s¥[©Y¨È·à±d¾Ö¦³¬ãµoASLAN004¤§¿W®aÅv§Q¡A°w¹ï¤HÅéªvÀø¡B¶EÂ_©Î¯e¯f¯gª¬¹w¨¾°õ¦æÁ{§É¶}µo¦Ü·§©À©ÊÅçÃÒ§¹¦¨,±À´ú§¹¦¨·§©À©ÊÅçÃÒ«á´N·|±ÂÅv, ±ÂÅv·íµMn¬Ý¤G´Á¼Æ¾Ú? ¦³¦n¼Æ¾Ú´N¤£¾á¤ß±ÂÅvª÷»PÃÄÃÒ¤F ! ²{¶¥¬q¥i¥H¥ý»EµJ©ó¤G½uÁx¹DÀù GÀù»P«æ©Ê°©ÀH©Ê¥Õ¦å¯f¤T¤j¾AÀ³¯g.äãÃ¥´ ¤@¨B¨B©¹¤U¨« ¹ï¤F½Ð±Ð¤@¤U¤G½uÁx¹DÀù¤@¯ë¤ÆÀøÃÄmPFS 2-3Ó¤ë, °²³]±Ä°ª¼Ð3Ó¤ë §A±À¦ô¹êÅç²ÕmPFSn¹F¦h¤ÖÓ¤ë¤~·|¦³®t²§? ¦³§OªºÃĪº¬ã¨s¼Æ¾Ú(¤H¼Æ¬ù110¤H¨ì130¤H) ±µªñ¤G½uÁx¹DÀù120¤H, ¬Ý¬Ý¨º¨ÇmPFS ¦³®t²§®É¨â²Õ¦U¬O´XÓ¤ë? ÁÂÁ¤ѩR¤j ¥H¤WÓ¤H¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤U¤È 08:18:44²Ä 303 ½g¦^À³
|
ASLAN0004 ªvÀø¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ 1/2´Á¡A2¦~¤º°µ§¹Á{§ÉºâºCªº¡C ¡A5¦~¨ú药µýè¦n¦Ó¤w¡C 5¦~¤º¬ü°ê¥[欧¬w±ÂÅvª÷¡A15-20»õ¬ü¤¸ªº¨È·àÀ禬¡A¥i´Á¡C 2020~2021¦~ñ约±ÂÅv¾÷·|°ª. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤U¤È 05:53:20²Ä 302 ½g¦^À³
|
ASLAN0004 ªvÀø¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ 1/2´Á¡A2¦~¤º°µ§¹Á{§ÉºâºCªº¡C ¡A5¦~¨ú药µýè¦n¦Ó¤w¡C 5¦~¤º¬ü°ê¥[欧¬w±ÂÅvª÷¡A15-20¬ü¤¸ªº¨È·àÀ禬¡A¥i´Á¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤U¤È 03:42:40²Ä 301 ½g¦^À³
|
´¼Àº2011¦~ªº ¼Ú¬w¡Ï¨È¬w(¤£§t¥xÆW)±ÂÅvª÷ ¥i±o2.2»õ¬ü¤¸ªº ñ¬ù¤Îùµ{ª÷ ¦]¦¹YASLAN 0004 ±ÂÅv¦æ±¡ 22»õ¬ü¤¸ªºÃ±¬ùª÷+ùµ{ª÷, ¥t¥~¾P°â¤À¼í 10%~15%¥H¤W ¥H¤W¶·©M¤W´å¬ãµo¤½¥qCSL¦U¤À¤@¥b? ³Ì¤Ö¤]¦³10~11»õ¬ü¤¸ªºÃ±¬ù¡Bùµ{ª÷ ,3~5¦~¤º.(¤G´ÁÁ{§É°µ§¹) ¡X¡X¡X www.pharmaengine.com/upload/news/´¼Àº¤½¥q%20·s»D½Z%2020140926%20FINAL.pdf ´¼Àº¤½¥q»P±ÂÅv¦X§@¹Ù¦ñ¬ü°ê Merrimack ¤½¥qñ©w±ÂÅv¦X¬ù¤§×§ï¨ó©w ´¼Àº¤½¥q±N¦¬¨ì¬üª÷ 1,200 ¸U¤¸¥B¦³Åv¦¬¨ú³Ì°ª¹F¬üª÷ 3,950 ¸U¤§¦A±ÂÅv¦¬¤J (2014 ¦~ 9 ¤ë 26 ¤é¥x¥_°T)´¼Àº¥Í§Þ»sÃĪѥ÷¦³¤½¥q(TWO:4162)¤µ¤é«Å§G¡A»P±ÂÅv ¹Ù¦ñ¬ü°ê Merrimack ¤½¥q(NASDAQ: MACK)¦@¦Pñ¸p PEP02(§Y MM-398)±ÂÅvº[¦X§@«´ ¬ù¤§×§ï¨ó©w¡CMerrimack ¤½¥q©ó³o¬P´Á«Å§G¡AMerrimack ¤½¥q»P¬ü°ê Baxter ¤½¥q(NYSE: BAX¡A¦Ê¯SÂåÀø)ñ¸p¤@¥÷ MM-398 ±MÄݱÂÅv¦X¬ù¡AMerrimack ¤½¥q±N MM-398 ¦b¬ü°ê¤Î¥x ÆW¥H¥~ªº°Ï°ì±MÄݱÂÅvµ¹¤© Baxter ¤½¥q¡C2011 ¦~ 5 ¤ë¡A´¼Àº¤½¥q±N PEP02 ¦b¼Ú¬w¤Î¨È¬w (¥xÆW¦a°Ï°£¥~)¤§µo®i¡B»s³y¤Î°Ó·~¤Æµ¥Åv§Q±MÄݱÂÅv¤© Merrimack ¤½¥q¡A´¼Àº¤½¥q¦]¦¹±N ¥iÀò±o¬üª÷ 22,000 ¸U¤¸¤§±ÂÅvª÷¡B¦¹¥~¡AÁÙ¦³«ö·Ó¤£¦P¤ñ¨Ò¤§¾P°âÅv§Qª÷¤Î¦A±ÂÅv¦¬¤J (sublicense revenue)¡C2014 ¦~ 5 ¤ë¡AMerrimack ¤½¥q»P´¼Àº¤½¥q¦@¦P«Å§G¦¨¥\¹F¦¨ MM- 398 ¤§¥þ²y²Ä¤T´ÁÁ{§É¸ÕÅ窺¥Dn¸ÕÅç¥Ø¼Ð(primary endpoint)¡A¸Ó¸ÕÅç¥Dn¬O°w¹ï´¿±µ¨ü §t¼Ð·Ç¤ÆÀøÃĪ« gemcitabine ªvÀø¥¢±ÑªºÂಾ©Ê¯ØŦÀù±wªÌ¡C ¥»¦¸Âù¤è©Òñ©w¤§×§ï¨ó©w¡A±N¨Ï´¼Àº¤½¥q¥i¥ß§YÀò±o¬üª÷ 700 ¸U¤¸¡A¦P®É½T©w¤F¬üª÷ 500 ¸U¤¸¶¥¬q±ÂÅvª÷¤§³Ì±ß¥I´Ú®É;ì¨Ì PEP02 ±ÂÅv¦X¬ù¤¤³W©w¡AMerrimack ¤½¥qÀ³¦b¦V¬ü°ê FDA ¨ú±oªk³W¯S©w¼f®Öµ{§Ç«á¡A¤è¤ä¥I¬üª÷ 500 ¸U¤¸¶¥¬q±ÂÅvª÷µ¹´¼Àº¤½¥q¡A²{¨Ìקï¨ó©w ¤§³W©w¡A¤£ºÞ¬ü°ê FDA ¬O§_¦P·N¯S©w¼f®Öµ{§Ç¡AMerrimack ¤½¥q³Ì±ßÀ³¦b 2015 ¦~ 4 ¤ë©³«e§¹ ¦¨¤ä¥I¡C°£¤Wz¤§¥~¡A¦]קï¨ó©w¥[³t¤F Merrimack ¤½¥qªº¦A±ÂÅv®Éµ{¡A±o¥H°§C¦A±ÂÅv¦¬¤J (sublicense revenue)¤§¤À¨É¤ñ¨Ò¡A¬G¦b±Æ°£ Baxter ¤½¥q©Ò¤ä¥I¤§¦A±ÂÅvñ¬ùª÷¤Î³Ì°ª¹F¬ü ª÷ 15,000 ¸U¤¸¤§µo®i¨½µ{¸O±ÂÅvª÷«á¡A´¼Àº¤½¥q¥t¥~ÁÙ¥i¨Ì¾Ú MM-398 µo®i¤Îªk³W¶i«×¡A¦ô p³Ì°ª¥iÀò±o¹F¬üª÷ 3,950 ¸U¤¸¤§¦A±ÂÅv¦¬¤J¡C ì¦X¬ù©|¥¼¤ä¥I¤§ªk³W¨½µ{¸O±ÂÅvª÷(¬üª÷ 20,000 ¸U)¡B¾P°â¨½µ{¸O±ÂÅvª÷¤Î¾P°âÅv§Qª÷¤ñ¨Ò¡A ¬Òºû«ù¤£ÅÜ¡C¦]¦¹¡A´¼Àº¤½¥q¥¼¨ÓÁÙ¥i¦A«ùÄòÀò±o³Ì°ª¬°¬üª÷ 25,150 ¸U¤¸¤§¦X¬ùª÷ÃB¡A¸Óª÷ ÃB¨Ã¤£¥]§t´¼Àº¤½¥q¥ý«e¤w¦¬¨ú¤§¬üª÷ 1,000 ¸U¤¸¤§Ã±¬ùª÷»P¬üª÷ 500 ¸U¤¸¤§µo®i¨½µ{¸O±ÂÅv ª÷¡C ´¼Àº¤½¥qÁ`¸g²zº[°õ¦æªø¸±`µ×³Õ¤hªí¥Ü:¡u§Ú«D±`°ª¿³×§ï¨ó©wªº¤º®e¯à¥[³t Merrimack ¤½ ¥q»P Baxter ¤½¥q¤§±ÂÅv¥æ©ö¡A¹w´Á Baxter ¤½¥q±N©ó 2015 ¦~¦b¬ü°ê¥H¥~ªº°Ï°ì¶i¦æÃÄ«~¤W¥« ®Ö¥i¥Ó½Ð¡C³oÂùĹªº¦X§@¹Ù¦ñÃö«Y¡A±N¥i´£¨Ñ´¼Àº¤½¥q¬üª÷ 1,200 ¸U¤¸ªºµu´Á¦¬¤J¡AµM«á¡A¦A ÂǥѦX§@¹Ù¦ñªº¦@¦P¶}µo§V¤O¡A¥i¶i¦æ§ó¦hÁ{§É¸ÕÅ窺¤¤´Á§ë¸ê¡A³Ì«á¡AɧU Baxter ¤½¥q¦b ¥þ²yªºÂåÀø¶°¹Î¥¬§½¯à¤O¡A¨ÓÀò¨ú¥«³õ¾P°âªºªø´Á§Q¼í¡C¡v |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤U¤È 03:23:44²Ä 300 ½g¦^À³
|
¥xÁÞ¤j, ASLAN0004 ¤T´ÁÁ{§Én±ÂÅv¥X¥hµ¹¤j¼t°µÁ{§É©M¾P°â,40~50»õ¬ü¤¸ªº¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢) °ê»Ú¦æ±¡Ã±¬ùª÷¡Bùµ{ª÷ ¦h¤Ö¿ú¡H ¦p´¼Àº·íªì±ÂÅv ¯ØŦÀù¸¹ºÙ¥þ²y10»õ¬ü¤¸¡A¦ý¥u¦b¼Ú¬w5»õ¬ü¤¸. ©Ò¥HÀ³·í¦³10¿©ó´¼Àºªº¯ØŦÀùñ¬ùª÷¡Bùµ{ª÷¡B¾P°â¤À¼í¡H? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤U¤È 02:43:16²Ä 299 ½g¦^À³
|
ªvÀø¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ ¾P°â·~ÁZ Dupixent Approval History FDA approved: Yes (First approved March 28th, 2017) Brand name: Dupixent Generic name: dupilumab ¾P°âÃB :¦Ê¸U¬ü¤¸ 2017¡CQ2 US 28 2017Q3 US 89 2017Q4 US 139 ¥þ¦~¦Xp US 256 ¡X¡X¡X¡X¡X¡X- 2018, Q1 us 117 out of US14 ¦Xp 131 2018 , Q2 US¡A181 ou of US28 ¦Xp 209 ¥b¦~²Öp340 ¦Ê¸U¬ü¤¸¡]¤W¥««á²Ä¥|~¤©u) ¤W¥«²Ä¤@¦~²Öp387¦Ê¸U¬ü¤¸ ¥Ø«e¬ü°ê°Ï¨C©u¬ù¥H·s¼W50¦Ê¸U¬ü¤¸ªº¾P°âÃB¼W¥[¤¤¡C ¹wp40~50»õ¬ü¤¸ªº¾P°â°ª®p. files.shareholder.com/downloads/REGN/6360252393x0x983112/67E0E219-BCC3-45ED-9FD0-C5F1CF08B0C6/REGN_News_2018_8_2_General_Releases.pdf |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤W¤È 11:39:16²Ä 298 ½g¦^À³
|
1.FDA ®Öã¤é´Á 2017,3¤ë28¤é www.drugs.com/history/dupixent.html Dupixent Approval History FDA approved: Yes (First approved March 28th, 2017) Brand name: Dupixent Generic name: dupilumab Dosage form: Injection Company: Sanofi and Regeneron Pharmaceuticals, Inc. Treatment for: Atopic Dermatitis 2.ªÑ»ù 388¬ü¤¸º¦¨ì517¬ü¤¸(2017/03/28~2017//07/17) finance.yahoo.com/quote/REGN/?p=REGN Dupliumab ¥h¦~FDA 3¤ë®Ö·Ç, ¬ãµo¤½¥qREGENERON ªÑ²¼¥«È3Ó¤ë¤jº¦¬ù140»õ¬ü¤¸. ¨È·à±dASLAN004 ªvÀø ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ªºÀø©MDupliumab ¤ñ¸û,¥\¯à®t¤£¦h¡A¥ÎÃħóªø®Ä. dupliumab 2¶g¥´¤@¦¸°w. aslan004 4¶g¥´¤@¦¸°w. ¥|Ӥ몺ªvÀø. °Æ§@¥Î§ó§C. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤W¤È 11:12:50²Ä 297 ½g¦^À³
|
·sÃĤ½¥q¥«Èn¼Æ¿Â½¾aªº¬OÁ{§É¼Æ¾Ú¤Î¦UºØ¾P°â¼ç¤O¤jªº·sÃÄÁ{§É. ¨È狮±dªºASLAN004 ¤¤¡B««×²§¦ì©Ê¥Ö½§ª¢ ¬ü°ê50¸U¦WªvÀø¤¤, Dupilumab¼Ð¹vÃĪ«4Ó¤ëªvÀøªá2¸U¬ü¤¸¡A¬O100»õ¬ü¤¸¥«³õ. º¯³z²v50% , 50»õ¬ü¤¸. ²Ä3´ÁÁ{§É ¥Dn«ü¼Ð¥un1¦~.¨ú±o ®³ÃÄÃÒ ±q3´Á¶}©l2¦~¥b¥ª¥k. clinicaltrials.gov/ct2/show/NCT02277743 Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1) Study Type : Interventional (Clinical Trial) Actual Enrollment : 671 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Study Start Date : October 2014 Actual Primary Completion Date : November 2015 Actual Study Completion Date : February 2016 ¥t¥~ý³Ý ¬ü°ê¥«³õ¬ù60»õ¬ü¤¸¥«È, º¯³z²v50%, 30»õ¬ü¤¸. Dupilumab¼Ð¹vÃĪ« ¹wp¤µ¦~©³¥i¨ú±oý³Ýªº¬ü°êÃĵý. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤W¤È 08:21:15²Ä 296 ½g¦^À³
|
finance.yahoo.com/quote/ASLN?p=ASLN ¨È·à±dADR½L«á¤jº¦ 19.95% , ¨ì8.9¬ü¤¸. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/7 ¤W¤È 06:27:36²Ä 295 ½g¦^À³
|
globenewswire.com/news-release/2018/08/06/1547265/0/en/ASLAN-Pharmaceuticals-Reports-Second-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html SINGAPORE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today reported financial results for the quarter ended 30 June 2018 and provided an update on its clinical activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: ¡§Our successful financing and listing on NASDAQ during the second quarter places us in a strong financial position to accelerate the development of our pipeline of candidates that address unmet medical needs. We are preparing to initiate a phase 1 trial for ASLAN004 for the treatment of atopic dermatitis. The focus is on achieving our milestones, and we look forward to sharing new data from our global late-stage clinical trials for varlitinib later this year.¡¨ Second quarter 2018 and recent business highlights Completed successful IPO in the US that raised gross proceeds of US$42.2 million and began trading on NASDAQ in May 2018 Presented study design of ongoing global pivotal clinical trial of varlitinib, the TREatmEnT OPPortunity (TREETOPP) study, at the 2018 American Society of Clinical Oncology Meeting in June. Study on track to report topline data in 2019 Presented new phase 1b data on varlitinib in combination with paclitaxel in advanced solid tumours at the 2018 American Society of Clinical Oncology Meeting Filed Clinical Trial Authorisation with Singapore¡¦s Health Sciences Authority to initiate first-in-man studies for ASLAN004 Anticipated upcoming milestones Topline China pivotal trial data on varlitinib as second line treatment for biliary tract cancer in late 2018 Topline global phase 2 data on varlitinib in gastric cancer in second half of 2018 Interim phase 1/2 data on varlitinib as first line treatment for biliary tract cancer in late 2018 Interim phase 2 data on ASLAN003 in acute myeloid leukaemia (AML) in second half of 2018 Topline global pivotal trial (TREETOPP) data on varlitinib as second line treatment for biliary tract cancer in 2019 Second quarter 2018 financial highlights Cash used in operations for the quarter ended 30 June 2018 was US$10.0 million compared to US$9.0 million in the same period in 2017 Research and development expense was US$8.3 million and general and administrative expense was US$3.1 million for the second quarter of 2018, compared to US$7.0 million and US$1.9 million respectively in the same period in 2017 Staggered upfront payments of US$12 million in the first quarter and US$11 million in the second quarter of 2018 to Array BioPharma for full exclusive global rights of varlitinib were recorded as intangible assets Net loss for the second quarter of 2018 was US$11.0 million compared to a net loss of US$9.2 million for the second quarter of 2017 Cash, cash equivalents and short-term investments totaled US$45.0 million as of 30 June 2018, which includes proceeds from the US public offering completed in May 2018, compared to US$69.7 million as of 30 June 2017 ASLAN Pharmaceuticals Limited Consolidated balance sheet1 (US dollars, unaudited) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/7 ¤W¤È 12:05:07²Ä 294 ½g¦^À³
|
èè¬Ý¨ì¨È·à±dµo§G·s»D½Z aslanpharma.com/zh/2018/08/06/aslan-pharmaceuticals-reports-second-quarter-2018-financial-results-provides-corporate-update/ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/6 ¤U¤È 11:53:11²Ä 293 ½g¦^À³
|
·à¤l¬ãµoªº¾AÀ³¯g¥]¬A:Áx¹DÀù¡AGÀù¡A¤j¸zª½¸zÀù¡A¨xÀù¡A¨ÅÀù¡A«æ©Ê°©Åè©Ê¥Õ¦å¯f¡A²§¦ì©Ê¥Ö½§ª¢»P®ð³Ý¡A¬ãµo¶i«×©ú½T¡A¬ãµo¹Î¶¤»P¦X§@¾Ç³N³æ¦ì°}®e±j¡A©t¨àÃĵ¦²¤ÆF¬¡¡A¼Ð¹v©ú½T¡A¦¨¥\¾÷²v¤ñ¤@¯ëÀù¯g¬ãµo¦¨¥\¾÷²v¤j±o¦h¡A°]°È°·¥þ¡A°ê»Ú¤Æ¯à¨£«×±j¡AÄw½X¶°¤¤Ã©w¡C¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/6 ¤U¤È 10:46:56²Ä 292 ½g¦^À³
|
A ¤w¦³«æ©Ê°©Åè©Ê¥Õ¦å¯fÃĪ«³Q¬ü°êFDA½T»{¬°©t¨àÃÄ www.pharmpro.com/news/2018/01/fda-grants-orphan-drug-designation-treatment-acute-myeloid-leukemia B ¦³¼ç¤OªºASLAN003 ASLAN003¬°¤@ºØ±j®ÄªºDHODH¤fªA§í¨î¾¯¡A¥i±æ¦¨¬°«æ©Ê°©Åè©Ê¥Õ¦å¯f¦P¯Åº¨£¤§Àøªk¡C2013¦~¨È·à±d¦ÛAlmirall±ÂÅv¤Þ¶iASLAN003«D¥~¥Î¤Î«D¥Ö½§¯f¾AÀ³¯g¤§¥þ²yÅv§Q¡C «æ©Ê°©Åè©Ê¥Õ¦å¯f¬°µo¥Í©ó°©Åè©Ê²ÓMªºÀù¯g¡A¯SÂI¬°°©Å褺²§±`¥Õ¦å²y²ÓM§Ö³t¼W´Þ¦Ó¼vÅT¥¿±`³y¦å²ÓMªº²£¥Í¡C §Ú̥ثe¥¿°w¹ï«æ©Ê°©Åè©Ê¥Õ¦å¯f¶i¦æ¤G´ÁÁ{§É¸ÕÅç¡A¦P®É°w¹ï¨ä¥L¥i¯à»PDHODH¾÷¨î¦³Ãöªº¹êÅé¸~½FÃþ«¬¬ãµo¡A¦p¤T³±©Ê¨ÅÀù©M¨x²ÓMÀù¡C ASLAN003 ¾Ö¦³¦¨¬°Àù¯gªvÀø»â°ì¤¤¦P¯Åº¨£DHODH§í¨î¾¯ªº¼ç¤O¡A¨äÀu¶Õ¦p¤U¡G ±j®Ä§í¨îDHODH¡AASLAN003ªºµ²¦X±j«×¸û²Ä¤@¥NDHODH§í¨î¾¯¦pleflunomide»Pteriflunomide°ª¥X¨âӼƶq¯Å¡C³o¼Ë¹ï¤H·½DHODHªº°ª«×¯S©w©Ê¤Î±j®Ä§í¨î¥i±æ¥i¹F¨ìÀù¯gªvÀø¤¤¨ã³ÆÀø®Äªº¤ô¥¡C µL²Ä¤@¥N§í¨î¾¯©M¨ä¥L«æ©Ê°©Åè©Ê¥Õ¦å¯f·s«¬Àøªk¦p midostaurin©Menasidenib¤§¬ÛÃö¬r©Ê¡C²{¦³ªºDHODH§í¨î¾¯¡A¦pleflunomide»Pteriflunomide¡A¦³¨x¬r©Ê¬ÛÃöªºÅãµÛ°Æ§@¥Î¡C¨â¶µÃĪ«¬Ò»Ý¤T¨ì¥|¶g¤~¯à¹F¨ìªvÀø°Ï¶¡¡A¦Ó¥B°±ÃĨâ¦~¤~¯à¦ÛÅ餺²M°£¡C¤ÏÆ[ASLAN003¡A¨ä¥i¦b¤G¤Q¥|¤p®É¹F¨ì³Ì¨Î®Ä¤O¡A¥b°I´Á¬°¤Q¤K¤p®É¡A°±ÃĹL«á¥i§Ö³t¦ÛÅ餺²M°£¡C¦AªÌ¡A³Ìªñ¤W¥«ªº«æ©Ê°©Åè©Ê¥Õ¦å¯fÀøªk¡A¦pmidostaurin»Penasidenib¬Ò¦³«¤jªº¦å²G¤Î¨x¬r©Ê¡C³\¦h¦~ªø©ÎµLªk©Ó¨ü¬r©Êªº¯f±w¬ÒµLªk±µ¨ü³oÃþÀøªk¡C¦]¦¹¡A¥Ñ©óASLAN003ªº¦w¥þ©Ê¸û¨Î¡A§Ú̬۫H¥i¾A¥Î©ó³oÃþ¯f±w¡C ¥i¨Ï«æ©Ê°©Åè©Ê¥Õ¦å¯fªÞ²ÓM¦¨¥\¤À¤Æ¬°Áû²É²y¡A¨Ã¥i±æ±N¾A¥Î©ó§ó¬°¼sªxªº«æ©Ê°©Åè©Ê¥Õ¦å¯f¯f±w¡CASLAN003¨ã³Æ¨Ï«æ©Ê°©Åè©Ê¥Õ¦å¯f²ÓM®è¤À¤Æªº¯à¤O¡A¨Ã¹ï©ó¼ÆºØ¹ï¥þ¤Ï¦¡ºû¥Ò»Ä (ATRA) µL¤ÏÀ³ªº²ÓM®è¦³®Ä¡CASLAN003¥i¯à¾A¥Î©ó¹ï¥þ¤Ï¦¡ºû¥Ò»Ä (ATRA) µL¤ÏÀ³ªº¯f±w¡A³oÃþ¯f±w¤j¬ù¦ûÁ`«æ©Ê°©Åè©Ê¥Õ¦å¯f¯f±wªº85%¡C ¹ï¤T³±©Ê¨ÅÀù¦³®ÄªºÃÒ¾Ú¡Cªñ´Á¼Æ¾ÚÅã¥ÜDHODH§í¨î¹ï¤T³±©Ê¨ÅÀù¤Î¨ä¥L¹êÅé¸~½Fªº°Êª«¼Ò«¬¬O¦³®Äªº¡A¤T³±©Ê¨ÅÀù¬°¤@ºØªvÀø¿ï¶µµ}¤Öªº°ª´c©Ê¨ÅÀù¡C aslanpharma.com/zh/drug/aslan003/ C «æ©Ê°©Åè©Ê¥Õ¦å¯f¥«³õ www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market 2016 ¹w¦ô¥«³õ15»õ¬ü¤¸ ¥H¦~½Æ¦X¦¨ªø²v10% ¼W¥[ ¤Ñ ©R¤j ¦p§A´£¨Ñªº¨È·à±d¤G½uÁx¹DÀù¦b2018 ASCOµoªíªº¬ã¨s³ø§i¤¤´£¨ì·|±´°QExploratory objectives Ó¤H»{¬°³o±N½T»{¥Íª«°O ! ¦³¥Íª«¼Ð°O¤S¦³©t¨àÃĸê®æ ¦¨¥\¾÷²vÀ³¤ñ¥u¦³©t¨àÃĸê®æ§ó¤j ! ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/3 ¤U¤È 10:51:49²Ä 291 ½g¦^À³
|
kknews.cc/zh-tw/psychology/b2orapm.html ªø´Á¥ÎÃĪººë¯«¯e¯f |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/3 ¤U¤È 10:46:32²Ä 290 ½g¦^À³
|
to:¦³缘¤H www.canews.com/News_Center/News_2011/News_release_2011_1213001_01_05.html ¦h¦~¨Ó¥¼¨£¸Ñ¨Mªº°ÝÃD¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/3 ¤U¤È 09:05:55²Ä 289 ½g¦^À³
|
¦A×¥¿Google ½Ķ Ķ¤å¤¤¦³µ{§Ç¥þ³¡§ï¬°µ{¦¡¤ñ¸û³q¶¶ ¤°»ò¬OBenjamini-Hochberg µ{¦¡ ¦p¦ó¹BºâBenjamini-Hochberg µ{¦¡ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/3 ¤U¤È 07:42:08²Ä 288 ½g¦^À³
|
¤Ñ©R¤j What is the Benjamini-Hochberg Procedure? ( ×¥¿Google ½Ķ ) ¤°»ò¬OBenjamini-Hochbergµ{§Ç¡H Benjamini-Hochbergµ{§Ç¬O¤@ºØ±j¤jªº¤u¨ã¡A¥i¥H°§C¿ù»~µo²{²v¡C ½Õ¾ã³t²v¦³§U©ó±±¨î¦³®É¤pªºpÈ¡]¤p©ó5¢H¡^°¸µMµo¥Íªº¨Æ¹ê¡A³o¥i¯à¾ÉP±z¿ù»~¦a©Úµ´¯u¥¿ªºµêµL°²³]¡C´«¥y¸Ü»¡¡AB-Hµ{§Ç¥i¥HÀ°§U±zÁקKIÃþ¿ù»~¡]»~³ø¡^¡C pȬ°5¢Hªí¥Ü¦pªGµêµL°²³]¬°¯u¡A«h¥u¦³5¢Hªº¾÷²vÀò±oÆ[¹î¨ìªºµ²ªG¡C´«¥y¸Ü»¡¡A¦pªG§A±o¨ì5¢HªºpÈ¡A§AªºµêµL°²³]¤£¤Ó¥i¯à¬O¯uªº¡AÀ³¸Ó³Q©ß±ó¡C¦ý³o¥u¬O·§²v - «Ü¦h¦¸¡A¯u¥¿ªºµL®Ä°²³]¦]¬°µ²ªGªºÀH¾÷©Ê¦Ó³Q©ß±ó¡C ¤@Ó¨ãÅ骺¨Ò¤l¡G°²³]§A¦³¤@²Õ100¦W±wªÌ¡A§Aª¾¹D¥L̨S¦³¬YºØ¯e¯f¡C±zªº¹s°²³]¬O±wªÌ¨S¦³¯e¯f¡A¦Ó±zªº´À¥N¤è®×¬O¥L̽T¹ê±w¦³³oºØ¯e¯f¡C¦pªG±z¦b5¢Halpha¯Å§O¹Bºâ100¦¸²Îp´ú¸Õ¡A«h¤j¬ù5¢Hªºµ²ªG·|³ø§i¬°»~³ø¡C §A¥i¥H°µ«Ü¦h¨Æ±¡¨ÓÁקK³oºØ±¡ªp¡G·í§A¶i¦æ²Îp´ú¸Õ®É¡A¤@Ó¤À¼ÆÁ`¬O»~³ø¡C¦ý¬O¡A¹BºâB-Hµ{§Ç±N´î¤Ö»~³øªº¼Æ¶q¡C ¦p¦ó¹BºâBenjamini-Hochbergµ{§Ç ±N¦UÓpÈ«ö¤É§Ç±Æ¦C¡C ±Nµ¥¯Å¤À°tµ¹pÈ¡C¨Ò¦p¡A³Ì¤pªºµ¥¯Å¬°1¡A²Ä¤Gӳ̤pªºµ¥¯Å¬°2¡C ¨Ï¥Î¤½¦¡¡]i / m¡^Qpºâ¨CÓ³æ¿WªºpȪºBenjamini-HochbergÁ{¬ÉÈ¡A¨ä¤¤¡G i =Ó¤HpȪº±Æ¦W¡A m =´ú¸ÕÁ`¼Æ¡A Q =¿ù»~µo²{²v¡]¥Ñ±z¿ï¾Üªº¦Ê¤À¤ñ¡^¡C ±Nì©lpÈ»P¨BÆJ3¤¤ªºÃöÁäB-H¶i¦æ¤ñ¸û;§ä¨ì¤p©óÁ{¬ÉȪº³Ì¤jpÈ¡C ¨Ò¦p¡A¥H¤U¼Æ¾Ú¦CªíÅã¥Ü¤F25Ó´ú¸Õªº³¡¤Àµ²ªG¦Cªí¡A¨ä¤¤pȦb²Ä2¦C¤¤¡C¹ïpȦCªí¶i¦æ±Æ§Ç¡]¨BÆJ1¡^¡AµM«á¦b²Ä3¦C¤¤±Æ§Ç¡]¨BÆJ2¡^¡C²Ä4¦CÅã¥ÜÁ{¬ÉȪºpºâ¡A¿ù»~µo²{²v¬°25¢H¡]¨BÆJ3¡^¡C¨Ò¦p¡A¶µ¥Ø1ªº²Ä4¦Cpºâ¬°¡]1/25¡^* .25 = 0.01¡G ªºBenjamini-ÀN»®¨©®æ benjamini-hochberg |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/3 ¤U¤È 07:02:54²Ä 287 ½g¦^À³
|
¤Ñ©R¤j ¾\Ū³o¨â½g¬Ý¬Ý³oºØ²Îp¤ÀªRªk»P¦p¦ó²Îp (1995 ¦~¤~µo®i¥X¨Ó¥Íª«²Îp¤ÀªRªk) www.statisticshowto.com/benjamini-hochberg-procedure/ en.wikipedia.org/wiki/False_discovery_rate |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/3 ¤W¤È 05:57:47²Ä 286 ½g¦^À³
|
¥xÁÞ¤j¡A Ä@»D¨ä¸Ô¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/2 ¤U¤È 11:19:28²Ä 285 ½g¦^À³
|
¤Ñ©R¤j ½T©w¤G½uÁx¹DÀù¥þ²y¼Ï¯Ã¸ÕÅç²Îp¤ÀªR¤£¬O±Ä¥Î¥Öº¸´Ë¥d¤èÀË©w»P¸¤ó³sÄò©Ê×¥¿¡A¦³§ó¦nªº¤ÀªR¤Àªk¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/1 ¤U¤È 08:22:10²Ä 284 ½g¦^À³
|
§ó¥¿¡GÂåÃÄ«~¬dÅ礤¤ß¤~¹ï ¥H¤U¬O²Îp¼f¬d«ÂI www3.cde.org.tw/faq/faq_more?id=463 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/1 ¤U¤È 07:54:35²Ä 283 ½g¦^À³
|
¤Ñ©R¤j ³on¬Ý¬ü°êFDA¦bÃÄÃÒ¼f¬d®É²Îp¤ÀªR¬O§_±Ä¥Î¸¤ó³sÄò©Ê×¥¿¡A¦pªG¨S¦³´N¤£·|¦³½Õ¾ãªº°ÝÃD¡A¥i¥H°ÝÃÄÃÒ¬dÅ礤¤ß¦³Ãö²Îp³¡¥÷ªº³¡ªù¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/8/1 ¤U¤È 07:35:33²Ä 282 ½g¦^À³
|
¥Öº¸´Ë¥d¤èÀË©w ¸¤ó³sÄò©Ê×¥¿¡]^»y¡GYates¡¦s correction for continuity¡^¡C ®É¾÷: ¨î ¤@¡B¦pªGÓ§OÄæ¦ìªº´Á±æ¦¸¼Æ¤Ó§C¡A·|¨Ï¾÷²v¤À°tµLªkªñ¦ü©ó¥d¤è¤À°t¡C ¤@¯ën¨D¡G¦Û¥Ñ«× df>1 df>1®É¡A´Á±æ¦¸¼Æ¤p©ó5ªºÄæ¦ì¤£¦h©óÁ`Äæ¦ìªº20%¡C ¤G¡BY¦Û¥Ñ«× df=1 df=1¡A¥BY´Á±æ¦¸¼Æ <10 ¡A«hªñ¦ü©ó¥d¤è¤À°tªº°²³]¤£¥i«H¡C ¦¹®É¥i¥H±N¨CÓÆ[¹îȪºÂ÷®t´î¥h 0.5 0.5 ¤§«á¦A°µ¥¤è¡A³o«K¬O¸¤ó³sÄò©Ê×¥¿¡]^»y¡GYates¡¦s correction for continuity¡^¡C zh.m.wikipedia.org/zh-tw/¥Öº¸´Ë¥d¤èÀË©w |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/1 ¤U¤È 07:17:08²Ä 281 ½g¦^À³
|
¥d¤è¤À°tªí www.google.com.tw/search?q=¥d¤è¤À°tªí&oq=¥d&aqs=chrome.1.69i57j69i59j0l2.1559j0j4&client=ms-android-htc&sourceid=chrome-mobile&ie=UTF-8 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/8/1 ¤U¤È 07:06:03²Ä 280 ½g¦^À³
|
¤Ñ©R¤j ¥H«e´£¨ì¥d¤è¤À°tªí¦³Ãödf=1 ®Én°µ½Õ¾ã ¥i¥H¦A¬dÃÒ¤@¤U¡H §ÚÓ¤H»{¬°¥d¤è¤À°tªí¦¤w©w½Õ¡A¨S¦³©Ò¿×n½Õ¾ãªº°ÝÃD¡C¦pªG¦³½Õ¾ã¤À°tªí¤w¸g½Õ¾ã¦n¤F¡A¤£·|¤½§G¤@Ó¿ù»~ªº¼Æ¾Ú¡C¥H¤W¬OÓ¤H¬Ýªk¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/7/31 ¤U¤È 01:59:19²Ä 279 ½g¦^À³
|
ı±o³Ìªñ¶q¯à«Ü¤p¡AÀ³¸Ó³£¬O¦bµ¥¬ãµo¦¨ªGµo§G§a! ¨âÃäADR¸ò¥xªÑ¦¨¥æ¶q³£«Ü§C¡AªÑ»ù¤]¦b³oÃä¾_Àú¾ã²z¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/30 ¤U¤È 05:52:18²Ä 278 ½g¦^À³
|
2018 ¤U¥b¦~4ÓÁ{§É¬ã¨s¦¨ªG(§t1Ó¤¤°ê¼Ï¯ÃÁ{§É¥Dn«ü¼Ð)µoªí¶q¡A¦b¥xÆWªº·sÃĤ½¥q¤£¬ONO.1,¤]¬ONO.2 ¨È·à±d ¥«È2.2»õ¬ü¤¸. ¯uªº«K©y¨ìÃz! mops.twse.com.tw/nas/STR/649720180531M001.pdf p.25 ¨È·à2018,6.6 ªk説¸ê®Æ ¹w´Á¶iµ{ ¤@¡B Varlitinib (Áx¹DÀù) ²Ä¤G½u(¤¤°ê) ¼Ï¯Ã¸ÕÅçn=68¤H ,ªì¨BÁ{§É¼Æ¾Ú (¦ô2018,9¤ë30¤é) ,·Ç³Æ¥Ó½Ð¤¤°êÃĵý¥Î¡C ¤G¡B Varlitinib (Áx¹DÀù) ²Ä¤@½u ,²Ä¤@/¤G´Á ,´Á¤¤¼Æ¾Ú (¦ô2018,9¤ë30¤é) ¤T¡B Varlitinib (GÀù) ²Ä¤@½u,²Ä¤G/¤T´Á ²Ä¤G´Á¸ÕÅç n=40(20:20)¤H, ªì¨BÁ{§É¼Æ¾Ú (¦ô2018,8¤ë30¤é) ¥|¡B ASLAN003 («æ©Ê°©Åè©Ê¥Õ¦å¯f) ²Ä¤G´Á¸ÕÅç n=20¤H,´Á¤¤¼Æ¾Ú (¦ô2018,8¤ë30¤é) ¤¡AASLAN004 IND 7¤ë4¤é°e¥ó¥Ó½Ð·s¥[©YÁ{§É¼f¬d. :¥»¤½¥q¤w¦V·s¥[©Y½Ã¥Í¬ì¾Ç§½(HSA)´£¥æASLAN004°w¹ï²§¦ì©Ê¥Ö½§ª¢¤§¤@´Á (¦ô¬ü°ê50»õ¬ü¤¸¥«³õ) µù:¥H¤W¤é´Á¹w¦ô¡A¨ÌP.25 ªº®É¶¡¹ÏÂà´«¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/30 ¤W¤È 09:21:28²Ä 277 ½g¦^À³
|
¦U¦ì¤j¤j, mBC Âಾ©Ê¨ÅÀù, ì¦ìÀù¦b¨Å©Ð¦ì¸m¡AÂX´²¨ìªÍ¡B¨x¡B...¸g HER2¡BHER3 ªº§í¨î¾¯Herceptin¡BPerjeta ,¦Ó±q30¦~«e¤ÆÀømos 23¤ë¡A©µªø¥Í©R¨ìmos56.5 ¤ë¡C ³o¬O½æ30¦~¡A¥þ²y¤W¥ü¬ü¤¸ªº¾P°â¼Æ¦r·í¨Ì¾Ú¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/30 ¤W¤È 08:19:32²Ä 276 ½g¦^À³
|
¥xÁÞ¤j, ARQ087 & ASLAN001 ¬O2ӥثe°w¹ïÁx¹DÀù2缐°µ1bÁ{§ÉªºÃĪ«. ¦P¼Ë¥i§í¨î²ÓMªº¼W¥Í¤Î¨Ï²ÓM¦º¤`¡C ARQ087 ªºSD PFS ®i²{¥X«D±`º}«Gªø®É¶¡ªº§í¨î¯à¤O SD ªºMPFS ¹F5.6Ó¤ë. ¤ñ 2½u¤ÆÀø MPFS 1.8¤ë(³æÃÄ)//2.6(Âù¤ÆÀø) ¦h¥X2~3¿. ASLAN001 ¥i¦P®É§í¨îHER2¡BHER1¡BHER3¡AHER4 , ¦b¶PÀù¥¶ÈHER2´NºÙÅQ30¦~, Ó¤H¦]¦¹«Ü¦³«H¤ß. ¤×¨ä MBC ¤@缐 HERCEPTIN ªºHER2§í¨î+PERJETA HER3§í¨î ¥i©µªø15Ó¤ëMOS. ¥NªíHER3ªº§í¨î¬O¦³¥t¥~ªºÁ{§É®Ä¯qªº¡C ARQ087 ¶È§í¨îFGFR2 ¤@Ó¨ü¾¹ ´N¦³¦p¦¹¦nªº®Ä¯q¡A¨ÌARQ087 1bªºÁ{§É¼Æ¾Ú«Ü¦³¥i¯à¥u¬OASLAN001ªº°ò¥»®Ä¯q¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/29 ¤U¤È 11:32:08²Ä 275 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d1b´ÁÁ{§É¸ÕÅç¯e¯f±±¨î²v¬O¦Ê¤À¤§87 ¡]CR+PR+SD¡^¡A¦³¿ìªk±qDCR»Pduring response¥h±À´úmPFS? ÁÂÁ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/29 ¤U¤È 11:21:42²Ä 274 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº¤À¨É ¨Ï¥Î¦³ORR¯f±wªºdurable responses ¨Ó±À´úmPFSºâ¬O¦X²z±À´ú¡C¦]¬°mPFS¬Opºâ©Ò¦³¹êÅç²Õ»P¹ï·Ó²Õ¯f±w±q¦¬®×¨ìPD®Éªº¸g¹L®É¶¡¡A¥]¬ACR,PR,SD»PPDªº©Ò¦³¯f±w¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/29 ¤U¤È 10:56:26²Ä 273 ½g¦^À³
|
¶PÀù¥HERCEPTIN, HER2 + ,IHC3 ¶PÀù¹çPERJETA HER3¡Ï,IHC+3 ¥H¤W¨âӼйvÃĪ«Áp¥Î¡A¨ÏMBC ¤@缐 MOS ¼W¥[¨ì56.5Ó¤ë.¹ï·Ó组¶PÀù¥¡Ï¤ÆÀøÃĪ«MOS¥u¦³40.8¤ë,©µªø15.7Ó¤ë www.nejm.org/doi/full/10.1056/NEJMoa1413513?af=R&rss=currentIssue#t=articleDiscussion (HER®a±Ú¤§HER2/HER3¤§§í¨î剤 ¬O¦b¨ÅÀù¤ÎGÃĪº¦~¾P°â(§tHERCEPTIN¡ÏPERJETA) ¶W¹L100¬ü¤¸¥@¬É¯Å¤jÃÄ. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/29 ¤U¤È 10:39:54²Ä 272 ½g¦^À³
|
¥xÁÞ¤j, files.shareholder.com/downloads/ARQL/0x0x952609/7FD86678-3664-476F-A556-8B92F36E9C80/Derazantinib_ARQ_087_FGFR_Inhibitor_-_August_2017.pdf mops.twse.com.tw/nas/STR/649720180531M001.pdf ORR 20% VS. 20.7% PFS ¨È·à¨S§¹¥þ¤½§G¡A¥u¤½¥¬3ÓORRªº¤ÏÀ³´Á. ¦Ó2ºØ ORR¥§¡¤ÏÀ³´Ádurable responses ¬Ò¬ù42¶g ,±ÀÂ_¦P¬O¦¨ªø¦]¤l¨ü¾¹§í¨î¥\¯à¡A¬Û®t¤£¦h. ¼Ð¹v§í¨î¾¯ ORR/SD ®t§O¦bÓ§O¯f¤HIHC +3/+2/+1 ªº¤ñ²v¡C IHC +3¤H¼Æ·U¦h,ORR¤H¼Æ·U¦h. IHC+2/+1 ®ÄªG¸¨¦bSD. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/29 ¤U¤È 10:37:10²Ä 271 ½g¦^À³
|
¤Ñ©R¤j»P¦U¦ì·à¤Í¦pªG¦³¿³½ì¥i¥H·j´MECOG performance status ¦bÁx¹DÀù»P OS,PFS,ORR¤§¶¡ªºÃö«Y¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/29 ¤U¤È 10:28:37²Ä 270 ½g¦^À³
|
¥t¥~¤j®anª`·Nªº¬O³o¦¸¥þ²y¼Ï¯Ã¸ÕÅ禬ªº¯f¤H¬O Eastern Cooperative Oncology Group (ECOG)performance status of 0 or 1 ¡A 0,1»P2 ¦bÀø®Ä»P¤ÏÀ³²v·|¦³¬ÛÃö¡A³o¤]´N¬O¬°¤°»ò§ÚÓ¤H·|´£°ª¹ï·Ó²ÕªºORRªºì¦]¡C¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤j®a¦h§ä¸ê°T¤À¨É¥H¨D©P©µ¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/29 ¤U¤È 10:15:01²Ä 269 ½g¦^À³
|
³o¨â®a¤½¥qªvÀøÁx¹DÀù¾÷¨î¤£¦P¡A§t»\¤H¤f¤ñ²v¤£¦P¡A¦¬¯f¤Hªº´Á§O¤ñ²v»P¯f¤H°·±dª¬ºA¤£¦P¡AnÃþ±ÀmPFS§Ú»{¬°¦³¨ä§xÃø«×¡C¦]¬°¤½¥q¨Ã¨S¦³¤½§imPFS,mOS. §Ú¥uª¾¹DORR»P0S¦³Ãö¡APFS»POS¦³Ãö¡A¶¡±µ±À´úORR»PPFS¥i¯à¦³Ãö¡A¥H¤W¤À¨É¶È¨Ñ¤Ñ©R¤j»P·à¤Í°Ñ¦Ò¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/29 ¤U¤È 09:43:06²Ä 268 ½g¦^À³
|
û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/29 ¤W¤È 10:36:58²Ä 210 ½g¦^À³ ·PÁ¤ѩR¤jªº¤À¨É~~Ãö©óVARLITINIB(¦Ñ·à)¤ÎDerazantinib(ARQ-087)¦bÁx¹DÀùÁ{§É¸ÕÅ窺¾÷Âà¤À¨É¦p¤U: 1.VARLITINIB:¤p¤À¤lÃĪ«¦b²ÓM¤º§@¥ÎÄÝ©óEGFR¾÷Âà,¯S¦â¬O¥iª½¶¡±µÃö³¬¥|Ó°T¸¹¶Ç»¼(Singal Transdution)~³o ¤]¬O¦Ñ·à¥i²[»\ªvÀø½d³ò¤j©óARQ-087ªºì¦]¨ä¤@,ù¤óªºLapatinib¤]¬O®t¤£¦hªº¾÷¨î,¦ýVAR¥i¤©¥H Ävª§¥ç¥i¦X§@(¦bªñ´ÁMBCªºÁ{§É¸ÕÅ禳«ü¥X¤è¦V)~~~ A.VARLITINIB¤¶²Ð¦p¥k:pubchem.ncbi.nlm.nih.gov/compound/varlitinib#section=Top B.EGFR¾÷Âश²Ð¦p¥k(ÂI¹Ï):www.selleckchem.com/EGFR(HER).html 2.ARQ-087:¤p¤À¤lÃĪ«¦b²ÓM¤º§@¥ÎÄÝ©óFGFR¾÷Âà,Ãö³¬¤@Ó°T¸¹¶Ç»¼~~ A.(ARQ-087)¤¶²Ð¥k:pubchem.ncbi.nlm.nih.gov/compound/Derazantinib#section=Top B.FGFR¾÷Âश²Ð¦p¥k(ÂI¹Ï):www.selleckchem.com/FGFR.html »²¥H°ê»ÚÁx¹DÀù¯e¯f²Îp¼Æ¾Ú¬Ò«ü¥XVARÃĮĥi¯à²[»\½d¬°¬Ò¤j©óARQ-087~~©Ò¥H¤Ñ©R¤j»¡ªº3.5¿¬Oµ´¹ï¦³¥i¯àªº~~ ¥H¤W¨Ñ°Ñ¦Ò~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/29 ¤U¤È 09:03:23²Ä 267 ½g¦^À³
|
¤Ñ©R¤j arq087 1b ¦n¹³¤£¬O¿zÀËher®a±Ú¡A¦Ó¬O¿z¿ïFGFR2°ò¦]¬ðÅÜ¡A¾A¥Î¤H¤f¬ù¦Ê¤À¤§¤Q |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/28 ¤U¤È 11:37:26²Ä 266 ½g¦^À³
|
MPFS¥Harq087 1b¹Ï¬°°ò¦¦V¥ª²¾ì¦]. arq087 1b ¦³¿zÀËher2, ¦ýaslan001 1b µL¿zÀË¡A¥i¯à§t30%«DHER®a±Ú¡A¦Ó¨ÏORR¤U°¨ì15~17%¡AMPFS¦ÛµM¦V¥ª²¾.. ²¾¦h¤Ö? aslan 001¡Ïcap. Mpfs =orr 16%¡Ïsd 34%=¬Û·í©óSDªºMPFS. ¡X¡X¡X- ARQ087 1b PR MPFS7.9¤ë, SD 5.6 MPFS 5.6¤ë www.arqule.com/wp-content/uploads/ARQ-087_FGF-levels_AACR-poster_2018_final.pdf ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/25 ¤U¤È 04:57:09²Ä 258 ½g¦^À³ ¨È·à±d ASLAN001 ªvÀø¤G½u Áx¹DÀù , ¥þ²yÁ{§É PȱӷP«×¤ÀªR. ¨È·à±d1b Á{§É ORR 20% (3/15) //ARQ087 ORR21%(5/29)¡X- ¤@¡B°²³]¥»Á{§É±wªÌ¦³HER®a±Ú¨ü¾¹ªÌ¦û70%,¡AµLHER(NON-HER)±wªÌ30% HER 70%/NON-HER 30% ¨Ì¾Ú¤G½uÁxºÞÀùÂù¤ÆÀø¤åÄmORR=7.6%. 1.±aNON-HER ORR ¨ÑÄm30%x7.6%=2.28%(Âù¤ÆÀø) 2.HER ORR ¨ÑÄm 20%-2.28%=17.72%(Âù¤ÆÀø¡ÏASLAN 001) (1)¨Ì¾ÚARQ 087 , ASLAN001 ¦Ü¤Ö¨ÑÄm21%x70%=14.7% (2)Âù¤ÆÀøÃĪ«¨ÑÄmORR 17.72-16%=1.72%¡X¡X(A) ¤G¡B¦ôN=120 , 60:60 ´Á¼Ï¯ÃÁ{§É, ORR ,¤ÎP È ±Ó·P«×¤ÀªR µ²½× :¹ï·Ó²Õ4%¥H¤º,PȬҥi<5%. ¡X¡X¡X¡X¡X¡X¡X °²³]¥»Á{§É±wªÌ¦³HER®a±Ú¨ü¾¹ªÌ¦û70%,¡AµLHER(NON-HER)±wªÌ30% ¨Ì¾Ú ARQ087 1bÀø®Ä ORR21% ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- 1. Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 1.2% NON-HER: ³æ¤ÆÀøÃĪ«¨ÑÄm ORR 30%x1.2%=0.36% HER: ASLAN001 ¨ÑÄmORR 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«¨ÑÄm ORR 1.2%/7.6%x1.72%(A)=0.27% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï0.36%¡Ï0.27%=15.33% ORR 15.33% VS 1.2% 9.2/60 VS 0.72/60 X^2 =6.148, P =1.3% 2.Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 2.4% NON-HER ORR ³æ¤ÆÀøÃĪ«¨ÑÄm 30%x2.4%=0.72% HER ASLAN001 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«2.4%/7.6%x1.72%=0.54% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï0.72%¡Ï0.54%=15.96% ORR 15.96% VS 2.4% 9.58/60 VS 1.44/60 X^2 =5.092, P =2.4% 3. Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 3.6% NON-HER ORR ³æ¤ÆÀøÃĪ«¨ÑÄm 30%x3.6%=1.08% HER ASLAN001 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«3.6%/7.6%x1.72%=0.81% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï1.08%¡Ï0.81%=16.59% ORR 16.59% VS 3.6% 9.95/60 VS 2.16/60 X^2 =4.234 P =4.0% 4. Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 4.0% NON-HER ORR ³æ¤ÆÀøÃĪ«¨ÑÄmORR 30%x4.0%=1.2% HER ASLAN001 ORR 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«ORR 4.%/7.6%x1.72%=0.91% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï1.2%¡Ï0.91%=16.81% ORR 16.81% VS 4.0% 10.01/60 VS 2.4/60 X^2 =3.927 P =4.8% |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/28 ¤U¤È 11:00:34²Ä 265 ½g¦^À³
|
¤Ñ©R¤j ¥HARQ087 ¬°°ò¦,¦V¥ª²¾¨Ó¹w¦ô?ì¦]¬O¤°»ò¡I¬ùn¥ª²¾¦h¤Ö¡H¥ª²¾mPFS¤£¬O·|§óµu¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/28 ¤U¤È 10:45:32²Ä 264 ½g¦^À³
|
files.shareholder.com/downloads/ARQL/0x0x952609/7FD86678-3664-476F-A556-8B92F36E9C80/Derazantinib_ARQ_087_FGFR_Inhibitor_-_August_2017.pdf p.11 ¥HARQ087 ¬°°ò¦,¦V¥ª²¾¨Ó¹w¦ô. ¥t°Ñ¦Ò www.ncbi.nlm.nih.gov/pmc/articles/PMC5344285/#!po=1.61290 ¹Ï1, ³æÃÄ. , ¦³©µ¦ù©Ê¬ã¨sHERªºPFS ¹Ï.¤]·|¤½§G. §Úºû«ù¤§«eªº§PÂ_¡A³Ì«áFDA /CFDA ¤Î¥«³õ¬Ò·|n¨D´ú§¹HER ¡A¦A¨Ó¥ÎÃÄ¡A¤~¦X¥G¼Ð¹vÃĪ«ªº¤ÏÀ³¡C ´N¹³¶PÀù¥ªvÀøÂಾ©ÄGÀù,³Ì¨Î¬OHER¤Q2, IHC ¡Ï3 ,.³Ì¦³®Ä¡C IHC+0/+1,¦bOS®Ú¥»©M¹ï·Ó²ÕµL®t²§. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/28 ¤U¤È 10:27:27²Ä 263 ½g¦^À³
|
¤Ñ©R¤j «e½g¤À¨ÉMPFS¹êÅç²Õ(ASLAN001+CAP.)5~5.6¤ë VS.¹ï·Ó²Õ(CAP.) 1.8~2.6¤ë, P < 0.05 ½Ð°Ý¹êÅç²ÕmPFS¬O¦p¦ó¦ôºâ¥X¨Óªº¡HÁÂÁ¸Ѵb¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/26 ¤W¤È 10:58:10²Ä 262 ½g¦^À³
|
¨È·à±dASLAN0001 120 ¤H (60:60) , ¤G½uÁxºÞÀù¼Ï¯Ã¥þ²yÁ{§É. ¥Dn«ü¼Ð ORR,PFS ¤@.Áö¥¼¿zÀËHER®a±Ú¹LÃöªº¾÷·|¬Û·í°ª. ORR ¹êÅç²Õ(ASLAN001+CAP.)15~17% VS.¹ï·Ó²Õ(CAP.)1.2~4.0% , P < 0.05 MPFS¹êÅç²Õ(ASLAN001+CAP.)5~5.6¤ë VS.¹ï·Ó²Õ(CAP.) 1.8~2.6¤ë, P < 0.05 ¤G.¿zÀËHER®a±Úªº¨Æ«á©µ¦ù¬ã¨s(·|©M¤Wz¦P®É¤½§G) ORR ¹êÅç²Õ(ASLAN001+CAP.)20~21%(±µªñARQ 087 ORR21%)(% VS.¹ï·Ó²Õ(CAP.)1.2~4.0% MPFS¹êÅç²Õ(ASLAN001+CAP.)6¤ë(±µªñARQ087 MPFS6Ó¤ë) VS.¹ï·Ó²Õ(CAP.) 1.8¤ë, aslanpharma.com/app/uploads/2018/06/2018-ASCO-ASLAN001-009.pdf Exploratory objectives: • Part 1 1. To explore the role of HER family status as a predictor of benefit to varlitinib 2. To explore possible relationships between HER family and downstream signaling protein and phospho-protein expression levels and clinical outcomes 3. To explore possible relationships between gene mutational status and clinical outcomes |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/26 ¤W¤È 07:42:40²Ä 261 ½g¦^À³
|
¤¤°ê68¦ìÁxºÞÀù¤G½uªºASLAN0001+CAP.³æÁuOpen label Á{§É¡A ORR >15%¥H¤Wªº¾÷²vÓ¤H»{¬°90%-95%. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/25 ¤U¤È 11:14:19²Ä 260 ½g¦^À³
|
¨È·à±d³o®a¥Í§Þ¤½¥q¯uªº«Ü°È¹ê,¦³®Ä²v,¦³·ÀI »P¦¨¥»Æ[©À,¦³µ¦²¤ ·ÀI»P¦]À³¹ïµ¦ (¤½¶}¸ê°TÆ[´ú¯¸ ¦~³ø p46 p47 ) (1) ·sÃĶ}µo¯Ó¶O¤j¶q®É¶¡¤Î¸êª÷¥H¶i¦æÁ{§É¸ÕÅç¤ÎÃĪ«¥Í²£ ¦]À³¹ïµ¦: • ¤£³]¸m¦Û¦³¬ãµo³]¬I: ¥Ñ©ó³Ì·s³]³Æ©Ò»Ý¤§¤jÃB¸ê¥»¤ä¥X¤Î«ùÄò©Ê¬ãµo¤Hû¦¨¥»¡A«Ø¥ß¦Û¦³ªº¬ã µo³]¬I¬Û·í©ù¶Q¡C¥»¤½¥q©Î¥H¤Þ¤J±ÂÅv¨ú±oÔ¿ïÃĪ«¡A©ÎÂǥѵ¦²¤¹Ù¦ñ¶}µo¡A¦]¦¹¬ãµo¦¨¥»¬Û ¹ï¸û§C¡A¥H¨Ï¸êª÷¶°¤¤©óÁ{§É¶}µo¤¤³Ì¨ã»ùȳгyªº³¡¥÷¡C • ¤£³]¸m¦Û¦³¥Í²£³]¬I: «Ø¥ß¦Û¦³ªº¥Í²£³]¬I¤]¬Û·í©ù¶Q¡A¥»¤½¥qµø»Ýn¥I¶O¡B±N¥Í²£¬¡°Ê¥~¥]¡A ¥HÀò¨ú¤j«¬¥Í²£¤½¥qªº®Ä¯q¡C • ®Ä²v¼Ò¦¡: ¥»¤½¥q¦b¶i¦æÁ{§É¸ÕÅç®É¡A³q¹L©ö©ó©Û¶Ò¯f±wªºÁ{§É¤¤¤ß¥H¤Î»PÁ{§É¤¤¤ßij©wÀu´f±ø ¥ó¦Ó¼W¶i®Ä²v¡C³z¹L©e°U¬ã¨s¾÷ºc¶i¦æ¤j«¬¸ÕÅç¡A¥i¨Ï¥»¤½¥q¥H¬Û¹ï¸û¤pªº¹Î¶¤ºÞ²z¤j«¬¸Õ Åç¡A¨Ã¶i¦Ó°§C§@·~¦¨¥»¡C • ¯S©w¤§¯f±w¸sÅé: Âê©w¥Ñ¥Íª«¼Ð°O©Ò©w¸qªº¯f±w±Ú¸s¡A¥iÁY¤pÁ{§É¸ÕÅç³W¼Ò¡C • »EµJ¨u¨£¯e¯f: ¥»¤½¥q¶}µo¤¤ªº¦h¶µ¯e¯f¦b¬ü°ê¤Î¼Ú¬w¬Û¹ï¨u¨£¡A³Qµø¬°¡u©t¨à¯e¯f¡v¡C°ò¥» ¤W¡A¶}µo³oÃþ¯e¯fªº³t«×¸û§Ö¡A¦³¾÷·|¥H¸û¤Öªº¸ê®Æ¨ú±o®Öã¡C • ©ó¨È¬w¶i¦æ¬ãµo: ½Ñ¦pGÀù¤ÎÁx¹DÀù¦b¨È¬w¤§²±¦æ²v¬Û·í°ª¡A¥i§Ö³t¨ú±o¯f±w¡A¾ÉPÁ{§É¸ÕÅ礧 ®É¶¡¸ûµu¡A¦¨¥»¸û§C¡C • °í±jªºªÑªF°}®e: ¨È·à±dªÑªF°}®e°í±j¡A¥]§t³\¦h¥þ²y©Ê¾÷ºc§ë¸ê¤H¡C§ë¸êª÷ÃB¨´¤µ¬Û·í¥iÆ[¡A ¤£¹L¤]¬°¥¼¨Ó¹w¯d§ó¤jµ§ªº¸êª÷¡A¥²n®É±N´£°ª¹ï¨È·à±dªº§ë¸êª÷ÃB¡C • ´£«e¶Ò¸ê: ¨È·à±dªº¸êª÷¹B¥Î¨}¦n¡A¨Ã¥B©ó¹ê»Ú»Ýn¸êª÷«e´£¦¶Ò¸ê¡C • ¦b¯S©w°Ï°ì´£¦Âà¥X±ÂÅv³Ð³yÀ禬°§C·ÀI: ¥»¤½¥q¤w±Nvarlitinib Áú°ê¦a°Ï¤§ÃĪ«°Ó«~¤ÆÅv§Q±Â Åv»P²{¥NÃļt¡AASLAN002 ¥þ²y¤§ÃĪ«°Ó«~¤ÆÅv§Q±ÂÅv»PBMS¡A³Ð³y¦´Á¶¥¬q¤§À禬¡A°§C· ÀI¡C¥»¤½¥q¨Ã«ùÄò©ó¨ä¥L°Ï°ì´M§ä±ÂÅv¹Ù¦ñ¡A¥]¬A¤é¥»¤Î¼Ú¬w¤§±ÂÅv¡C (2) ·sÃĶ}µo¥Rº¡·ÀI¡AÁ{§É¸ÕÅçµ²ªGµLªk¹wª¾¡A¥»¤½¥qµLªk½T«O©Ò¦³ÃĪ«¬Ò¯à¦¨¥\°Ó«~¤Æ ¦]À³¹ïµ¦: • ¿ï¾ÜÀu½èªºÃĪ«: ¨È·à±dÀ˵ø¤W¦ÊºØÃĪ«¡A±q¤¤¬D¿ï¤Ö¼Æ¾A¦XªÌ¨ú±o±ÂÅv¡A½T«O¬D¿ï¥X³ÌÀu¨}¤§ ÃĪ«¡C • »PºÊ·þºÞ²z¾÷Ãö¤§¦´Á±K¤Á°Q½×: ¦b¶}©l¥DnÁ{§É¬ã¨s¤§«e¡A¥»¤½¥qº¥ýµû¦ô®Ú¾Ú®Öã©Ò»Ý¤§¤º ®e¡A¦p«ü¼Ð¡B¹ï·Ó«~¡B¼Ë¥»¼Æ¡A¼sªx¿Ô¸ßºÊ·þºÞ²z¾÷ºc¡A¼x¨D¨ä¹ïÃöÁä°ÝÃD¤§·N¨£¡C¦b¹L¥h¥» ¤½¥q¤w¸g»P¤é¥»PMDA¡BÁú°êKFDA¡B»OÆWTFDA¡B·s¥[©YHSA ©M¬ü°êFDA ¶i¦æ·|½Í¡C • »P¥þ²y»â¥ý¤§©e°U¬ã¨s¾÷ºc»P©e°U¥Í²£¾÷ºc¦X§@: »P¥»¤½¥q¦X§@¤§¤½¥q¥]¬A©ø®õ¡B»OÆW¯«¶©¡BÃÄ ©ú±d¼w¡B³ß±d¡B·R®¦§Æ¤ÎShasun¡C • ±Mª`©ó¯S©w¤§¯f±w¸sÅé: °w¹ï¥Ñ¥Íª«¼Ð°O©Ò©w¸qªº¯f±w±Ú¸s¶}µoÃĪ«¡A¨ä¦¨¥\²v¸û¤§¬°©Ò¦³¯f±w ©Ò¶}µoªºÃĪ«§ó°ª¡C • ¦h¼Ë¤ÆÃĪ«¡B§¡¿Å·ÀI: ÃÄ«~¬ãµo¦s¦b¥¢±Ñ·ÀI¡A¨Ã«D¨CÓ¬ãµoªºÃĪ«³Ì²×³£¯à¤W¥«¡C¥»¤½¥q²{ ¦³¥|¶µ²£«~¡Aªñ´Á±N¦A¤Þ¶i§ó¦h¡C³\¦h¤½¥q³£¶È¦³¤@¶µ³B©ó±ß´Á¶}µo¶¥¬qªº²£«~¡A¥»¤½¥q»{¬° ±N¤½¥qªº¥¼¨Ó©ã¦b³æ¤@ÃĪ«ªº·ÀI·¥°ª¡A¦]¦Ó¿ï¾Ü¤À´²·ÀI¡A§Y¨Ï¤@¶µÃĪ«¥¢±Ñ¡A¨ä¥LÃĪ«¤´ µM±j¦Ó¦³¤O¡A¨Ã¥i¤Þ¤J·sÃĪ«´À¥N¡C (3) ¥»¤½¥q¤º³¡¨Ã¥¼¦Û¦æ¶i¦æ¬ã¨s¡A¦]¦Ó¥õ¿à¦Û¨ä¥L¤½¥q±ÂÅv¨ú±oÃĪ« ¦]À³¹ïµ¦: • °í¹êªº¤Þ¤J±ÂÅv°ò¦: ¥»¤½¥q¦Ü¤µ¤w¦³¤¶µ°ª»ùÈÃĪ«ªº±ÂÅv¡A¨ä¥L·sÃĪ«ªº±ÂÅv¥¿¦b¶i¦æ¤¤¡C • Âǥѵ¦²¤Áp·ùºc«Ø¿W¦³¤§²£«~²Õ¦X: ¥»¤½¥q¨Ì¾Ú¹ï©ó¯e¯fªº»{ª¾¡A»PA*STAR ¤Î«n¬v²z¤u¤j¾Ç (NTU) ¦X§@¶i¦æ·sÔ¿ïÃĪ«¤§¬ãµo¡Aªñ´Á¥»¤½¥q»P«n¬v²z¤u¤j¾Ç¦X§@¥i±æ¬ãµo¤T¶µ·sÃÄ¡C • ¦h¤¸Â×´Iªº¾÷·|¥i¨Ñ¿ï¾Ü: ¥Ñ©ó¥»¤½¥qÅé½è»PÃö«YѨΡA¦]¦¹Ú¨Ñ¿ï¾ÜªºÃÄ«~·¥¬°¦h¤¸Â×´I¡A¨C Ӥ볣¦³¦h®a¤½¥q¡A¦V¥»¤½¥q±´¸ß¦X§@©Î±ÂÅvÃĪ«¤©¥»¤½¥q¤§¥i¦æ©Ê¡C (4) µLªk±NÃĪ«Âà¥X±ÂÅv¦Ó²£¥Íµu´ÁÀ禬 ¦]À³¹ïµ¦: • ¤w°w¹ïÂà¥X±ÂÅv¤§À禬³Ð³y«Ø¥ß°lÂܾ÷¨î: ¥»¤½¥q¤w±Nvarlitinib ©óÁú°ê¦a°Ï¤§ÃĪ«°Ó«~¤ÆÅv§Q±Â Åv»P²{¥NÃļt¡AASLAN002 ¥þ²y¤§ÃĪ«°Ó«~¤ÆÅv§Q±ÂÅv»PBMS¡A³Ð³y¦´Á¶¥¬q¤§À禬¡A°§C· ÀI¡C¥»¤½¥q¨Ã«ùÄò©ó¨ä¥L°Ï°ì´M§ä±ÂÅv¹Ù¦ñ¡A¥]¬A¤é¥»¤Î¼Ú¬w¤§±ÂÅv¡C • ·~¬ÉÂ×´Iªº¸gÅç»P©¹¨ÓÃö«Y: ¥»¤½¥q¸gÀç¹Î¶¤¦b·~¬É¨ã³Æ²`«p¨}¦nªº¤H¯ßÃö«Y¡A±`»P¥þ²y¥Dn¤j ¼tªºÃöÁä¨Mµ¦ªÌ¥æ¬y; ¥»¤½¥q¨Æ·~¶}µo³¡ªù¥H©¹¤]¦³²³¦h¦¨¥\®×¨Ò¡AÂ×´Iªº¸gÅçÀ³¯à½T«O¶¶§Q§¹ ¦¨ÃĪ«Âà¥X±ÂÅv¡C (5) ¬Y¨Ç¾AÀ³¯g¦p¨ÅÀùªºÁ{§É¸ÕÅç¯Ó®É¥B©ù¶Q¡AYµL¦X§@¹Ù¦ñ¡A¨È·à±d©Î»Ý·s¸êª÷Ѻª`¤~¯à¦Û¦æ§¹¦¨ varlitinib ©Ò¦³ªº¸ÕÅç ¦]À³¹ïµ¦: • ¥»¤½¥q¹wp±Nvarlitinib Âà¥X±ÂÅv¡A¥Ñ¦X§@¹Ù¦ñ¥þÅv¶i¦æ¨ÅÀùÁ{§É¸ÕÅç¡A¥»¤½¥q¤w¹w¯d¥R¨¬¸êª÷ °õ¦æ¥Ø«e¶i¦æ¤¤ªº¸ÕÅç¡A¸ÕÅçµ²ªG¦³§U©ó½T«O¥¼¨Ó¤§¹ï¥~±ÂÅv¡C • ¥»¤½¥q²{ª÷³¡¦ì¥R¨¬¡A¯à°÷¤äÀ³©Ò¦³¨M©w¶i¦æ¤§Á{§É¸ÕÅç¡C¥»¤½¥q·|¹ï¦UºØ¾AÀ³¯g±Æ©w¶}µo¤§ Àu¥ý¶¶§Ç¡AY¸êª÷¤£¨¬«h¤£·|±Ò°ÊÁ{§É¸ÕÅç¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/25 ¤U¤È 10:34:12²Ä 259 ½g¦^À³
|
ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.429# ¼vÅT¤G½uÀø®Äªº¬ÛÃö¦]¯À www.croh-online.com/article/S1040-8428(13)00113-3/pdf |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/25 ¤U¤È 04:57:09²Ä 258 ½g¦^À³
|
¨È·à±d ASLAN001 ªvÀø¤G½u Áx¹DÀù , ¥þ²yÁ{§É PȱӷP«×¤ÀªR. ¨È·à±d1b Á{§É ORR 20% (3/15) //ARQ087 ORR21%(5/29)¡X- ¤@¡B°²³]¥»Á{§É±wªÌ¦³HER®a±Ú¨ü¾¹ªÌ¦û70%,¡AµLHER(NON-HER)±wªÌ30% HER 70%/NON-HER 30% ¨Ì¾Ú¤G½uÁxºÞÀùÂù¤ÆÀø¤åÄmORR=7.6%. 1.±aNON-HER ORR ¨ÑÄm30%x7.6%=2.28%(Âù¤ÆÀø) 2.HER ORR ¨ÑÄm 20%-2.28%=17.72%(Âù¤ÆÀø¡ÏASLAN 001) (1)¨Ì¾ÚARQ 087 , ASLAN001 ¦Ü¤Ö¨ÑÄm21%x70%=14.7% (2)Âù¤ÆÀøÃĪ«¨ÑÄmORR 17.72-16%=1.72%¡X¡X(A) ¤G¡B¦ôN=120 , 60:60 ´Á¼Ï¯ÃÁ{§É, ORR ,¤ÎP È ±Ó·P«×¤ÀªR µ²½× :¹ï·Ó²Õ4%¥H¤º,PȬҥi<5%. ¡X¡X¡X¡X¡X¡X¡X °²³]¥»Á{§É±wªÌ¦³HER®a±Ú¨ü¾¹ªÌ¦û70%,¡AµLHER(NON-HER)±wªÌ30% ¨Ì¾Ú ARQ087 1bÀø®Ä ORR21% ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- 1. Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 1.2% NON-HER: ³æ¤ÆÀøÃĪ«¨ÑÄm ORR 30%x1.2%=0.36% HER: ASLAN001 ¨ÑÄmORR 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«¨ÑÄm ORR 1.2%/7.6%x1.72%(A)=0.27% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï0.36%¡Ï0.27%=15.33% ORR 15.33% VS 1.2% 9.2/60 VS 0.72/60 X^2 =6.148, P =1.3% 2.Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 2.4% NON-HER ORR ³æ¤ÆÀøÃĪ«¨ÑÄm 30%x2.4%=0.72% HER ASLAN001 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«2.4%/7.6%x1.72%=0.54% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï0.72%¡Ï0.54%=15.96% ORR 15.96% VS 2.4% 9.58/60 VS 1.44/60 X^2 =5.092, P =2.4% 3. Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 3.6% NON-HER ORR ³æ¤ÆÀøÃĪ«¨ÑÄm 30%x3.6%=1.08% HER ASLAN001 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«3.6%/7.6%x1.72%=0.81% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï1.08%¡Ï0.81%=16.59% ORR 16.59% VS 3.6% 9.95/60 VS 2.16/60 X^2 =4.234 P =4.0% 4. Y¹ï·Ó²Õ¬°³æ¤ÆÀøÃĪ«ORR 4.0% NON-HER ORR ³æ¤ÆÀøÃĪ«¨ÑÄmORR 30%x4.0%=1.2% HER ASLAN001 ORR 70%x21%=14.7% ¡Ï³æ¤ÆÀøÃĪ«ORR 4.%/7.6%x1.72%=0.91% ¦Xp ¹w¦ô¹êÅç²ÕORR = 14.7%¡Ï1.2%¡Ï0.91%=16.81% ORR 16.81% VS 4.0% 10.01/60 VS 2.4/60 X^2 =3.927 P =4.8% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/25 ¤W¤È 08:54:45²Ä 257 ½g¦^À³
|
¤@¡BPhase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations clinicaltrials.gov/ct2/show/NCT01752920?term=arqule Study Type : Interventional (Clinical Trial) Actual Enrollment : 109 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion Study Start Date : December 2012 Estimated Primary Completion Date : June 2018 Estimated Study Completion Date : December 2018 Experimental: ARQ 087 Subjects will receive ARQ 087 orally at dose levels specified for their respective dose cohorts on a 28-day schedule. Subjects will receive treatment with ARQ 087 until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented. ARQ 087 ¤G缐Áx¹DÀùICCA 1/2´ÁÁ{§É, ¨S¥Î¤ÆÀøÃĪ«. ¥u¥ÎARQ087 ¹êÅç²Õ³æÃÄ. ORR ¹F21%(3/29) MPFS ªñ6Ó¤ë(2017 ASCO) ¤G¡BARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma clinicaltrials.gov/ct2/show/NCT03230318?term=087-301&rank=1 Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Actual Study Start Date : November 10, 2017 Estimated Primary Completion Date : September 2020 Estimated Study Completion Date : March 2021 Drug: ARQ 087 ARQ 087 will be orally administered at 300 mg once per day one hour prior to or two hours after a meal and is supplied as 100 mg capsules. ³Ìªñªº¤G´ÁÁx¹DÀù¤G½u¡A¤]¬OµL¥Î¥ô¦ó¤ÆÀøÃĪ«. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/25 ¤W¤È 06:15:56²Ä 256 ½g¦^À³
|
¥xÁÞ¤j, ·PÁÂ! ¦¹¦¸±z´£¨Ñªº¬O¤¤¦ì¼ÆN=22¦ì¡A¦@761¦ì±wªÌªº¸ê®Æ. ¦@25¶µ(14¶µII´ÁÁ{§É¸ÕÅç¡A9¶µ¦^ÅU©Ê¤ÀªR©M2¨Ò¯f¨Ò³ø§i) ,¨t²Î©Êªº¦^ÅU¤Î2´ÁÁ{§É³ø§i ¥§¡¤ÏÀ³PR 7.7¢H¡]95¢HCI 4.6-10.9¡^. ¬Ý¨Ó¤W¦¸ORR=1.2%(3/255) ³æÃÄ¡ÏORR7.6%(5/66) Âù¤ÆÀøªvÀøªº¬ã¨s¤£¦b¦¹¦¸ªº²Îp½d³ò! Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients www.ncbi.nlm.nih.gov/pmc/articles/PMC5344285/ ¥i¦³¨ú³æÃÄ(¤ÆÀø)¥Î©ó2½uÁxºÞÀùªº¨ä¥L¤åÄm? ÀH¾÷NCRN III´ÁABC-02¸ÕÅ笰±ß´ÁÁx¹DÀù¡]ABC¡^¤¤¶¶¹`©M¦N¦è¥LÀØÁp¦XªvÀøªº¤@½u¤ÆÀø´£¨Ñ¤FA¯ÅÃÒ¾Ú¡C¥»¨t²Î¤åÄmºîz¦®¦bµû¦ôABC±wªÌ¦bÁ`¥Í¦s¡]OS¡^¡A¤ÏÀ³¡A¬r©Ê©M¥Í¬¡½è¶q¤è±¨Ï¥Î¤G½u¤ÆÀøªºÃÒ¾Ú¤ô¥¡C¨Ï¥ÎMedline¡AASCO¡AESMO©MWorld Gastrointestinal Congress¼Æ¾Ú®w½T©w²Å¦X±ø¥óªº¬ã¨s¡C·j¯Á³Ì«á§ó·s©ó2013¦~12¤ë15¤é¡C²Å¦X±ø¥óªº¬ã¨s³ø§i¤F±µ¨ü¤G½u¥þ¨¤ÆÀøªºABC±wªÌªº¥Í¦s²v©M/©Î¤ÏÀ³¼Æ¾Ú¡C¸Ó¨t²Îµû»ù¤w¦bPROSPERO¼Æ¾Ú®w¡]½s¸¹CRD42013004205¡^¤¤µù¥U¡C¦bMedline¡]n = 342¡^¡AASCO¡]n = 160¡^¡AESMO¡]n = 27¡^©M¥@¬ÉG¸z¤j·|¡]n = 29¡^ªº·j¯Á¤¤½T©w¤F555¶µ¬ã¨s¡C¤G¤Q¤¶µ¬ã¨s²Å¦X±ø¥ó¡G14¶µII´ÁÁ{§É¸ÕÅç¡A9¶µ¦^ÅU©Ê¤ÀªR©M2¨Ò¯f¨Ò³ø§i¡CÁ`¦@³ø§i¤F¨Ó¦Û761¦W±wªÌªº¼Æ¾Ú¡A¨C¶µ¬ã¨s¤¤¥]¬Aªº±wªÌªº¤¤¦ì¼Æ¬°22¡]½d³ò9-96¡^¡C¥§¡OS¬°7.2Ó¤ë[95¢H¥i«H°Ï¶¡¡]CI¡^6.2-8.2] [²Ä¤G¶¥¬q¡G6.6¡]95¢HCI 5.1-8.1¡^;¦^ÅU©Ê¤ÀªR¡G7.7¡]95¢HCI 6.5-8.9¡^]¡C¥§¡µL¶i®i¥Í¦s´Á¡]PFS¡^¡A¤ÏÀ³²v¡]RR¡^©M¯e¯f±±¨î²v¬°3.2Ó¤ë¡]95¢HCI 2.7-3.7¡^¡A7.7¢H¡]95¢HCI 4.6-10.9¡^©M49.5¢H¡]95¢HCI 41.4-¤À§O¬°57.7¡^¡C¹ï©ó©Ò¦³¬ã¨s¡]r = 0.54; P = 0.01¡^©MOS»PPFS¡]r = 0.61; P = 0.04¡^©MOS©MRR¡]r = 0.62; P = 0.03¡^ªºII´Á¡AOS©MPFS¤§¶¡ªº³Ì¨Î¬ÛÃö©Ê¬ã¨s¤À§O¡C¤wª¾Áx¹DÀù¬O¤Æ¾Ç¤ÏÀ³©Ê¯e¯f¡C¨S¦³¨¬°÷ªºÃÒ¾Ú¡]C¯Å¡^±ÀÂËABCªº¤G½u¤ÆÀø¤è®×¡A¾¨ºÞ²{¦³¼Æ¾Úªí©ú¤@²Õ±wªÌ¥i¯à·|¨ü¯q¡C»Ýn¶i¤@¨Bªº«e¤©Ê©MÀH¾÷¬ã¨s¨ÓÄÄ©ú¤G½u¤ÆÀø¦b³oºØ±¡ªp¤Uªº¬Û¹ï»ùÈ¡C The randomized NCRN phase III ABC-02 trial provided level-A evidence for first-line chemotherapy with cisplatin and gemcitabine combination in advanced biliary cancer (ABC). This systematic literature review aims to evaluate the level of evidence for the use of second-line chemotherapy for patients with ABC in terms of overall survival (OS), response, toxicity and quality of life. Eligible studies were identified using Medline, ASCO, ESMO and the World Gastrointestinal Congress databases. Searches were last updated on 15 December 2013. Eligible studies reported survival and/or response data for patients with ABC receiving second-line systemic chemotherapy. This systematic review was registered in the PROSPERO database (No. CRD42013004205). Five hundred and fifty-eight studies were identified from the searches in Medline (n = 342), ASCO (n = 160), ESMO (n = 27) and World Gastrointestinal Congress (n = 29). Twenty-five studies were eligible: 14 phase II clinical trials, 9 retrospective analyses and 2 case reports. In total, data from 761 patients were reported with median number of patients included in each study of 22 (range 9-96). The mean OS was 7.2 months [95% confidence interval (CI) 6.2-8.2] [phase II: 6.6 (95% CI 5.1-8.1); retrospective analysis: 7.7 (95% CI 6.5-8.9)]. The mean progression-free survival (PFS), response rate (RR) and disease control rate were 3.2 months (95% CI 2.7-3.7), 7.7% (95% CI 4.6-10.9) and 49.5% (95% CI 41.4-57.7), respectively. The best correlations were between OS and PFS for all studies (r = 0.54; P = 0.01) and between OS and PFS (r = 0.61; P = 0.04) and OS and RR (r = 0.62; P = 0.03) for phase II studies, respectively. Biliary tract cancer is known to be a chemo-responsive disease. There is insufficient evidence (level C) to recommend a second-line chemotherapy schedule in ABC, although the available data suggest that a cohort of patients may benefit. Further prospective and randomized studies are needed to clarify the relative value of second-line chemotherapy in this setting. PMID 24769639 [Indexed for MEDLINE] www.ncbi.nlm.nih.gov/m/pubmed/24769639/ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/24 ¤U¤È 10:32:59²Ä 255 ½g¦^À³
|
¤G½uÁx¹DÀù¬ã¨s½g¼Æ¬Û·í¦h¡A¦³¿³½ìªº·à¤ÍÀ³¦h¾\Ū¡C³o½g¬Ý°_¨Ó¬O²Î¾ã¡C www.ncbi.nlm.nih.gov/m/pubmed/24769639/ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2018/7/24 ¤W¤È 11:06:45²Ä 254 ½g¦^À³
|
¥xÁÞ¤j, Áp¦XªvÀø²Õ ¤G½u including ¥H¤U ¥Dn¬O capecitabine plus cisplatin 60¤H ¦pªG§âcisplatin ®³±¼¬O§_ORRÁÙ¦³7.6% ¤]¬Oȱo±´°Q? ³o½g¬ã¨s³ø§i Table 3 Table 4 «Üȱo°Ñ¦Ò ! capecitabine plus cisplatin in 60, 5-fluorouracil plus cisplatin in 2, 5-fluorouracil plus oxaliplatin in 2 capecitabine plus oxaliplatin in 2. ¤Wzªº³æÃÄÁ{§ÉORR 3/250 , Y©â様»~®t5%, 3~6/250ªº¤ñ²v´N«Ü°ª¤F. ¤Wz66¤H¤QCISPLATIN ªºÁpÃÄORRºî®Ä¦³¹F4~5%ªºÃB¥~®Ä¯q.¥²¶·´î°£. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/23 ¤U¤È 10:45:09²Ä 253 ½g¦^À³
|
¤Ñ©R¤j ´£°ª¹ï·Ó²Õ¼Ð·ÇÁÙ¦³¤@Óì¦]¬O³o¦¸¦¬®×¹ï¶H¨Å骬ºAÄÝ©ó¤ñ¸û¦nªº, ¬Û¹ïªº¹êÅç²Õ«ÈÆ[¤Ï¬M²v¤]¥i¯à´£°ª ( Áp¦XªvÀø²Õ ¤G½u including ¥H¤U ¥Dn¬O capecitabine plus cisplatin 60¤H ¦pªG§âcisplatin ®³±¼¬O§_ORRÁÙ¦³7.6% ¤]¬Oȱo±´°Q? ³o½g¬ã¨s³ø§i Table 3 Table 4 «Üȱo°Ñ¦Ò ! capecitabine plus cisplatin in 60, 5-fluorouracil plus cisplatin in 2, 5-fluorouracil plus oxaliplatin in 2 capecitabine plus oxaliplatin in 2. º|±¼¤@²Õ §ó¥¿¦p¤U: ¹ï·Ó²Õ¥ÎÃÄCape«ÈÆ[¤ÏÀ³²vORR¬ã§P¡A¥H¤U¤À¨É¦³¥i¯à¬OÓ¤H°¾¨£¡A¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú¡A ¤j®a»Ý¦A¬Ý§ó¦h§ó·sªº¤åÄm¡C Cape ORR --- / ¾÷²v)/(CR+PR ¤H¼Æ) ¦Ê¤À¤§7.5-8.3 /¡]15¡^ / (5) ¦Ê¤À¤§5.9-7.4 /¡]30¡^ / (4) ¦Ê¤À¤§4.2-5.8 /¡]30¡^ / (3) ¦Ê¤À¤§3-4.1 / (15) /(2) ¦Ê¤À¤§1-2 /¡]10¡^ / (1) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/23 ¤W¤È 08:39:31²Ä 252 ½g¦^À³
|
¹ï·Ó²Õ«ÈÆ[¤ÏÀ³²v¾÷²v¬ã§P¡A¥H¤U¤À¨É¦³¥i¯à¬O°¾¨£¡A¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú¡A¤j®a»Ý¦A¬Ý§ó¦h§ó·sªº¤åÄm¡C ¦Ê¤À¤§8¥H¤W¡]10¡^ ¦Ê¤À¤§6-7¡]50¡^ ¦Ê¤À¤§5¡]30¡^ ¦Ê¤À¤§5¥H¤U¡]10¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/23 ¤W¤È 08:17:18²Ä 251 ½g¦^À³
|
¤Ñ©R¤j Ó¤H266½gªº¤À¨É«á¨Óµo²{³o²Õ¨Ï¥Îcapeªº¼Ë¥»¥u¦³4Ó¤H¤~¦b267§ó¥¿¡AÀ³¸Ón°Ñ¦ÒÁp¦X¥ÎÃIJըº66¤H¤~¤ñ¸û¦X²z¡A¦Ñ´¤j¤]¬O¥Î¦Ê¤À¤§6¥ª¥k°µ¤F¤åÄm¤Wªº±´°Q¡A«Øij¤Ñ©R¤j«¬Ý¨º½g¬ã¨s³ø§i¡C ¡@ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/22 ¤U¤È 10:35:22²Ä 250 ½g¦^À³
|
¤Ñ©R¤j §A¤W¦¸°Ýªº°ÝÃD¥i°Ñ¦Ò§Ú¦b·à°ê¤T§qª©267½g§ó¥¿ª©¦³½×z,cape ¦]¬°¨S¦³³æÃĬã¨s³ø§i,¥u¦³ÁpÃĩγæÃÄÁpÃIJV¦b¤@°_¬ã¨s.¨È·à±dÁx¹DÀù¥þ²y¼Ï¯Ã¸ÕÅç¬O²Ä¤@Ó¹ï·Ó²Õ¥H³æÃı´°QÀø®Ä , §Ú·|§â¼Ð·Ç´£°ª,¤]´N¬Oª½±µ¥ÎÁpÃĪºORR¥h±À½× (fluoropyrimidine and platinum) ¦]¬°¦³¥Î¨ìcapecitabine ªº¤H¼Æ°ª¹F62¤H ¦³°Ñ¦Ò»ùÈ The other patients (21%, n=66) received a combination of fluoropyrimidine and platinum, including ÁpÃĪvÀø²Õ¤ÀªR (fluoropyrimidine and platinum ) capecitabine plus cisplatin in 60¤H 5-fluorouracil plus cisplatin in 2¤H 5-fluorouracil plus oxaliplatin in 2¤H capecitabine plus oxaliplatin in 2¤H ( ORR 7.6 % mOS 6.2 Ó¤ë mPFS 2.6 Ó¤ë ) Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients www.ncbi.nlm.nih.gov/pmc/articles/PMC5344285/ °Ñ¦Ò¦Ñ´¤j¦b·à°êª©¤]¦³±M·~ªº±À¦ô ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò ,½Ð¤Å·í¨Ì¾Ú¬°§ë¸ê |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/17 ¤U¤È 06:35:21²Ä 249 ½g¦^À³
|
·PÁ½Ѧì¤j¤j°^Äm©Òª¾,Åý«Ü¦h°ª§C¼Ðªº±¡§Î³£²M·¡¼ÒÀÀ~~§Æ±æ¦Ñ·àÁ{§É¤Î±ÂÅvªº¶i«×³£¯à¦p¹w´Á¶i¦æ,¦Ü©ó60/60¤HªºÁx¹DÀù¼Ï¯Ã¸ÕÅç,Y¦³¹F42/42¥H¤W§Y¥i¸Ñª¼,·Q¥²³o¨Ç¦Ñ·àªº±M®a̳£¼ÒÀÀ¹L¤F,¤@©w¬O¹LÃö¾÷²v°ª,¤£µM«ç¦³¼Ï¯Ã¸ÕÅç©O? ¥H¤W¨Ñ°Ñ¦Ò~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/17 ¤W¤È 08:57:23²Ä 248 ½g¦^À³
|
·PÁ²q·Q¤j ¤Ñ©R¤jªº²Îp¤è±ªº¤À¨É¡A ¦³®Õ¥¿¨S®Õ¥¿³£¦³¥i°Ñ¦Òªº¼ÒÀÀ¼Æ¾Ú¡A¹ï·Ó²Õ±Ä¥Î§C¼Ð»P°ª¼Ð¡A«ÈÆ[¤ÏÀ³¤H¼Æ±q1-5¤]³£¦³°Ñ¦Òªº¼ÒÀÀ¼Æ¾Ú¡A¯u¬O·P®¦·PÁÂ! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2018/7/16 ¤U¤È 05:18:18²Ä 247 ½g¦^À³
|
·q·Rªº²q·Q¤j¤j¡G ±z©MCliff¤j¤j¦b·sÃÄ»â°ì¤Wªºª¾ÃѤÀ¨É ¤p§ÌµÛ¹ê¨ü´f¨}¦h ¤p§Ì¥u¦³·PÁ¦A·PÁ¡I ¤p§Ì¯à¤O»P°]¤O¦³ ¥u¯à±Mª`¦b¤@Ó»â°ì ¨ä¥¦»â°ì¤p§Ì¦w¦wÀRÀRªY½à±z̪º¨Î§@ ·sÃÄ»â°ìªºª¾ÃѯEÃv¥BÄvª§¿E¯P ¨S¦³¹³§b¥Ê¯ëªº¤@ªÑ¶Ì«l¬O¤£¥i¯à§â¿úªø´Á©ñµÛ ¤p§ÌÁÙ¬O¬Û«HY¾÷Âà¹ï¤F ªÑ»ù³Ì²×·|¤ÏÀ³°ò¥»± ¤£ºÞ¬OÀù¯g¥ÎÃĩκ믫¯e¯f¥ÎÃÄ ³Ì²×±N·|¥X²{¬ü¦nªºµ²§½ ¯¬ºÖ±z ¤ß·Q¨Æ¦¨¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/16 ¤U¤È 02:14:48²Ä 246 ½g¦^À³
|
§ó¥¿»P¸É¥R ¤Ñ©R¤j:²q·Q¤j¤w¸g¦ô¥X¤»²Õ¥d¤èȵ¹¤j®a°Ñ¦Ò¡A³o¤»²Õ¥i§_½Ð¤Ñ©R¤j¥ÎÁB¥¿ªº¤è¦¡¦ôºâ¥d¤èÈ¡A¥t¥~¦A¥[¤»²ÕÁ`¦@¤Q¤G²Õ¡A°ª§C¼Ð³£¦³¤F¡AÁÂÁ¤ѩR¤jªº¥Î¤ß»P¤À¨É 10/2 10/3 10/4 10/5 11/2 11/3 11/4 11/5 12/2 12/3 12/4 12/5 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/16 ¤U¤È 02:10:32²Ä 245 ½g¦^À³
|
·q·Rªº¤p©_¤j¤j ¦n¤[¤£¨£ »¡¤]¦½ÃC , ¤pªº³ºµLªkªÖ©w , ±z·Qn»¡ªº¬O§_©M¤p§Ì·Qªº¤@¼Ë? ·Ó¹D²z»¡ , ¥H¹L¥hÆp¬ã¼ÒÀÀPD¼Æªº¶Ì«l , 192³oӼƦrÀ³¦³¥X²{¹L ¥u¤£¹LÀHµÛ·³¤ë¥^¥^ , ¸£µ¬¤£¹³±q«eÆF¥ú n±q¦sÀÉ¸Ì , ´M¦^¹L¥hªº°O¾Ð , ¤]¦]¹q¸£¬G»Ù½·s , µL¥H´_±o ¤p§Ì¤]¸ÕµÛ¦^·Q , µM²Ó¸`¤w¤£´_°O¾Ð ±q«eªº¤ß¦å , ¤]¥u¯d¤U¤Ö¼Æ§Ü¾Ô ¤@¨Ó¦Ç¤ß¤F ¤G¨Ó³oÓ»â°ì¤Ó¹LÄvª§ , ¥[¥HÓ¤Hª¾ÃѦ³ , n½Í§PÂ_ , ·Pı¤O¦³¥¼¶e ¯uªº«Ü©êºp! ¤p§ÌµLªk§¹¦¨¨Ï©R , ¦Û»@¤TªMÁ¸o ¤]½Ð±`¤W¨Ó²á²á ÁÂÁ±z! ¤]½Ð¦A¤@¦¸½Ì¸Ñ¤p§ÌªºµL¯à! ¤Ñ©R¤j ÁÂÁ±оÇ! ¥xÁÞ¤j ¶¶¤ß´r§Ö ·à¤Í̤jÂצ¬ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/7/16 ¤U¤È 02:03:15²Ä 244 ½g¦^À³
|
³Ìªñ·Pı¥xÆW³oÃ䪺¦¨¥æ¶qÁÙ¦³¬ü°êADRªº¦¨¥æ¶q³£ÁY¨ì¤@ӫܤpªº¶q¤F¡A¤£ª¾³o§«ôªº¥Í§Þ®i¡A¨È·à±d¦³¨S¦³¤°»ò·sªº®ø®§n¤½¥¬©O? ¥h¦~»¡ªº®ü¥~±ÂÅv¤£ª¾Ô£®É¤~·|µo¥Í©O? §Æ±æ»°ºò¦³¤@¨Ç·sªº®ø®§¤½¥¬¡A¨ë¿E¤@¤U¶R½L¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/16 ¤U¤È 01:58:38²Ä 243 ½g¦^À³
|
²q·Q¤j ÁÂÁ·P®¦¡A¯¬ºÖ§ë¸êªº¤ß®®¥ÍÂå¯à¦¨¥\ ¤Ñ©R¤j:²q·Q¤j¤w¸g¦ô¥X¤»²Õ¥d¤èȵ¹¤j®a°Ñ¥[¡A³o¤»²Õ¥i§_½Ð¤Ñ©R¤j¥ÎÁB¥¿ªº¤è¦¡¦ôºâ¥d¤èÈ¡A¥t¥~¦A¥[¤T²Õ§C¼Ð10/2 11/2 12/2¡AÁ`¦@¤E²Õ ÁÂÁ¤ѩR¤jªº¤À¨É |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/16 ¤U¤È 12:47:58²Ä 242 ½g¦^À³
|
¤Ñ©R¤j ·í¦Û¥Ñ«×¯S别¤p¡A¤×¨ä¬O¥|®æªí³o¼Ë¥u¦³1ªº时Ô¡Apºâ¥Xªº¥d¤èÈ°¾¤p¡A½Ð°Ý°²¶§©Êªº·§²v¼W¤j¬O¤°»ò·N«ä¡C¬°¦ó®Õ¥¿«á¥d¤èȤñ¤£®Õ¥¿ÁÙ§C¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/16 ¤U¤È 12:19:40²Ä 241 ½g¦^À³
|
¤Ñ©R¤j 4 //56 60 12//48 60 16//104 n=120 ´Á±æÈ 8.00 52.00 60.00 8.00 52.00 60.00 16.00 104.00 120.00 x^2 = (4-8)^2/8 + (12-8)^2/8 + (56-52)^2/52 + ( 48-52)^2/52 = 4.615 ¥H¤W¬O¤£®Õ¥¿®Éªº X^2 ¦Ó±z©Òªþªº³sµ² , ±a¦³¤@Ó®Õ¥¿È(¤p§Ì¤£ª¾¹D¦óºØ±¡ªp»Ýn®Õ¥¿?) , ¤]´N¬O x^2 = (8-4-0.5)^2/8 + (12-8-0.5)^2/8 + (56-52-0.5)^2/52 + (52-48-0.5)^2/52 = 3.534 ¤p§Ì¤]¤£ª¾n±Ä¥Î¦óÈ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2018/7/16 ¤W¤È 10:58:56²Ä 240 ½g¦^À³
|
²q·Q¤j¤j¡G ¤p§ÌÉ·à¤lªºª©¸ò±z½Ð±Ð¤@Ó°ÝÃD ½Ð°Ý±z ¬O§_´¿¦b¬YÓprotocol¤W¬Ý¹L¤@Ó192ªº¼Æ¦r¡H ¤p§Ì¹ï¤@Ó°ÝÃDºÃ´b¤F«Ü¤[ ·Q·Q¸ò±z½Ð±Ð³Ì¦³¾÷·|¸Ñµª ¤£ºÞ±z¦³¨S¦³¬Ý¹L©ÎªÌ¾A¤£¾A¦X¦^µª ¤p§Ì³£·PÁ±z ÁÂÁ¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/16 ¤W¤È 10:38:04²Ä 239 ½g¦^À³
|
¤Ñ©R¤j ¹ï·Ó²Õ¥Î¤ñ¸û°ªªº¼Ð·Ç¨Ó¼ÒÀÀÀ˵ø¤£ªí¥Ü¯u¹êªº±¡ªp¥²µMµo¥Í¡A´Nºâµo¥Í¡A¦pªG¹êÅç²ÕORR¬Û¹ïÀ³ªº´£¤É¤]¬O¦³¹F¼Ð¾÷·|¡C¼ÒÀÀ´N¬On°²³]¦UºØ¥i¯àªº±¡ªpÅý·à¤Í¿W¥ßµû¦ô ¥i¯àªº¾÷·|»P·ÀI¡C ¤Ñ©R¤j ¬O§_¤]½Ð¼ÒÀÀ10/2 ¬Ý¬Ý¥d¤èȬO¦h¤Ö¡H ÁÂÁ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/16 ¤W¤È 10:22:12²Ä 238 ½g¦^À³
|
¥xÁÞ¤j 12/4 , X^2 = 4.615 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/16 ¤W¤È 10:05:48²Ä 237 ½g¦^À³
|
ÁÂÁ²q·Q¤j §Ú¥Î¤ñ¸û°ªªº¼Ð·Ç¡]¹ï·Ó²ÕORR ¦Ê¤À¤§5-¦Ê¤À¤§8¡^½Ð²q·Q¤j¼ÒÀÀªº¡C²q·Q¤jªº¼ÒÀÀ¤ÀªR¶È¨Ñ·à¤Í°Ñ¦Ò¡A¹êÅç²Õ¹ï·Ó²Õ¯u¥¿ORRnµ¥¤½¥q¤½§i¬°·Ç ¤£¦n·N§Ú¦n¹³¸¨±¼12/4 ³o¤@²Õ¡AÁÂÁ²q·Q¤j¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/16 ¤W¤È 08:46:02²Ä 236 ½g¦^À³
|
¥xÁÞ¤j ¤p§Ì«D¬ì¯Z¥Í ,Æ[©À¤]¬OªF±½¦è¾ß ,¦^µª±zªº°ÝÃD ,©Î¦³»~®t¿ù»~ ,Y¦³ ,½Ð®ü²[ ¤]½Ð±M·~¤j¤jÌ«ü¾É«ü¥¿ ¦b¤p§ÌªºÆ[©ÀùØ §Ú̥ѩÒq©wªº £\ , £] , ®ÄªG¶q ...¥hpºâ¼Ë¥»¼Æ ·í¼Ë¥»¼Æ½T©w«á (¦p±zÁ|¨Òªº 120 ), ¹êÅç¥X¨Óªº¼Æ¾ÚY¤]½T©w ( ¦p±zÁ|ªº 10/3 ...µ¥ ) «h¥i¥Hºâ¥XPÈ , POWERÈ , ¦A»Pì¥ý©Ò³]©wªº£\ , £]¬Û¤ñ¸û Y«ezµLªkº¡¨¬,¦bÃĮĤ£Åܪº°²³]¤U , ¥u¦³¼W¥[¼Ë¥»¼Æ , ¤è¯à¹F¨ìì¥ý©Ò³]©w£\ , £]ªºªùÂe (PÈ<0.05 , POWERÈ>80 or 90 % ) ¦Ü©ó±zn¤p§Ì¼ÒÀÀªº¥d¤èÈ ,¥Î§Ú¦Û¤v«Ø¥ßªºEXCEL¸Õºâµ²ªG¦p¤U 10/3 , X^2 = 4.227 10/4 , X^2 = 2.911 11/4 , X^2 = 3.733 11/5 , X^2 = 2.596 12/5 , X^2 = 3.358 Y§Ú̱N ( 11/5 )ªº¼Ë¥»¼Æ¥[¿ , ÃĮĤ£ÅÜ ( ORR¤£ÅÜ ) §Y ¥Î¹êÅç²Õ ¹ï·Ó²Õ¼Ë¥»¼Æ¦U¬° 120 , ORR¤H¼Æ 22/10 ºâ±o X^2 = 5.192 ¹F¨ì P < 0.05 ªºÅãµÛ¥Ø¼Ð ¥xÁÞ¤j¥H¤Î·à¤ÍÌ ¨£¯º¤F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/16 ¤W¤È 12:07:17²Ä 235 ½g¦^À³
|
²q·Q¤j À³¸Ó¬O¤²Õ¼ÒÀÀ¤~¹ï¡A³o¥u¬O²Îp¾Ç¤W¦³Ãö¥d¤èȪº¼ÒÀÀpºâ¤À¨É¡A¤£¬OÁ{§É¸ÕÅç¹ê»Úªºµ²ªG¡A¶È¨Ñ°Ñ¦Ò¦Ó¤w¡A¥t¥~·Q½Ð°Ýpower80©Î90·|¼vÅT¥d¤èȶܡH¥t¥~²q·Q¤jªº¼ÒÀÀ¼Æ¾Ú¥u¬O²Îp¾Ç¤Wªº±Ð¾Ç¤À¨É¦Ó¤w¡A¤j®a¤]À³¾Ç²ß¼ÒÀÀ¸Õºâ¬Ý¬Ý¡I¦p¦¹¤~·|¤£Â_ºë¶i¦¨ªø¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/15 ¤U¤È 11:39:43²Ä 234 ½g¦^À³
|
²q·Q¤j ¦³½Ð«e½ú¸Õºâ¬Ý¬Ý¤U±¥|²Õ¥d¤èÈ¡A¦³¤F¥d¤èȬdªí´N¯à¬ù²¤±À´úPȬO§_¹F¼Ð¡Adf=1 ¹êÅç²Õ/²Õ¹ï·Ó²Õ¦U60¤H¹F¨ìCR+PR¤H¼Æ ¼ÒÀÀ¦p¤U4²Õ 10/3 ¡B10/4 ¡B 11/4 ¡B 11/5 12/5 ±Àºâ²z½×¦¸¼Æ»P¤W±Æ[¹î¦¸¼Æ¥Hdf=1 pºâ¥X¨Óªº¥d¤èȬù¦h¤Ö¡H ÁÂÁ²q·Q¤j |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/15 ¤U¤È 10:48:42²Ä 233 ½g¦^À³
|
¤Ñ©R¤j ¹ï·Ó²Õ4 56 = 60 , ORR 6.7 ¹êÅç²Õ12 48 = 60 , ORR 20 ²z½×¦¸¼Æ¹êÅç²Õ¹ï·Ó²Õ³£¬O¡]16/120¡^x60=8/52 Æ[¹î¦¸¼Æ¹ï·Ó²Õ¬O4/56 ¹êÅç²Õ 12/48 pºâ¥X¨Óªº¥d¤èÈ¥Hdf=1±¡ªp¤U¬dªípȤw¸g¤p©ó0.05 ¡A¹ï·Ó²ÕCR+PR¦³«Ü°ª«Ü°ªªº¾÷²v¸¨¦b3.4.5¤H¥i¥H¼ÒÀÀ¬Ý¬Ý¡C ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/15 ¤U¤È 05:22:51²Ä 232 ½g¦^À³
|
Ãö©ó¬ü°ê120¤HÁx¹DÀù¼Ï¯Ã¸ÕÅç½Ð¤j®aÀ°¦£½T»{¤@¤U¦p¤U : 1.¤j®a´£¨ì120¤Hªº¸ÕÅç½s¸¹À³¬ONCT03129074(²Î¤@ÃÒ¨é±i¬ã¨sû©Ò´£),¦ý¦¹¸ÕÅç¤wºM¦^(³sµ²ºô§}²Ä¤»Ó¸ÕÅç).. 2.¦Ó²Ä¥|Ó³sµ²¤~¬OÁx¹DÀù¼Ï¯Ã¸ÕÅç½s¸¹À³¬ONCT03093870,¦ý¨ä¦¬®×¼Æ¬O490¤H.....¦Ó»P120¤H¬ÛÃöªº¶È¦bPrimary Outcome Measures´£¨ì when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1--¤Ï±À84/0.7=120¤H,¬O§_ªí¥Ü¹êÅç/¹ï·Ó¶È»Ý42/42=¦@84¤H´Nºâ²Å¦X³Ì§C¸Ñª¼¤H¼Æ ??? FDA³sµ²¦p¥k : clinicaltrials.gov/ct2/results?cond=Varlitinib&term=&cntry=&state=&city=&dist= |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/15 ¤W¤È 08:12:16²Ä 231 ½g¦^À³
|
¤Ñ©R¤j «e±¤À¨Éªº³oӼƾڹêÅç²Õ¹ï·Ó²Õ¤ñȬù¨â¿´N¹F¼Ð¤F¡A·Q¤£³q¬°¦ó·à¤l¦b¹êÅç²Õ»P¹ï·Ó²Õ¼ÒÀÀ¤¤ORR¤ñȹF3.3¿ÁÙµLªk¹F¼Ð? ¦³¿ìªk¦A§ä¤@¨Ç¨â²Õ¤H¼Æ¦b110-130¥ª¥k¡A¬Ý¬Ý«ÈÆ[¤ÏÀ³²v¤ñȦh¤Ö·|¹LÃö¡C ÁÂÁ¤ѩR¤j¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/14 ¤U¤È 11:44:07²Ä 230 ½g¦^À³
|
¤Ñ©R¤j 1¦Ñ´¤j¬O¬°¤F·V«°_¨£¥Î³ÌÄY®æ¼Ð·Ç´Ó¤J°Ñ¼Æ¡A°Oºâ¥X¨Óµ¹¤j®a°Ñ¦Ò¥Îªº¡A¥u¬O§ÚÌ ¤£²M·¡¦Ñ´¤jªºpºâ¹Lµ{¡H 2npºâ¥d¤èȨ䣧xÃø¡A¨Ì¾Ú¤½¸Õºâ¥X¹êÅç²Õ»P¹ï·Ó²Õ´Á±æ¦¸¼Æ»PÆ[¹î¦¸¼Æ¥N¤J¤½¸Õ¬Û¥[±o¨ì¥d¤èÈ«á¬dªí«K¥i±o¨ì¬ù²¤PÈ ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/13 ¤U¤È 10:46:13²Ä 229 ½g¦^À³
|
Varlitinib¦b¦¹¦¸Áx¹DÀù¼Ï¯Ã¸ÕÅç¬O¦³©t¨àÃĸê®æªº,¥[¤W¦Ñ·àªº¬ãµo¤Î¦æ¾Pµ¦²¤¦¨û̳£¬O°ê»Ú¤jÃļtªº¦Ñ¤â~~YORR¹F¼Ð(¨Ì¤Ñ©R¤j°T®§±À¦ô25~28%*0.7=À³¦³17.5~19.5%),¥Î²{¦³2018-ASCO³W¹ºHER+°Ï¤À«á¼Æ¾Ú¨Ó¨úÃÒ¤]¬O¥i¯à©Ê¯Å°ª~~ ¥H¤W¨Ñ°Ñ¦Ò..... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/13 ¤U¤È 10:10:16²Ä 228 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d¥þ²y¼Ï¯Ã¸ÕÅç¬O¨S¦³¿zÀËHER®a±Ú¡A ¦ý¬O2018 ASCO ©Ò´£¨ì¨º¨Ç¬ÛÃö©Ê¬ã¨s·|¤£·|¬O¤@ºØµ¦²¤¡A¦pªG¤£¿z¿ï¦³®Ä¸Õ¥Îªº¤H¤f§ó¦h¡A¦pªG¼Æ¾Úµo²{¿z¿ïªº¯S©w±Ú¸s®ÄªG¤~·|¥X¨Ó¡A¨ì®ÉÔ¦AÁY¤p¾A¥Î¤H¤f¡A¥u¬O¥i¥H¥Î¿z¿ïªº¦¸±Ú¸sªº¼Æ¾Ú¥h¥Ó½ÐÃÄÃÒ¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/13 ¤U¤È 08:51:47²Ä 227 ½g¦^À³
|
¤Ñ©R¤j ¤G½uÁx¹DÀù¤ÆÀøÃÄ«ÈÆ[¤ÏÀ³²vORR±q¦Ê¤À¤§2-4 ³£¦³¡A¤]¦³¦Ê¤À¤§5-8¡A§ÚÌÀ³¸Ó±Ä¨ú¤ñ¸ûÄY®æ¼Ð·Ç¨Óµû¦ô¹ï·Ó²ÕªºORR¡A§A»{¬°°²³]¹ï·Ó²ÕORR¬O5¡B6¡B7¡B8 ®É¹êÅç²Õn¹F¼Ð»Ýn¦h¤ÖORR¡H |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/13 ¤W¤È 11:01:31²Ä 226 ½g¦^À³
|
¤¤°êÁx¹DÀùªºORR¥Dn¸ÕÅç¬O§_¹F¼Ð?¥ý«e1bªº¸ÕÅç¤w¸g¥P¤H«ü¸ô«ü¥X¹F°ª¼Ðªº¼ç¤O¤F~~¦p¤U³sµ²: mops.twse.com.tw/nas/STR/649720180531M001.pdf P15¤ÎP18 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/12 ¤U¤È 03:55:34²Ä 225 ½g¦^À³
|
¤Ñ©R¤j Ó¤H²L¨£:¤¤°êÁx¹DÀù¼Ï¯Ã¸ÕÅç¨S¦³¹ï·Ó²Õ¬O¸ò¶Ç²Î¤ÆÀøÃħ@¤ñ¸û¡A«ÂI°£¤Fn¯à³q¹L²Îp¦ÒÅç¥~¡AORR¼Æ¾Ú³Ì¦n°ª¤@ÂI¥H«áÃĤ~½æ±o¥X¥h¡C¨Ì¾Ú²Î¤@§ëÅU¤ÀªR¹LÃöORR¬ù»Ý15-20 |
|
|
|